

Clinical Practice Guideline: Electric Stimulation for Pain, Swelling and Function in the Clinic Setting

Date of Implementation: June 16, 2016

Product: Specialty

Related Policies:
CPG 121: Passive Physiotherapy (Therapeutic) Modalities
CPG 135: Physical Therapy Medical Policy/Guidelines
CPG 155: Occupational Therapy Medical Policy/Guidelines
CPG 269: H-Wave Electrical Stimulation

Table of Contents

GUIDELINES 2

DESCRIPTION/BACKGROUND 6

 Contraindications and Precautions10

EVIDENCE REVIEW11

 Transcutaneous Electrical Nerve Stimulator (TENS).....11

 Microcurrent Electrical Nerve Stimulation.....23

 H-WAVE®24

 Interferential Current (IFC)26

 High Volt Galvanic Stimulation (HVGS).....29

 PENS and PNT30

 NMES and FES32

 Orthopedic Conditions.....32

 Neurological Conditions.....38

 Dysphagia.....49

 Heart Conditions.....54

 Pelvic Floor Stimulation (electric or electromagnetic)55

 Threshold Electrical Stimulation (TES)60

 Neufit Neubie device61

 RST-SANEXAS neoGEN® Electric cell-Signaling Treatments (EcST)61

 Hako-Med.....61

 Transcutaneous electrical modulation pain reprocessing (TEMPR) (e.g., Scrambler therapy, Calmare®)61

PRACTITIONER SCOPE AND TRAINING64

1	References	65
---	------------------	----

2

3 **GUIDELINES**

4 I. American Specialty Health – Specialty (ASH) considers use of electric stimulation
 5 (e.g., TENS, EMS) medically necessary in a clinic setting and under the direct
 6 supervision of a physical therapist or similar professional for an individual when
 7 prescribed as part of a comprehensive treatment program for pain and swelling, and
 8 only used short term (e.g., up to 2 weeks).
 9

10 Note: The medical records must document the response to the use of electrical stimulation,
 11 including specific parameters related to the type of electric stimulation (e.g., low or high
 12 frequency TENS, electrode placement).
 13

14 II. Neuromuscular Electrical Stimulation (NMES) is considered medically necessary
 15 for disuse atrophy where the nerve to the muscle is intact, and the individual has
 16 any of the following non-neurological reasons for the disuse atrophy and only in
 17 conjunction with active exercise:

- 18 • Major hip or knee surgery where there is failure to respond to basic
 19 therapeutic exercises as initiated in physical therapy/rehabilitation; or
- 20 • Previous immobilization (e.g., casting or splinting) of an extremity (arm or
 21 leg).
 22

23 III. Microcurrent electrical nerve stimulation (MENS) therapy is considered unproven
 24 for the treatment of chronic back pain and all other indications.
 25

26 IV. Microcurrent point stimulation is considered unproven for the treatment of chronic
 27 pain and any other indications.
 28

29 V. H-WAVE® stimulation is considered unproven for diabetic peripheral neuropathy
 30 and for all other indications including:

- 31 • To accelerate healing
- 32 • To reduce edema
- 33 • To reduce pain from causes other than chronic diabetic peripheral
 34 neuropathy
- 35 • To treat chronic pain due to ischemia
 36

37 VI. Threshold Electrical Stimulation is considered unproven for any condition.

1 VII. Pelvic floor stimulation (electric and magnetic stimulation is considered unproven
2 for the treatment of urinary or fecal incontinence except for the following
3 condition):

- 4 • Pelvic floor electrical stimulation with a non-implantable stimulator may be
5 covered as medically necessary for the treatment of stress and/or urge
6 urinary incontinence in cognitively intact patients who are a Medicare
7 beneficiary and who have failed a documented trial of pelvic muscle
8 exercise (PME) training.
 - 9 ○ A failed trial of PME training is defined as no clinically significant
10 improvement in urinary continence after completing 4 weeks of an
11 ordered plan of pelvic muscle exercises designed to increase
12 periurethral muscle strength.
 - 13 ○ The patient's medical record must indicate that the patient receiving
14 a non-implantable pelvic floor electrical stimulator was cognitively
15 intact, motivated, and had failed a documented trial of pelvic muscle
16 exercise (PME) training.
 - 17 ○ Stimulation delivered by vaginal or anal probes connected to an
18 external pulse generator may be billed as 97032. Stimulation
19 delivered via electrodes should be billed as G0283.
 - 20 ○ Utilization of electrical stimulation may be necessary during the
21 initial phase of treatment, but there must be an improvement in
22 function. These modalities should be utilized with appropriate
23 therapeutic procedures to effect continued improvement.
 - 24 ○ Medicare beneficiary has an intact nerve supply to the muscle,
25 including brain, spinal cord, and peripheral nerves, and other non-
26 neurological reasons for disuse are causing the atrophy (e.g., post-
27 casting or splinting of a limb, and contracture due to soft tissue
28 scarring).
 - 29 ○ Documentation must clearly support the medical necessity of
30 electrical stimulation if used more than 12 visits as an adjunctive
31 therapy or for muscle retraining.

33 VIII. Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous
34 Neuromodulation Therapy (PNT) are considered unproven for any indication.
35

36 IX. NMES/Electrical Stimulation (e.g., Guardian dysphagia dual chamber unit,
37 VitalStim Therapy device) is considered unproven for the treatment of dysphagia.
38

39 X. Deep Pharyngeal Neuromuscular Stimulation (DPNS) is considered unproven.
40

41 XI. RST-SANEXAS neoGEN® Electric cell-Signaling Treatments (EcST) is
42 considered unproven for any indication (e.g. peripheral neuropathy).

1 XII. Hako-Med treatments are considered unproven for any indication (e.g. peripheral
2 neuropathy).

3
4 XIII. Transcutaneous electrical modulation pain reprocessing (TEMPR) (e.g., Scrambler
5 therapy, Calmare®) is considered unproven for any indication.

6
7 XIV. Neufit Neubie device is considered unproven for any indication.
8

9 Note: Use should be to support an active care approach (i.e., therapeutic exercise, active
10 self-care). Its use in the treatment of sub-acute or chronic conditions beyond the acute
11 inflammatory response time frame requires demonstration of clinically meaningful and
12 lasting improvements in function and pain, documentation of the anticipated benefit, as
13 well as condition-specific rationale in order to be considered medically necessary.
14

15 Electrical stimulation (except NMES) is contraindicated in areas of sensory deficits. A
16 patient's sensory deficits (decrease or loss) do not allow them to provide the correct
17 feedback necessary for the safe and effective application to the affected area. Electrical
18 stimulation in other related areas without sensory deficits may be appropriate.
19

20 The use of electrical muscle stimulation with pediatric patients is contraindicated if the
21 patient cannot provide the proper feedback necessary for safe application.

22 **Home Electrical Stimulation Devices (Electrical Stimulators)**

23 If coverage for an in-home electrical stimulation device is available, the following
24 conditions apply. In-home electrical stimulation units are considered medically necessary
25 for the following scenarios:
26

- 27 • Neuromuscular electrical stimulation (NMES) (HCPCS Code E0745) and related
28 supplies (HCPCS Code A4595) are considered medically necessary when used as
29 a component of a comprehensive rehabilitation program for the treatment of disuse
30 atrophy when the nerve supply to the atrophied muscle is intact.
- 31 • A transcutaneous electrical nerve stimulator (TENS) (HCPCS Code E0720, E0730)
32 and related supplies (HCPCS Code A4595) are considered medically necessary for
33 supervised or unsupervised, in-home use as an adjunct to conventional post-
34 operative pain management within 30 days of surgery.
- 35 • Conductive Garment: A conductive garment (HCPCS Code E0731) is considered
36 medically necessary when used in conjunction with a medically necessary in-home
37 NMES or TENS device for ANY of the following clinical situations:
 - 38 ○ The use of conventional electrodes, tapes or lead wires is not feasible either
39 because the individual has a large area requiring treatment or a large number
40 of sites requiring stimulation.
 - 41 ○ The site(s) requiring stimulation (i.e., back) is/are difficult to reach with
42 conventional electrodes, tapes or lead wires.

- 1 ○ A co-existing medical condition (e.g., skin problems) precludes the use of
2 conventional electrodes, tapes, or lead wires. In-home electrical stimulation
3 units for all other scenarios are considered unproven.
4

5 ASH peer review clinical committees recommend the following guidelines for the use of
6 passive therapeutic modalities:

- 7 • Generally used to manage the acute inflammatory response, pain, and/or muscle
8 tightness or spasm in the early stages of musculoskeletal and related condition
9 management (e.g., short term and dependent upon patient condition and
10 presentation; a few weeks). When the symptoms that prompted the use of certain
11 passive therapeutic modalities begin to subside (e.g., reduction of pain,
12 inflammation, and muscle tightness) and function improves, the medical record
13 should reflect the discontinuation of those modalities, so as to determine the
14 patient’s ability to self-manage any residual symptoms.
15 • Use in the treatment of sub-acute or chronic conditions beyond the acute
16 inflammatory response time frame requires documentation of the anticipated
17 benefit and condition-specific rationale (e.g., exacerbation, inclusion with active
18 care as an alternative for pharmacological management of chronic pain) to be
19 considered medically necessary. Passive therapeutic modalities can be appropriate
20 in these situations when they are preparatory and essential to the safe and effective
21 delivery of other skilled therapeutic procedures (e.g., chiropractic manipulation,
22 manual therapy [CPT 97140], therapeutic exercise, acupuncture) that are
23 considered medically necessary.
24 • Used as a stand-alone treatment is rarely therapeutic, and thus not required or
25 indicated as the sole treatment approach to a patient’s condition. Therefore, a
26 treatment plan should not consist solely of passive therapeutic modalities but
27 should also include skilled therapeutic procedures (e.g., chiropractic manipulation,
28 manual therapy [CPT 97140], therapeutic exercise, acupuncture).
29 • Should be selected based on the most effective and efficient means of achieving the
30 patient’s functional goals. Seldom should a patient require more than one (1) or two
31 (2) passive therapeutic modalities to the same body part during the therapy session.
32 Use of more than two (2) passive therapeutic modalities on a single visit date and
33 for a prolonged period is unusual and should be justified in the documentation for
34 consideration of medical necessity.
35

36 General Medical Necessity Criteria that must be met in addition to criteria above.

- 37 • The patient’s condition has the potential to improve or is improving in response to
38 this therapy service.
39 • This therapy service is intended to improve, adapt or restore functions which have
40 been impaired or lost as a result of illness, injury, loss of a body part, or congenital
41 abnormality.

- 1 • The use of this therapy service is applied only for a brief period in the early stages
- 2 of treatment or during the acute period of an exacerbation/flare-up of the patient’s
- 3 condition(s) and is used as preparatory to other skilled treatment procedures or is
- 4 necessary in order to provide other skilled treatment procedures safely and
- 5 effectively.
- 6 • The use of this therapy service (e.g., dosage, frequency) corresponds with the
- 7 current nature, status, and severity of the patient’s condition(s).
- 8 • The use of this therapy service is decreased as the patient displays improvement
- 9 and the plan of care transitions into other skilled treatment procedures that can
- 10 safely and effectively restore, adapt or improve the patient’s impaired function(s).
- 11 • The use of this therapy service is safe and effective for the patient’s condition, and
- 12 the patient is able to properly provide the necessary feedback for its safe
- 13 application.
- 14 • The use of this therapy service is not redundant with other therapy services used on
- 15 the same body part during the same session and is not duplicative with another
- 16 practitioner’s treatment plan

17
18 **CPT®/HCPCS Codes and Descriptions**

CPT®/HCPCS Code	CPT®/HCPCS Code Description
97014	Application of a modality to 1 or more areas; electrical stimulation (unattended)
97032	Application of a modality to one or more areas; electrical stimulation (manual) each 15 minutes
G0283	Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)

19
20 **DESCRIPTION/BACKGROUND**

21 Electrical stimulation (ES) therapy involves the application of electrodes to the affected

22 area of the body for the purpose of delivering electrical current. There are several forms of

23 electrical current used in rehabilitation settings. Electrical stimulation is used for muscle

24 re-education (disuse atrophy), pain relief, reduction of swelling, and healing enhancement.

25 This clinical practice guideline (CPG) will focus on the use of electric stimulation for pain,

26 swelling and function (muscle re-education/disuse atrophy) when used in the outpatient

27 clinic setting.

28

29 A TENS unit must be distinguished from other electrical stimulators (e.g., neuromuscular

30 stimulators) which are used to directly stimulate muscles and/or motor nerves.

31 Transcutaneous electrical nerve stimulation (TENS) is characterized by biphasic current

32 and selectable parameters such as pulse rate and pulse width. TENS uses a battery-operated

1 device that applies electrical stimulation via transmission of pulses of various
2 configurations at the site of pain by wired electrodes that are taped to the surface of the
3 skin. For example, conventional TENS or high frequency TENS delivers 40–150 hertz (Hz)
4 compared to acupuncture-like TENS that delivers a low frequency at 1–10 Hz. Pulsed
5 TENS uses low-intensity firing in high-frequency bursts at 100 HZ. Units often have preset
6 programs with variations and modulations of frequencies and durations of pulses. TENS
7 has been used for a number of applications. In theory, TENS stimulates sensory nerves to
8 block pain signals; it also stimulates endorphin production to help normalize sympathetic
9 function. TENS has been used to relieve acute or chronic pain related to musculoskeletal
10 conditions, pain associated with active or post-trauma injury, obstetrical pain, or
11 postoperative pain. TENS for pain control occurs via the gate theory or the endogenous
12 opiate theory. Conventional transcutaneous electrical stimulation (TENS) is an example of
13 the use of the gate theory to control or block pain. Low-rate TENS is an example of the use
14 of the endogenous opiate theory of pain control. TENS can also be delivered through the
15 use of a form-fitting conductive garment (for example, a garment with conductive fibers
16 that are separated from the individual's skin by layers of fabric). This garment is applied
17 when a condition exists that precludes conventional TENS electrode placement.

18
19 In an editorial by Johnson and Jones (2016), the contradictory nature of TENS research
20 evidence was noted, creating uncertainty for practitioners. For example, it is recommended
21 in NICE guidelines that TENS should be offered for short-term relief of osteoarthritis,
22 rheumatoid arthritis and musculoskeletal pain secondary to multiple sclerosis, but not for
23 nonspecific low back pain. Authors recommend that practitioners be mindful that
24 recommendations not to offer TENS are based on a paucity of evidence on which to make
25 a judgment rather than evidence of inferiority or equivalence to placebo. Trying to interpret
26 research on TENS is challenging because summarizing research findings is hindered by
27 inconsistent terminology, variability in clinical technique and poor study design. Current
28 research evidence suggests that it is reasonable to offer TENS as an adjunct to core
29 treatment for most painful conditions, especially because it is inexpensive and has a
30 favorable safety profile compared with long-term medication. However, it must be kept in
31 mind that it should be combined with an active exercise program.

32
33 Microcurrent Electrical Nerve Stimulation (MENS) involves the use of a device that
34 delivers small amounts of electrical current (millionths of an amp) to help relieve pain and
35 heal soft tissues of the body. The application of microcurrent stimulation to an injured area
36 is proposed to realign the body's electrical current and increase the production of adenosine
37 triphosphate, resulting in increased healing and recovery and blocking of perceived pain.
38 The electrical current is subsensory and usually not felt. MENS differs from TENS in that
39 it uses a significantly reduced electrical stimulation (i.e., 1,000 times less current than
40 TENS). The goal of TENS is to block pain, while MENS acts on naturally occurring
41 electrical impulses to decrease pain by stimulating the healing process (Frequency Specific
42 Microcurrent, 2014). Frequency specific microcurrent (FSM) is a type of microcurrent

1 therapy. The microcurrent device has two separate channels that allow both the frequency
2 and current to be set independently for each channel. FSM is proposed as a treatment option
3 for nerve and muscle pain, shingles, and herpes (Frequency Specific Microcurrent, 2011).
4 The H-WAVE[®] electrical stimulation device generates a biphasic, exponentially decaying
5 waveform with pulse-wide widths. Its waveform distinguishes it from TENS and other
6 forms of electrical stimulators. H-WAVE[®] is classified as a powered muscle stimulator.
7 The hypothesis that the H-WAVE[®] device (Electronic Waveform Lab, Inc., Huntington
8 Beach, CA), a small-diameter fiber stimulator, is a paradigm shift of electrotherapeutic
9 treatment of pain associated with human neuropathies and sports injuries is based on a
10 number of its properties. The primary effect of H-WAVE[®] device stimulation (HWDS) is
11 the stimulation of "red-slow-twitch" skeletal muscle fibers. The authors propose, based on
12 the unique waveform, that the H-WAVE[®] device specifically and directly stimulates the
13 small smooth muscle fibers within the lymphatic vessels ultimately leading to fluid shifts
14 and reduced edema. The H-WAVE[®] device was designed to stimulate an ultra-low
15 frequency (1-2 Hz), low tension, non-tetanzing, and non-fatiguing contraction, which
16 closely mimics voluntary or natural muscle contractions. The H-WAVE[®] device can
17 stimulate small fibers due in part to its exponentially decaying waveform and constant
18 current generator activity. The main advantage of these technologies over currently applied
19 electrical stimulators (e.g., TENS, interferential, NMES high-volt galvanic, etc.) is that H-
20 WAVE[®] small fiber contraction does not trigger an activation of the motor nerves of the
21 large white muscle fibers or the sensory delta and C pain nerve fibers, thus eliminating the
22 negative and painful effects of tetanizing fatigue, which reduces transcapillary fluid shifts.
23 Another proposed function of the H-WAVE[®] device is an anesthetic effect on pain
24 conditions, unlike a TENS unit which in the short term activates a hypersensory overload
25 effect (gate theory) to stop pain signals from reaching the thalamic region of the brain.
26 When the H-WAVE[®] device is used at high frequency (60 Hz), it supposedly acts
27 intrinsically on the nerve to deactivate the sodium pump within the nerve fiber, leading to
28 a long-lasting anesthetic/analgesic effect due to an accumulative postsynaptic depression.
29 The large pulse width theoretically enables contraction in the muscle for extended periods
30 of time at a low fatigue rate and increases circulation, muscle relaxation, pain relief and
31 wound healing. H-WAVE[®] stimulation has been used in the treatment of pain related to a
32 variety of etiologies, such as diabetic neuropathy, muscle sprains, temporomandibular joint
33 dysfunctions, or reflex sympathetic dystrophy. H-WAVE[®] electrical stimulation must be
34 distinguished from the H-waves that are a component of electromyography.

35
36 Other waveforms are used for pain modulation as well, including interferential current
37 (IFC), which is produced by two interfering alternating currents. Interferential stimulation
38 (IFS) is characterized by 2 alternating-current sine waves of differing medium frequencies
39 that combine together to produce an interferential current that is also known as a beat pulse
40 or alternating modulation frequency. One of the 2 currents is held at 4,000 Hz, and the
41 other can be held constant or varied over a range of 4,001 to 4,100 Hz. Interferential therapy
42 (IFT) delivers a crisscross current at 4,000–4,150 pulses per second, resulting in deeper

1 muscle penetration. It is theorized that IFT prompts the body to secrete endorphins and
2 other natural painkillers and stimulates parasympathetic nerve fibers to increase blood flow
3 and reduce edema. Interferential currents reportedly can stimulate sensory, motor, and pain
4 fibers. Because of the frequency, the interferential wave meets low impedance when
5 crossing the skin to enter the underlying tissue. This deep tissue penetration can be adjusted
6 to stimulate parasympathetic nerve fibers for increased blood flow. According to
7 proponents, interferential stimulation differs from TENS because it allows a deeper
8 penetration of the tissue with more comfort (compliance) and increased circulation.

9
10 High Voltage Galvanic Stimulation (HVGS) or high volt pulsed current (HVPC) is
11 characterized by high voltage pulsed stimulation and is proposed primarily for local edema
12 reduction through muscle pumping and polarity effect. High volt pulsed current (HVPC)
13 is used for tissue healing and edema control based on polarity principles. Edema is
14 comprised of negatively charged plasma proteins, which leak into the interstitial space. The
15 theory of HVPC is that the high voltage stimulus applies an electrical potential which
16 disperses the negatively charged proteins away from the edematous site, thereby helping
17 to reduce edema (Cameron, 2017).

18
19 Neuromuscular electric stimulation (NMES) is the application of electrical current through
20 electrodes on the skin to targeted muscles to elicit muscle contraction. NMES is proposed
21 to promote neuromuscular re-education, improve motor unit recruitment, and thus to
22 prevent or diminish muscle atrophy and is an established treatment modality for disuse
23 atrophy when the nerve supply to the muscle is intact. NMES is typically used as a
24 component of a comprehensive rehabilitation program. Compared to TENS, NMES
25 delivers a stronger current with a wider pulse width. Neuromuscular electrical stimulation
26 can be grouped into 2 categories: (i) stimulation of muscles to treat muscle atrophy due to
27 disuse (e.g., post-surgical, immobilization), and (ii) enhancement of functional activity in
28 neurologically impaired individuals. These devices within the second category use
29 electrical impulses to activate paralyzed or weak muscles in precise sequence and have
30 been utilized to provide SCI patients with the ability to walk (e.g., The Parastep I System).
31 Neuromuscular electrical stimulation used in this manner is commonly known as functional
32 electrical stimulation (FES).

33
34 Electric stimulated muscle contraction/neuromuscular electric stimulation (NMES) has
35 been found to enhance muscle function gains post-surgically. Patients who have received
36 an anterior cruciate ligament (ACL) reconstruction have demonstrated accelerated
37 recovery and greater muscle function when NMES is used in combination with exercise;
38 however, the impact on functional outcomes is inconsistent (Cameron, 2017). Similar
39 results were noted with knee OA patients and for other inflammatory conditions of the
40 knee. Most research studied the use of NMES on the quadriceps muscle, however clinically
41 NMES may be used for other joints and muscle groups (Cameron, 2017). Functional
42 electric stimulation (FES) is proposed for use in certain neurologic populations. As an

1 example, FES can be applied to the anterior tibialis muscle to assist in dorsiflexion during
 2 gait for patients with foot drop. Several studies support the integration of FES for patients
 3 with spinal cord injury or who have sustained a stroke for various activities. As long as the
 4 peripheral nervous system is intact, any patients with central nervous system dysfunction
 5 may benefit from FES use. In these situations, effectiveness of FES is thought to be most
 6 likely due to the direct effect of muscle strengthening in addition to increased excitability
 7 of the motor neuron pool produced by the motor level electrical stimulation (Cameron,
 8 2017).

9
 10 PENS and PNT combine the theories of electroacupuncture, and TENS and the terms are
 11 often used interchangeably. PENS involves the delivery of an electrical current through the
 12 insertion of a needle below the skin at the site of pain compared to acupuncture that places
 13 needles based on energy flow. It is not the same as acupuncture. PENS is similar to TENS
 14 except that the needles are inserted one to four centimeters around or adjacent to the
 15 applicable nerve. Up to 10 needles with 5 electrical channels may be used. PENS is
 16 generally reserved for patients who fail to obtain pain relief from TENS. PENS may also
 17 involve the application of electric stimulation to needles placed at the dermatomal levels
 18 corresponding to the painful area. PNT is a variation of PENS which was developed as a
 19 treatment for neck and back pain. This treatment involves insertion of very fine needle-like
 20 electrodes into the skin of the neck or back to stimulate nerve fibers in the deep tissues.
 21 The treatment regimen suggested by manufacturers typically consists of 2 to 3, 30-minute
 22 sessions per week, for 2 to 6 weeks.

23
 24 VitalStim[®] Therapy is a type of NMES that uses a mild electrical current that is intended
 25 to treat dysphagia by re-educating the muscles and improving swallowing. Guardian
 26 dysphagia dual chamber unit is proposed for use for muscle re-education by application of
 27 external stimulation for pharyngeal contraction. VitalStim[®] therapy was approved by the
 28 US Food and Drug Administration in 2001 for the treatment of dysphagia through the
 29 application of neuromuscular electrical stimulation to cervical swallowing muscles. To
 30 date, however, aside from the developer's own studies, there are no peer-reviewed
 31 publications supporting these claims. Deep pharyngeal neuromuscular stimulation (DPNS)
 32 is an electrical stimulation therapy for people with dysphagia. DPNS stimulates the cranial
 33 nerves by directly touching specific areas within the mouth and throat. This causes the
 34 pharyngeal and lingual muscles to contract. Over time, this is postulated to strengthen the
 35 patient's gag reflex and help to improve long-term swallowing functionality.

36 37 **Contraindications and Precautions**

38 Contraindications for use of Electrical Currents include:

- 39 • Demand pacemakers, implantable defibrillator, or unstable arrhythmia
- 40 • Placement of electrodes over carotid sinus
- 41 • Areas where venous or arterial thrombosis or thrombophlebitis is present
- 42 • Pregnancy – over or around the abdomen or low back

1 Precautions for Electrical Current use include:

- 2 • Cardiac disease
- 3 • Impaired mentation
- 4 • Impaired sensation
- 5 • Malignant tumors
- 6 • Areas of skin irritation or open wounds

7
8 **EVIDENCE REVIEW**

9 **Transcutaneous Electrical Nerve Stimulator (TENS)**

10 There are many published reports regarding the use of TENS for various types of
11 conditions such as low back pain (LBP), myofascial and arthritic pain, sympathetically
12 mediated pain, neurogenic pain, visceral pain, diabetic neuropathy, and postsurgical pain.
13 While randomized controlled trials (RCTs) have focused on both high and low frequency
14 TENS, all of the currently available studies have methodological flaws that limit
15 interpretation, including inadequate blinding, lack of reporting of dropouts, lack of
16 reporting of stimulation variables, and lack of proper outcome measures (Johnson et al.,
17 2015). However, it is recognized that TENS is widely accepted in the physician and therapy
18 community as a treatment of a variety of etiologies of pain in combination with
19 comprehensive treatment program.

20
21 According to the Philadelphia Panel Evidence-Based Clinical Practice Guidelines on
22 Selected Rehabilitation Interventions for Low Back Pain publication (2001), TENS
23 demonstrated no effectiveness for improvements in pain or function in subjects with
24 chronic low back pain (LBP). Evidence was stated as good (level I). The Panel
25 recommends that there is poor evidence to include or exclude TENS alone as an
26 intervention for chronic LBP. According to The Cochrane Collaboration systematic review
27 on TENS for chronic LBP (Khadilkar et al., 2005) there is limited and inconsistent
28 evidence to support the use of TENS as an isolated intervention for chronic LBP. In 2010,
29 the Therapeutic and Technology Assessment Subcommittee of the American Academy of
30 Neurology (AAN) published a report finding TENS ineffective for chronic low back pain
31 (Dubinsky and Miyasaki, 2010). The results indicated that there are conflicting reports of
32 TENS compared to sham TENS in the treatment of chronic low back pain, with two Class
33 II studies showing benefit, but two Class I studies and another Class II study not showing
34 benefit. Because the Class I studies are stronger evidence, TENS is established as
35 ineffective for the treatment of chronic low back pain. Their recommendations were that
36 TENS is not recommended for the treatment of chronic low back pain (Level A) and further
37 research into the mechanism of action of TENS is needed, as well as more rigorous studies
38 for determination of effectiveness. Per ACOEM guidelines, TENS for acute or sub-acute
39 LBP or acute radicular pain syndromes is not recommended given insufficient evidence
40 (ACOEM, 2007). In a review by Poitras and Brosseau (2008), it was determined that
41 globally, high- and low-frequency TENS appears to have an immediate impact on pain
42 levels in subjects with non-specific chronic LBP, with high-frequency TENS achieving

1 better results. Studies included were of relatively poor quality and the lack of consistent
2 parameters from study to study makes comparisons difficult. Based on this review, TENS
3 appears to be of no benefit for long term pain or perceived disability (Poitras and Brosseau,
4 2008). Khadilkar et al. (2008) updated the 2005 Cochrane Review to determine whether
5 TENS is more effective than placebo for the management of chronic LBP. Only
6 randomized controlled clinical trials (RCTs) comparing TENS to placebo in patients with
7 chronic LBP were included. Four high-quality RCTs (585 patients) met the selection
8 criteria. Clinical heterogeneity prevented the use of meta-analysis. There was conflicting
9 evidence about whether TENS was beneficial in reducing back pain intensity and
10 consistent evidence in two trials (410 patients) that it did not improve back-specific
11 functional status. There was moderate evidence that work status and the use of medical
12 services did not change with treatment. In general, patients treated with acupuncture-like
13 TENS responded similarly to those treated with conventional TENS. However, in two of
14 the trials, inadequate stimulation intensity was used for acupuncture-like TENS, given that
15 muscle twitching was not induced. Adverse effects included minor skin irritation at the site
16 of electrode placement. Authors concluded that the evidence from the small number of
17 placebo-controlled trials does not support the use of TENS in the routine management of
18 chronic LBP. Further research was encouraged.

19
20 The American Society of Anesthesiologists (ASA) and American Society of Regional
21 Anesthesia and Pain Medicine (ASRA) support the use of TENS in their revised guideline
22 recommending that "TENS should be used as a multimodal approach to pain management
23 for patients with chronic back pain and may be used for other pain conditions (e.g., neck
24 and phantom limb pain)" (ASA/ASRA, 2010). A Cochrane review that identified 25
25 eligible RCTs was not favorable in their analysis of the literature support of TENS for
26 various chronic pain conditions, primarily due to the quality of the available literature
27 (Nnoaham and Kumbang, 2008). These authors found positive results for pain relief in 13
28 out of 22 studies that compared TENS to a placebo or other inactive control group. In
29 studies that compared different TENS modes, seven of nine studies found no difference in
30 pain relief between high vs. low frequency TENS. Overall, the low methodological quality
31 and low power of the available literature did not allow the authors to make firm conclusions
32 regarding the effectiveness of TENS for chronic pain.

33
34 In 2013, Pivec et al. studied the clinical and economic impact of TENS in patients with
35 chronic LBP through analysis of a national database. This study evaluated patients who
36 were given TENS compared with a matched group without TENS prior to intervention and
37 at one-year follow-up. Patients who were treated with TENS had significantly fewer
38 hospital and clinic visits, used less diagnostic imaging, had fewer physical therapy visits,
39 and required less back surgery than patients receiving other treatment modalities. Jaurequi
40 et al. (2016) conducted a systematic review and meta-analysis of the efficacy of TENS for
41 the treatment of chronic, musculoskeletal low back pain. Thirteen studies, which included
42 randomized controlled trials, cohort studies, and randomized crossover studies ($n=267$),

1 met inclusion criteria. Follow-ups ranged from 2–24 weeks with a mean follow-up of seven
2 week. The duration of treatment ranged from 2–24 weeks (mean 6 weeks). The overall
3 standardized mean difference in pain from pre- to post-treatment with TENS showed a
4 significant improvement of TENS on pain reduction. When subdivided into treatment
5 duration, patients that were treated for less than five weeks ($n=8$ studies) had significant
6 effects on pain, while those treated for more than five weeks did not. The heterogeneity
7 among studies was substantially significant among the TENS groups. Limitations of the
8 studies included: small patient populations; variations in treatment times, TENS frequency
9 and length of follow-up; and conflicting outcomes. The authors noted that despite the
10 positive results, large multi-center prospective randomized trials are needed to develop the
11 appropriate treatment protocols for this patient population. According to the AHRQ
12 Comparative Effectiveness publication on Non-Invasive Treatments for Low Back Pain
13 (2016), additional evidence demonstrates that TENS is not effective versus sham TENS.
14 Effectiveness of TENS was previously classified as insufficient, and the strength of
15 evidence remains low because of methodological limitations in the trials and imprecision.
16 Evidence on harms associated with TENS was limited but suggests an increased risk of
17 skin site irritation without an increased risk of serious adverse events (AHRQ, 2016).
18 According to the American College of Physician’s Noninvasive Treatments for Acute,
19 Subacute, and Chronic Low Back Pain clinical practice guideline (2017), evidence was
20 insufficient to determine the effectiveness of transcutaneous electrical nerve stimulation
21 (TENS).

22
23 Two practice guidelines support the use of TENS, one for rheumatoid arthritis based on
24 positive results in one RCT (Ottawa Panel Evidence-Based Clinical Practice Guidelines,
25 2004), and one for the treatment of knee osteoarthritis based on meta-analysis of 5 RCTs
26 included in the analysis (Philadelphia Panel Practice Guidelines, 2001). Johnson et al.
27 (2015) assessed the analgesic effectiveness of TENS, as a sole treatment, for acute pain in
28 adults. Only RCTs of adults with acute pain (< 12 weeks) were examined with TENS given
29 as a sole treatment and assessed pain was with subjective pain scales. The types of acute
30 pain included in this Cochrane Review were procedural pain, (e.g., cervical laser treatment,
31 venipuncture, screening flexible sigmoidoscopy) and non-procedural pain, (e.g.,
32 postpartum uterine contractions and rib fractures). There was a high risk of bias associated
33 with inadequate sample sizes in treatment arms and unsuccessful blinding of treatment
34 interventions. Seven trials reported minor adverse effects, such as mild erythema and
35 itching underneath the electrodes and participants disliking TENS sensation. Authors
36 concluded that this review offers tentative evidence that TENS reduces pain intensity over
37 and above that seen with placebo (no current) TENS when administered as a stand-alone
38 treatment for acute pain in adults. The high risk of bias associated with inadequate sample
39 sizes in treatment arms and unsuccessful blinding of treatment interventions makes
40 definitive conclusions impossible.

1 Jin et al. (2010) conducted a systematic review to evaluate the effectiveness of TENS on
2 diabetic peripheral neuropathy. Three randomized controlled trials ($n=78$) met inclusion
3 criteria. TENS was reported more effective than placebo in the reduction of mean pain
4 score at 4- and 6-weeks follow-up but not at 12 weeks. Pieber et al. (2010) conducted a
5 systematic review of the literature to evaluate electrotherapy, including TENS, for the
6 treatment of peripheral neuropathy in patients with diabetes. Three randomized controlled
7 trials ($n=76$) and one retrospective review ($n=54$) evaluating TENS met inclusion criteria.
8 The studies included short-term follow-ups and conflicting results. One study reported
9 significant improvement in pain and another study reporting recurrence of pain after
10 cessation of TENS. Due to the small patient populations, short-term treatment duration,
11 short-term follow-up and poor study methodology, large multi-center randomized
12 controlled trials are needed to further evaluate the long-term effect of TENS on diabetic
13 neuropathy. Hurlow et al. (2012) conducted an update review of the 2009 review by Robb
14 et al. One new study met inclusion criteria ($n=24$). There were significant differences in
15 participants, treatments, procedures and symptom measurement tools used in the studies.
16 The clinical utility of TENS for the treatment of cancer pain has not been established. Robb
17 et al. (2009) conducted a systematic review of the literature to evaluate TENS for the
18 treatment of cancer-related pain. Two randomized controlled trials ($n=64$) met inclusion
19 criteria. Meta-analysis was not conducted due to the disparities between patient population,
20 mode of TENS, treatment duration, and outcome measures prevented meta-analysis. There
21 is insufficient evidence to support TENS for the treatment of cancer-related pain.

22
23 Mulvey et al. (2010) conducted a systematic review of randomized controlled trials to
24 assess the effectiveness of TENS for the treatment of phantom pain and stump pain
25 following amputation in adults. No studies were identified. Johnson et al. (2015b)
26 conducted an update of this Cochrane review and found no new randomized controlled
27 trials evaluating TENS for the treatment of phantom pain and stump pain. Rheumatoid
28 Arthritis: In a systematic review of the literature, Brosseau et al. (2003) evaluated the
29 effectiveness of TENS for the treatment of rheumatoid arthritis of the hand. Three
30 randomized controlled trials ($n=78$) met inclusion criteria. Conventional TENS (C-TENS)
31 and acupuncture-TENS (acu-TENS) were compared to either placebo or each other. Pain
32 outcomes on the effect of TENS were conflicting. Acu-TENS was beneficial for reducing
33 pain intensity and improving muscle power scores compared to placebo. No clinical benefit
34 on pain was reported with C-TENS compared to placebo. C-TENS resulted in a clinical
35 benefit on the patients' assessment of change compared to acu-TENS. The authors
36 concluded that more well-designed studies with a standardized protocol and adequate
37 numbers of subjects were needed to fully identify the effect of TENS for the treatment of
38 RA of the hand.

39
40 Dissanayaka et al. (2016) compared the effectiveness of transcutaneous electrical nerve
41 stimulation and interferential therapy (IFT) both in combination with hot pack, myofascial
42 release, active range of motion exercise, and a home exercise program on myofascial pain

1 syndrome patients with upper trapezius myofascial trigger point. Following randomization
2 of patients into three groups (hot pack, active range of motion exercises, myofascial
3 release, and a home exercise program with postural advice), transcutaneous electrical nerve
4 stimulation-standard care and IFT-standard care-were administered eight times during
5 4 weeks at regular intervals. Pain intensity and cervical range of motions (cervical
6 extension, lateral flexion to the contralateral side, and rotation to the ipsilateral side) were
7 measured at baseline, immediately after the first treatment, before the eighth treatment, and
8 1 week after the eighth treatment. Immediate and short-term improvements were marked
9 in the transcutaneous electrical nerve stimulation group ($n = 35$) compared with the IFT
10 group ($n = 35$) and the control group ($n = 35$) with respect to pain intensity and cervical
11 range of motions ($P < 0.05$). The IFT group showed significant improvement on these
12 outcome measurements than the control group did ($P < 0.05$). Authors concluded that
13 TENS with standard care facilitates recovery better than IFT does in the same combination.

14
15 Page et al. (2016) completed a Cochrane Database Systematic Review on electrotherapy
16 modalities for rotator cuff disease. Examples included therapeutic ultrasound, low-level
17 laser therapy (LLLT), transcutaneous electrical nerve stimulation (TENS), and pulsed
18 electromagnetic field therapy (PEMF). These modalities are usually delivered as
19 components of a physical therapy intervention. Authors synthesized the available evidence
20 regarding the benefits and harms of electrotherapy modalities for the treatment of people
21 with rotator cuff disease. Randomized controlled trials (RCTs) and quasi-randomized
22 trials, including adults with rotator cuff disease (e.g., subacromial impingement syndrome,
23 rotator cuff tendinitis, calcific tendinitis), and comparing any electrotherapy modality with
24 placebo, no intervention, a different electrotherapy modality or any other intervention (e.g.,
25 glucocorticoid injection) were included. Trials investigating whether electrotherapy
26 modalities were more effective than placebo or no treatment or were an effective addition
27 to another physical therapy intervention (e.g., manual therapy or exercise) were the main
28 comparisons of interest. Main outcomes of interest were overall pain, function, pain on
29 motion, patient-reported global assessment of treatment success, quality of life and the
30 number of participants experiencing adverse events. Most trials ($n = 43$) included
31 participants with rotator cuff disease without calcification (four trials included people with
32 calcific tendinitis). Sixteen (34%) trials investigated the effect of an electrotherapy
33 modality delivered in isolation. Only 23% were rated at low risk of allocation bias, and
34 49% were rated at low risk of both performance and detection bias (for self-reported
35 outcomes). The trials were heterogeneous in terms of population, intervention and
36 comparator, so none of the data could be combined in a meta-analysis. Authors were
37 uncertain whether transcutaneous electrical nerve stimulation (TENS) was more or less
38 effective than glucocorticoid injection with respect to pain, function, global treatment
39 success and active range of motion because of the very low-quality evidence from a single
40 trial. Authors concluded that uncertainty exists as to whether TENS is superior to placebo,
41 and whether any electrotherapy modality provides benefits over other active interventions
42 (e.g., glucocorticoid injection) because of the very low quality of the evidence. Further

1 trials of electrotherapy modalities for rotator cuff disease should be based upon a strong
 2 rationale and consideration of whether they would alter the conclusions of this review.

3
 4 In an article by Vance et al. (2014) titled “Using TENS for pain control: the state of the
 5 evidence,” transcutaneous electrical nerve stimulation (TENS) is described as a
 6 nonpharmacological intervention that activates a complex neuronal network to reduce pain
 7 by activating descending inhibitory systems in the central nervous system to reduce
 8 hyperalgesia. Within the article, authors describe the current mechanisms of TENS
 9 reduction on analgesia, which is thought to be more complex than previously described.
 10 More specifically, TENS activates a complex neuronal network to result in a reduction in
 11 pain. At frequencies and intensities used clinically, TENS activates large diameter afferent
 12 fibers. This afferent input is sent to the central nervous system to activate descending
 13 inhibitory systems to reduce hyperalgesia. Specifically, blockade of neuronal activity in
 14 the periaqueductal gray (PAG), rostral ventromedial medulla (RVM) and spinal cord
 15 inhibit the analgesic effects of TENS showing that TENS analgesia is maintained through
 16 these pathways. In parallel, studies in people with fibromyalgia show that TENS can restore
 17 central pain modulation, a measure of central inhibition. Therefore, TENS appears to
 18 reduce hyperalgesia through both peripheral and central mechanisms. Authors do report
 19 that the evidence for TENS efficacy is conflicting. Sluka et al. (2013) suggests that certain
 20 factors should be considered when evaluating the research. These include dosing of TENS,
 21 negative interactions with long-term opioid use, the population and outcome assessed,
 22 timing of outcome measurement, and comparison groups. Population-specific systemic
 23 reviews and meta-analyses are emerging, indicating both high frequency (HF) and low
 24 frequency (LF) TENS being shown to provide analgesia, specifically when applied at a
 25 strong, non-painful intensity. They conclude that additional research is necessary to
 26 determine if TENS has effects specific to mechanical stimuli and/or beyond reduction of
 27 pain and will improve activity levels, function and quality of life. These authors are
 28 considered experts in the area of TENS research, and they offer these interesting practice
 29 points:

- 30 • High frequency (HF) and low frequency (LF) transcutaneous electrical nerve
 31 stimulation (TENS) activate different opioid receptors. Both applications have been
 32 shown to provide analgesia specifically when applied at a strong, non-painful
 33 intensity. HF TENS may be more effective for people taking opioids.
- 34 • Effective analgesia for chronic pain conditions may be limited by the development
 35 of tolerance to TENS if repeated application of either LF or HF TENS at the same
 36 frequency and intensity is used daily (i.e., same dose). Strategies to prolong
 37 analgesia may include varying these parameters.
- 38 • Targeting the use of TENS during movement or activity may be most beneficial.
- 39 • TENS may be effective in restoration of central pain modulation, a measure of
 40 central inhibition.
- 41 • A clearer picture of TENS effectiveness will emerge as trials with attention to
 42 optimal dosing and appropriate outcome measures increase in numbers.

1 Gibson et al. (2019) provided an overview of evidence from Cochrane Reviews of the
2 effectiveness of TENS to reduce pain in adults with chronic pain (excluding headache or
3 migraine). They included nine reviews investigating TENS use in people with defined
4 chronic pain or in people with chronic conditions associated with ongoing pain. The
5 evidence reported within each review was consistently rated as very low quality. The
6 authors considered the approach of combining sham and no intervention data to be
7 problematic since these different comparisons may be estimating different true effects.
8 Authors found the methodological quality of the reviews was good, but quality of the
9 evidence within them was very low. They were therefore unable to conclude with any
10 confidence that, in people with chronic pain, TENS is harmful, or beneficial for pain
11 control, disability, health-related quality of life, use of pain-relieving medicines, or global
12 impression of change. Pietrosimone et al. (2020) aimed to determine the effect of TENS +
13 therapeutic exercise (TE) on patient-reported function, quadriceps strength, and voluntary
14 activation, as well as physical performance compared with sham TENS + TE (Sham) and
15 TE alone in individuals with symptomatic knee OA and quadriceps voluntary activation
16 failure (QVAF). Ninety individuals participated in a double-blinded randomized controlled
17 trial. Everyone received 10 standardized TE sessions of physical therapy. TENS + TE and
18 Sham groups applied the respective devices during all TE sessions and throughout
19 activities of daily living over 4 wk. Improvements in WOMAC subscales, quadriceps
20 strength, and voluntary activation, 20-m walk times, chair-stand repetitions, and stair-climb
21 time were found at post 1 and post 2 compared with baseline for all groups ($P < 0.05$).
22 WOMAC Pain and Stiffness improved in the TENS + TE group compared with TE alone
23 at post 1 ($P < 0.05$); yet no other between-group differences were found. Authors concluded
24 that TE effectively improved patient-reported function, quadriceps strength, and voluntary
25 activation, as well as physical performance in individuals with symptomatic KOA and
26 QVAF but augmenting TE with TENS did not improve the benefits of TE.

27
28 A Best Practices for Chiropractic Management of Patients with Chronic Musculoskeletal
29 Pain: A Clinical Practice Guideline authored by Hawk et al. (2020), stated that for chronic
30 low back pain, TENS or interferential current may be beneficial as part of a multimodal
31 approach, at the beginning of treatment to assist the patient in becoming or remaining
32 active. For chronic neck pain, they recommend TENS and interferential current in the same
33 manner as for chronic low back pain.

34
35 Rapazo et al. (2021) investigated the effectiveness of electrical stimulation (ES) for neck
36 pain (NP). Main results showed evidence of moderate quality that ES combined with other
37 intervention significantly decreases the pain intensity compared to other intervention
38 immediately post-treatment and at short-term follow-up; evidence of low quality showed
39 significant effects of ES combined with other intervention in decreasing neck disability
40 compared to other intervention immediately post-treatment; evidence of very-low quality
41 that ES increased the pressure pain threshold compared to placebo immediately post-
42 treatment and that ES + other intervention also increased the pressure pain threshold

1 compared to other intervention at short-term follow-up. Authors concluded that ES
 2 combined with other intervention seems to be useful to relieve pain and to improve
 3 disability in people with NP, however, more studies are needed.

4
 5 Dias et al. (2021) compared the immediate analgesic effect of transcutaneous nerve
 6 stimulation (TENS) and interferential current (IFC), with different combinations of
 7 parameters, in individuals with chronic low back pain (CLBP). 280 individuals with CLBP
 8 were included in the study, both genders, randomized in 8 groups, all individuals
 9 underwent a single application of TENS or IFC for 30min. The assessments were carried
 10 out prior to the intervention, as well as immediately after, with the following outcomes:
 11 pain intensity (Numeric Pain Rating Scale-NPRS), qualitative pain characteristics (McGill
 12 Pain Questionnaire-MPQ), and pressure pain threshold (PPT) by pressure algometry (PA)
 13 in 4 points of the low back region. Authors concluded that both TENS and IFC presented
 14 immediate analgesic effect in CLBP, with emphasis on the interferential current of 4 KHz
 15 modulated at 100Hz.

16
 17 According to the National Institute for Health and Care Excellence (NICE) review (2021),
 18 they report the following for TENS:

- 19 • TENS versus sham TENS and usual care
 - 20 ○ Quality of life
 - 21 ▪ Moderate quality evidence from 1 study with 202 participants
 - 22 showed no clinically important difference between TENS and sham
 - 23 TENS at ≤ 3 months.
 - 24 ▪ Quality of life Moderate to low quality evidence from 1 study with
 - 25 202 participants showed no clinically important difference between
 - 26 TENS and usual care at ≤ 3 months.
 - 27 ○ Pain reduction
 - 28 ▪ Very low-quality evidence from 2 studies with 242 participants
 - 29 showed a clinically important difference for TENS compared to
 - 30 sham TENS at ≤ 3 months.
 - 31 ▪ Moderate quality evidence from 1 study with 40 participants showed
 - 32 a clinically important difference for TENS at > 3 months compared
 - 33 to sham TENS.
 - 34 ▪ Low quality evidence from 1 study with 202 participants showed
 - 35 no clinically important difference between TENS and usual care at
 - 36 ≤ 3 months.
 - 37 ○ Physical function
 - 38 ▪ High quality evidence from 1 study with 202 participants showed no
 - 39 clinically important difference between TENS and sham TENS at
 - 40 ≤ 3 months.

- 1 ▪ High quality evidence from 1 study with 202 participants showed
- 2 no clinically important difference between TENS and usual care at
- 3 ≤3 months.
- 4 ○ Psychological distress
- 5 ▪ Moderate to low quality evidence from 1 study with 202
- 6 participants showed no clinically important difference between
- 7 TENS and sham TENS at ≤3 months.
- 8 ▪ Moderate to low quality evidence from 1 study with 202
- 9 participants showed no clinically important difference between
- 10 TENS and usual care at ≤3 months.
- 11 ○ Pain interference
- 12 ▪ Low quality evidence from 1 study with 202 participants showed no
- 13 clinically important difference between TENS and sham TENS at
- 14 ≤3 months.
- 15 ▪ Low quality evidence from 1 study with 202 participants showed
- 16 no clinically important difference between TENS and usual care at
- 17 ≤3 months.
- 18 ○ Pain self-efficacy
- 19 ▪ High quality evidence from 1 study with 202 participants showed no
- 20 clinically important difference between TENS and sham TENS at
- 21 ≤3 months.
- 22 ▪ High quality evidence from 1 study with 202 participants showed no
- 23 clinically important difference between TENS and usual care at ≤3
- 24 months.

25

26 Paley et al. (2021) critically appraised the characteristics and outcomes of systematic

27 reviews evaluating the clinical efficacy of TENS for any type of acute and chronic pain in

28 adults. Authors included 169 reviews consisting of eight overviews, seven hybrid reviews

29 and 154 systematic reviews with 49 meta-analyses. Only three meta-analyses pooled

30 sufficient data to have confidence in the effect size estimate (i.e., pooled analysis of >500

31 events). Lower pain intensity was found during TENS compared with control for chronic

32 musculoskeletal pain and labor pain, and lower analgesic consumption was found post-

33 surgery during TENS. The appraisal revealed repeated shortcomings in RCTs that have

34 hindered confident judgements about efficacy, resulting in stagnation of evidence. Authors

35 concluded that this appraisal reveals examples of meta-analyses with 'sufficient data'

36 demonstrating benefit. There were no examples of meta-analyses with 'sufficient data'

37 demonstrating no benefit. Therefore, they recommend that TENS should be considered as

38 a treatment option.

39

40 Reichenbach et al. (2022) sought to determine the effectiveness of TENS at relieving pain

41 and improving physical function as compared to placebo TENS, and to determine its safety,

42 in patients with knee osteoarthritis. 220 participants with knee osteoarthritis were recruited

1 between October 15, 2012, and October 15, 2014. Patients were randomized to 3 weeks of
2 treatment with TENS ($n = 108$) or placebo TENS ($n = 112$). The primary endpoint was
3 knee pain at the end of 3-weeks treatment assessed with the WOMAC pain subscale.
4 Secondary outcome measures included WOMAC physical function subscale and safety
5 outcomes. There was no difference between TENS and placebo TENS in WOMAC pain at
6 the end of treatment, nor throughout the trial duration. Subgroup analyses did not indicate
7 an interaction between patient/treatment characteristics and treatment effect on WOMAC
8 pain at the end of treatment (P-interaction ≥ 0.22). The occurrence of adverse events was
9 similar across groups, with 10.4% and 10.6% of patients reporting events in the TENS and
10 placebo TENS groups, respectively (P = 0.95). No relevant differences were observed in
11 secondary outcomes. Authors concluded that TENS does not improve knee osteoarthritis
12 pain when compared to placebo TENS. Therapists should consider other potentially more
13 effective treatment modalities to decrease knee osteoarthritis pain and facilitate
14 strengthening and aerobic exercise.

15
16 Johnson et al. (2022) investigated the efficacy and safety of transcutaneous electrical nerve
17 stimulation (TENS) for relief of pain in adults in a systematic review and meta-analysis.
18 The review included 381 RCTs (24,532 participants). Pain intensity was lower during or
19 immediately after TENS compared with placebo (moderate-certainty evidence).
20 Methodological (e.g., sample size) and pain characteristics (e.g., acute vs chronic,
21 diagnosis) did not modify the effect. Pain intensity was lower during or immediately after
22 TENS compared with pharmacological and non-pharmacological treatments used as part
23 of standard of care (low-certainty evidence). Levels of evidence were downgraded because
24 of small-sized trials contributing to imprecision in magnitude estimates. Data were limited
25 for other outcomes including adverse events which were poorly reported, generally mild
26 and not different to comparators. Authors concluded that there was moderate-certainty
27 evidence that pain intensity is lower during or immediately after TENS compared with
28 placebo and without serious adverse events.

29
30 Wu et al. (2022) evaluated the effects of Transcutaneous Electric Nerve Stimulation
31 (TENS) on pain, function, walking ability and stiffness in people with Knee osteoarthritis
32 (KOA). Twenty-nine studies were found (1,398 people, age range 54-85, 74% are female)
33 and fourteen were included in this review. Intervention duration was divided as short term
34 (immediately after intervention), medium term (<4 weeks) and long term (≥ 4 weeks).
35 Active TENS showed greater improvement in Visual Analogue Scale (VAS) than sham
36 TENS. Combining TENS with other interventions produced superior outcomes compared
37 with other interventions for VAS in all the terms. In the meanwhile, TENS combined with
38 other interventions was superior to other interventions for the pain subgroup of Western
39 Ontario and McMaster Universities Arthritis Index in the medium term and long term.
40 TENS combined with other interventions was superior to other interventions for function
41 in the medium term and long term. Authors concluded that TENS could significantly

1 relieve pain, decrease dysfunction and improve walking ability in people with KOA, but it
2 is not effective for stiffness.

3
4 Beltran-Alacreu et al. (2022) determined if the use of PENS is more effective and should
5 be recommended when compared to TENS for the reduction of musculoskeletal pain
6 intensity. Nine RCTs were included in the qualitative analysis, with seven of them in the
7 quantitative analysis ($n = 527$). The overall effect of PENS on pain was statistically but not
8 clinically superior to TENS with a high level of heterogeneity. When only studies with a
9 lower risk of bias ($n = 3$) were analyzed, the heterogeneity decreased, and no difference
10 was observed between TENS and PENS with a moderate recommendation level according
11 to GRADE. There were no data concerning adverse effects. There is low-quality of
12 evidence for more pain intensity reduction with PENS, but the difference was not clinically
13 significant. However, when only studies with low risk of bias are meta-analyzed, there is a
14 moderate quality of evidence that there is no difference when TENS or PENS is applied
15 for pain intensity.

16
17 Evans et al. (2022) summarized the reported efficacy of transcutaneous single nerve
18 stimulators in management of migraine frequency and severity. Fourteen studies, which
19 treated 995 patients, met inclusion criteria, including 7 randomized controlled trials and 7
20 uncontrolled clinical trials. Transcutaneous nerve stimulators reduced headache frequency
21 in episodic migraines (2.81 fewer headache days per month, 95% CI 2.18-3.43, $I^2 = 21\%$)
22 and chronic migraines (2.97 fewer headache days per month). Transcutaneous nerve
23 stimulators reduced headache severity in episodic headaches (2.23 fewer pain scale points).
24 Authors concluded that preventive use of transcutaneous nerve stimulators provided
25 clinically significant reductions in headache frequency in individuals with chronic or
26 episodic migraines. Individuals with episodic migraines also experienced a reduction in
27 headache pain severity following preventive transcutaneous nerve stimulation.

28
29 Fertout et al. (2022) assessed the efficacy of transcutaneous electrical nerve stimulation
30 (TENS) for the management of temporomandibular disorders (TMD) and to determine the
31 indications and most appropriate application modalities in a systematic review. Fourteen
32 articles were retained, corresponding to a total of 532 patients, among which, 285 had a
33 TMD. Immediately after a TENS session, significant relief of pain (19.2% to 77%),
34 significant functional improvement (mouth opening amplitude increased by between 8.7%
35 and 19.46%), and reduced electromyographic activity of the anterior temporalis and
36 masseter muscles were observed. However, studies comparing TENS to other physical
37 medicine modalities (ultrasound and laser) reported equivalent results. Authors concluded
38 that further randomized comparative clinical trials will be necessary to optimize the use of
39 TENS (program, duration of sessions, duration of treatment) for different types of TMD.

40
41 Vance et al. (2022) addressed the continued uncertainty about the clinical efficacy of TENS
42 to alleviate pain, despite years of research and note that this uncertainty is related to the

1 quality of the clinical trials included in systematic reviews. This summary of the evidence
2 includes only trials with pain as the primary outcome. In comparison with their (2014)
3 review, there appears to be improvement in adverse events and parameter reporting.
4 Importantly, stimulation intensity has been documented as critical to therapeutic success.
5 Examinations of the outcomes beyond resting pain, analgesic tolerance, and identification
6 of TENS responders remain less studied areas of research. This literature review supports
7 the conclusion that TENS may have efficacy for a variety of acute and chronic pain
8 conditions, although the magnitude of the effect remains uncertain due to the low quality
9 of existing literature. In order to provide information to individuals with pain and to
10 clinicians treating those with pain, authors suggest that resources for research should target
11 larger, high-quality clinical trials including an adequate TENS dose and adequate timing
12 of the outcome and should monitor risks of bias. Systematic reviews and meta-analyses
13 should focus only on areas with sufficiently strong clinical trials that will result in adequate
14 sample size.

15
16 Davison et al. (2022) systematically reviewed and evaluated available literature examining
17 the effectiveness of using electrical stimulation to promote clinical outcomes after hip
18 fractures. Initial screening indicated 24 articles were appropriate for full-text review, and
19 four articles met the inclusion criteria. In included studies, electrical stimulation (i.e.,
20 TENS) reduced pain (mean difference (MD) = 3.3 points on 10-point Visual Analogue
21 Scale, $p < .001$), improved range of motion (ROM) (MD: 25.7° , $p < .001$), and accelerated
22 functional recovery immediately after hip fracture ($p < .001$). Conflicting evidence existed
23 when using neuromuscular electrical stimulation to improve muscle strength and other
24 functional outcomes (e.g., mobility); however, nine experts advised that longer-term
25 interventions might be necessary to achieve significant improvement in muscle strength.
26 Authors concluded that the available evidence, albeit limited, supports the early application
27 of noninvasive electrical stimulation (e.g., TENS) for improving clinical outcomes (i.e.,
28 reducing pain, improving ROM, and accelerating functional recovery after hip fractures).
29 They could not find conclusive evidence on the effectiveness of using electrical stimulation
30 to improve muscle strength. This review establishes the need for future additional high-
31 quality trials in this field.

32
33 Leemans et al. (2022) estimated the effects of musculoskeletal rehabilitation interventions
34 on movement-evoked pain and to explore the assessment methods/protocols used to
35 evaluate movement-evoked pain in adults with musculoskeletal pain. Meta-analysis was
36 conducted for outcomes with homogeneous data from at least 2 trials. The mean change in
37 movement-evoked pain was the primary outcome measure. Thirty-eight trials were
38 included, and 60 different interventions were assessed. There was moderate-certainty
39 evidence of a beneficial effect of exercise therapy compared to no treatment on movement-
40 evoked pain in adults with musculoskeletal pain. There was low-certainty evidence of a
41 beneficial effect of transcutaneous electrical nerve stimulation compared to no treatment.

1 There was no benefit of transcutaneous electrical nerve stimulation when compared to
2 sham transcutaneous electrical nerve stimulation.

3
4 Verville et al. (2023) evaluated benefits and harms of transcutaneous electrical nerve
5 stimulation (TENS) for chronic primary low back pain (CPLBP) in adults to inform a
6 World Health Organization (WHO) standard clinical guideline. Seventeen RCTs (adults, n
7 = 1027; adults ≥ 60 years, n = 28) out of 2010 records and 89 full text RCTs screened were
8 included. The evidence suggested that TENS resulted in a marginal reduction in pain
9 compared to sham (9 RCTs) in the immediate term (2 weeks), and a reduction in pain
10 catastrophizing in the short term (3 months) with TENS versus no intervention or
11 interventions with TENS specific effects (1 RCT). For other outcomes, little or no
12 difference was found between TENS and the comparison interventions. The certainty of
13 the evidence for all outcomes was very low. Authors concluded that on very low certainty
14 evidence, TENS resulted in brief and marginal reductions in pain (not deemed clinically
15 important) and a short-term reduction in pain catastrophizing in adults with CPLBP, while
16 little to no differences were found for other outcomes.

17
18 DeJesus et al. (2023) provided a systematic review of the literature to analyze the effects
19 of transcutaneous electrical nerve stimulation (TENS) on analgesia on sensitization
20 measures, in studies with chronic musculoskeletal pain and in studies with acute
21 experimental pain. Among 22,252 manuscripts found, 58 studies were included in the
22 systematic review and 35 in the meta-analysis. Thirty-four studies assessed pain intensity;
23 24 studies investigated hyperalgesia; temporal summation was only evaluated in 2 studies;
24 and conditioned pain modulation was not observed in the included studies. Meta-analyses
25 favored TENS, despite its limitations and heterogeneity. Primary hyperalgesia in studies
26 with musculoskeletal pain presented a high level of evidence, while other outcomes
27 presented moderate evidence in the studies that were included. It is not possible to infer
28 results about both temporal summation and conditioned pain modulation. Moderate
29 evidence suggests that TENS promotes analgesia by reducing both central and peripheral
30 sensitization, as shown by the reduction in primary and secondary hyperalgesia, pain
31 intensity at rest, and during movement in experimental acute pain and chronic
32 musculoskeletal pain. Overall, both types of studies analyzed in this review presented
33 meta-analyses favorable to the use of TENS (compared to placebo TENS), showing
34 reductions in both primary and secondary hyperalgesia, as well as decreases in pain
35 intensity at rest and in motion. Authors conclude that this article presents data from the
36 literature on the effect of TENS through sensitization assessments in individuals with
37 chronic musculoskeletal pain, or acute experimental pain. These data contribute to
38 knowledge about pain neuroscience research, using TENS technology.

39 40 **Microcurrent Electrical Nerve Stimulation**

41 There is insufficient evidence in the published peer-reviewed scientific literature to support
42 the safety and effectiveness of MENS including frequency specific microcurrent (FSM).

1 Studies include small patient populations and short-term follow-ups with conflicting
 2 outcomes and in some cases reported outcomes were no better than placebo (Rajpurohit et
 3 al., 2010; Zuim et al., 2006). More recently, microcurrent, using very small electrical
 4 devices contained within wound dressings, has been evaluated as a therapy to speed the
 5 closure of chronic wounds. However, research published to date has not produced findings
 6 that suggest this form of ES can accelerate wound closure (Houghton, 2014). Nair (2018)
 7 did not some positive findings for wound healing, however more research is needed to
 8 confirm results. Iijima and Takahashi (2021) summarized the level of knowledge regarding
 9 the effects of microcurrent therapy (MCT) on musculoskeletal pain in adults. Randomized
 10 controlled trials (RCTs) investigating the effects of MCT on musculoskeletal pain were
 11 included. Additionally, non-RCTs were included to assess the adverse events. The primary
 12 outcomes were pain and adverse events related to MCT. A comprehensive assessment of
 13 4 RCTs and 5 non-RCTs that met the inclusion criteria revealed that MCT significantly
 14 improved shoulder pain (1 study, 40 patients) and knee pain (1 study, 52 patients)
 15 compared with sham MCT without any severe adverse events. MCT has clinically
 16 significant benefits for knee pain. This study also revealed a clinically significant placebo
 17 response in treating knee pain. This evidence highlights the substantial effect of placebo
 18 response in clinical care. Authors concluded that the findings of this meta-analysis
 19 highlight the effect of placebo response in treating knee pain. MCT is a potential, core
 20 nonpharmacologic treatment option in clinical care with minimal adverse events and
 21 should be further investigated.

22
 23 Gikaro et al. (2023) studied the effectiveness of electrophysical agents in fibromyalgia.
 24 The primary outcomes were pain, functional status, and mood. Fifty-four studies involving
 25 3045 patients with fibromyalgia were eligible for qualitative synthesis and 47 (pain), 31
 26 (functional status), and 26 (mood) for network meta-analysis. The network consistency
 27 model revealed that, when compared with true control, transcutaneous electrical nerve
 28 stimulation and microcurrent improved pain symptoms; repetitive transcranial magnetic
 29 stimulation improved patient functional status; and microcurrent, repetitive transcranial
 30 magnetic stimulation, and no treatment significantly improved mood after intervention.
 31 Surface under the cumulative ranking indicated that microcurrent was most likely to be the
 32 best for managing pain and mood; low-level laser therapy for pain and mood; and repetitive
 33 transcranial magnetic stimulation for improving functional status and mood. Authors
 34 concluded that this review found low to moderate quality evidence that microcurrent, laser
 35 therapy, and repetitive transcranial magnetic stimulation are the most effective
 36 electrophysical agents for improving at least one outcome in fibromyalgia.

37 **H-WAVE®**

38
 39 There is insufficient evidence in the published peer reviewed scientific literature to support
 40 the safety and effectiveness of the H-WAVE® electrical stimulators. Blum et al. (2008)
 41 conducted a systematic review and meta-analysis of randomized and nonrandomized
 42 controlled trials to evaluate the safety and efficacy of H-WAVE® therapy. Five studies

1 ($n=6535$) met inclusion criteria. H-WAVE[®] was shown to decrease pain across various
2 chronic soft tissue inflammation and neuropathic pain conditions, decrease pain medication
3 intake ($n=2$ studies) and increase functionality ($n=2$ studies). However, author-noted
4 limitations of the studies included the heterogeneity of the studies, inconsistency of the
5 effects (e.g., reduction in pain medication, functionality), data were obtained from cross-
6 sectional studies, data were subjective in nature (i.e., there were no formal examination
7 findings, test results and/or laboratory values), various outcome measures, potential
8 selection bias of publications for this review, and due to a lack of reported data it was not
9 possible to statistically evaluate the safety of the therapy. Williamson et al. (2021)
10 systematically searched human clinical studies on H-Wave[®] device stimulation (HWDS)
11 was conducted as well as a comprehensive review of articles articulating possible HWDS
12 mechanisms of action. Studies unrelated to H-Wave[®] were excluded. Multiple clinical
13 studies have reported significant benefits for diabetic and non-specific neuropathic pain,
14 where function also improved, and pain medication usage substantially dropped. Authors
15 concluded that low- to moderate-quality HWDS studies have reported reduced pain,
16 restored functionality, and lower medication use in a variety of disorders, although higher-
17 quality research is needed to verify condition-specific applicability. HWDS has enough
18 reasonable evidence to be considered as an adjunctive component of non-opioid multi-
19 modal pain management, given its excellent safety profile and relative low cost. It is
20 important to consider that two authors have a conflict of interest as they are consultants for
21 Electronic Waveform Lab Inc. and have an interest in a positive outcome.

22
23 Allen et al. (2023) compared the relative effects of various forms of electric stimulation
24 (ES) on functional and pain outcomes. Authors report that varying forms of ES have
25 markedly different technical parameters, applications, and indications, based on clinically
26 meaningful impact on pain perception, function improvement, and medication reduction.
27 Authors explain that there is limited quality evidence for most forms of ES, although there
28 are several notable exceptions for treatment of specific indications. Neuromuscular
29 electrical stimulation (NMES) has well-demonstrated beneficial effects for rehabilitation
30 of selective spinal cord injured (SCI), post-stroke, and debilitated inpatients. Functional
31 electrical stimulation (FES) has similarly shown effectiveness in rehabilitation of some
32 stroke, SCI, and foot drop outpatients. H-Wave[®] device stimulation (HWDS) has
33 moderate supportive evidence for treatment of acute and refractory chronic pain,
34 consistently demonstrating improvements in function and pain measures across diverse
35 populations. Interestingly, transcutaneous electrical nerve stimulation (TENS), the most
36 widely used form of ES, demonstrated insignificant or very low levels of pain and
37 functional improvement. Authors concluded that ten of 13 reviewed forms of ES have only
38 limited quality evidence for clinically significant reduction of pain or improvement of
39 function across different patient populations. NMES and FES have reasonably
40 demonstrated effectiveness, albeit for specific clinical rehabilitation indications. HWDS
41 was associated with the most clinically significant outcomes, in terms of functional
42 improvement combined with reduction of pain and medication use. More rigorous long-

1 term clinical trials are needed to further validate appropriate use and specific indications
 2 for most forms of ES. Limitations of this study include that data was collected by the device
 3 manufacturer where there is a potential conflict of interest.

4
 5 Norwood et al. (2024) conducted a retrospective independent statistical analysis on Patient-
 6 Reported Outcome Measures (PROMs) data for users of H-Wave® device stimulation
 7 (HWDS) for chronic low back pain (cLBP) collected by the device manufacturer over a
 8 period of 4 years. Final surveys for 34,192 pain management patients were filtered for pain
 9 chronicity limited to 3-24 months and device use of 22-365 days, resulting in 11,503
 10 patients with "all diagnoses"; this number was then reduced to 2711 patients with
 11 nonspecific cLBP, sprain, or strain. Reported pain was reduced by 3.12 points (0-10 pain
 12 scale), with significant ($\geq 20\%$) relief in 85.28%. Function/activities of daily living (ADL)
 13 improved in 96.36%, while improved work performance was reported in 81.61%.
 14 Medication use decreased or stopped in 64.41% and sleep improved in 59.76%. Over 96%
 15 reported having expectations met or exceeded, service satisfaction, and confidence in
 16 device use, while no adverse events were reported. Subgroup analyses found positive
 17 associations with longer duration of device use, home exercise participation, and working,
 18 whereas older age and longer pain chronicity resulted in reduced benefit. Similar analysis
 19 of the larger all-diagnoses cohort demonstrated near-equivalent positive outcomes. Authors
 20 concluded that outcomes directly reported by cLBP HWDS patients demonstrated
 21 profound positive effects on function and ADL, robust improvement in pain perception,
 22 and additional benefits like decreased medication use, better sleep, and improved work
 23 performance, representing compelling new evidence of treatment efficacy. Limitations of
 24 this study include that data was collected by the device manufacturer where there is a
 25 potential conflict of interest.

26 27 **Interferential Current (IFC)**

28 Studies for IFC are primarily in the form of case reports, case series and some randomized
 29 controlled trials with small patient populations, short-term treatment sessions and short-
 30 term follow-ups. Randomized controlled trials with large patient populations and long-term
 31 follow-ups comparing IFT to established treatment options are lacking. The California
 32 Technology Assessment Forum (2005) evaluated the literature on IFT for the treatment of
 33 musculoskeletal pain and concluded that this treatment modality has not been shown to be
 34 as beneficial as alternative treatments such as nonsteroidal anti-inflammatory drugs and
 35 exercise therapy. Although IFT was found to be a generally safe technique, it did not meet
 36 the CTAF technology assessment criteria for the treatment of musculoskeletal pain.
 37 Fuentes et al. (2010) conducted a systematic review and meta-analysis of randomized
 38 controlled trials ($n=20$) to evaluate the pain-reducing effectiveness of IFC in the
 39 management of musculoskeletal pain. Twenty studies met inclusion criteria. Seven studies
 40 assessed IFC for joint pain (e.g., osteoarthritis), nine for muscle pain (e.g., low back pain,
 41 neck pain), three for soft tissue shoulder pain (e.g., tendinitis) and one for postoperative
 42 pain. Three studies were considered to be of poor methodological quality, 14 of moderate

1 quality and three of high quality. Methodological issues included small sample sizes,
2 heterogeneity of patient population, inappropriate handling of withdrawals and dropouts,
3 and lack of appropriate randomization, concealment of allocation and blinding of patients
4 and assessors. Fourteen studies ($n=1114$) were used for meta-analysis. Only three studies
5 reported adverse events (e.g., blisters, burns, bruising, swelling). The authors concluded
6 that the analgesic effect that IFC is superior to that of the concomitant interventions was
7 unknown; IFC alone was not significantly better than placebo or other therapy at discharge
8 or follow-up; the heterogeneity across studies and methodological limitations prevented
9 conclusive statements regarding analgesic efficacy; and the results should be viewed with
10 caution due to the limited number of studies that used IFC as a monotherapy. The American
11 College of Physicians and the American Pain Society Joint Clinical Practice Guideline for
12 the Diagnosis and Treatment of LBP (Chou and Huffman 2007) concluded that there was
13 not enough evidence to support the use of interferential therapy, TENS, traction,
14 ultrasound, or short-wave diathermy for acute or chronic LBP. These results were based
15 on systematic reviews and randomized trials of one or more of the aforementioned
16 therapies for treatment of acute or chronic LBP that reported pain outcomes, back specific
17 function, general health status, work disability or patient satisfaction. In a review by Poitras
18 and Brosseau (2008), they determined that due to limited studies of sufficient quality, no
19 recommendations could be made for the use of ultrasound, interferential current, or
20 electrical muscle stimulation for the treatment of chronic LBP.

21
22 Facci et al. (2011) compared the effects of TENS and interferential current among patients
23 with nonspecific chronic low back pain. One hundred and fifty patients were randomly
24 divided into three groups: TENS (group 1), interferential current (group 2) and controls
25 (group 3). The patients designated for electrotherapy received ten 30-minute sessions,
26 while the control group remained untreated. All patients and controls were evaluated before
27 and after treatment using a visual analog scale and the McGill Pain and Roland Morris
28 questionnaires, and regarding their use of additional medications. Results showed no
29 statistically significant difference between the TENS and interferential current groups. The
30 only difference was found between these groups and the controls, with noted improvement
31 in outcome measures for the treatment groups.

32
33 According to the AHRQ publication on Non-Invasive Treatments for Low Back Pain
34 (2016), insufficient evidence from four trials exists regarding the effectiveness of
35 interferential therapy versus other interventions, or interferential therapy plus another
36 intervention versus the other interventions alone for low back pain, due to methodological
37 limitations and imprecision. According to the American College of Physician's
38 Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain clinical practice
39 guideline (2017), evidence was insufficient to determine the effectiveness of electrical
40 muscle stimulation and inferential therapy.

1 Rutjes et al. (2009) conducted a systematic review of randomized or quasi-randomized
2 controlled trials of electrical stimulation, including IFT ($n=4$ studies), for the treatment of
3 osteoarthritis of the knee. Due to the poor methodological and reporting quality of the
4 studies, the effectiveness of IFT could not be confirmed.

5
6 Zeng et al. (2015) investigated the efficacy of different electrical stimulation (ES) therapies
7 in pain relief of patients with knee osteoarthritis (OA). Twenty-seven trials and 6 kinds of
8 ES therapies, including high-frequency transcutaneous electrical nerve stimulation (h-
9 TENS), low-frequency transcutaneous electrical nerve stimulation (l-TENS),
10 neuromuscular electrical stimulation (NMES), interferential current (IFC), pulsed
11 electrical stimulation (PES), and noninvasive interactive neurostimulation (NIN), were
12 included. IFC was the only significantly effective treatment in terms of both pain intensity
13 and change pain score at last follow-up time point when compared with the control group.
14 Meanwhile, IFC showed the greatest probability of being the best option among the 6
15 treatment methods in pain relief. However, the evidence of heterogeneity and the limitation
16 in sample size of some studies could be a potential threat to the validity of results. Authors
17 also state that although the recommendation level of the other ES therapies is either
18 uncertain (h-TENS) or not appropriate (l-TENS, NMES, PES and NIN) for pain relief, it
19 is likely that none of the interventions is dangerous.

20
21 Almeida et al. (2018) investigated the effects of transcutaneous electrical nerve stimulation
22 and interferential current on acute and chronic pain. Eight studies with a pooled sample of
23 825 patients were included. In general, both transcutaneous electrical nerve stimulation and
24 interferential current improved pain and functional outcomes without a statistical
25 difference between them. Authors concluded that transcutaneous electrical nerve
26 stimulation and interferential current have similar effects on pain outcome. The low number
27 of studies included in this meta-analysis indicates that new clinical trials are needed.

28
29 In 2019, Kadi et al. (2019) evaluated IFS for treating pain after total knee arthroplasty
30 surgery. A total of 113 individuals were randomized to IFS ($n=57$) or sham treatment
31 ($n=56$). There were 98 individuals (87%) who completed the study. After 30 days, there
32 was no significant difference between groups in pain assessed by a VAS, 0.278. Pain
33 medication use (paracetamol) also did not differ significantly between groups after
34 treatment and neither did outcome measures assessing range of motion or edema. In this
35 study, IFS was not beneficial at improving outcomes after total knee arthroplasty.

36
37 Hussein et al. (2022) aimed to analyze the recently available information regarding the
38 efficacy of IFC in alleviating the pain of musculoskeletal origin. This review included 35
39 trials of variable methodological quality from which 19 trials were selected for the meta-
40 analysis. In general, IFC alone versus placebo demonstrated a significant pain-relieving
41 effect. On the other hand, IFC showed no significant difference when added to standard
42 treatment compared to placebo plus standard treatment or standard treatment alone.

1 Similarly, IFC showed no significant difference when compared to other single
 2 interventions (laser, TENS, cryotherapy). Authors concluded that IFC alone is better than
 3 placebo at discharge. However, the low number of studies raises suspicions about this
 4 conclusion. IFC alone or added to other interventions is not more effective than
 5 comparative treatments in relieving musculoskeletal pain. Rampazo et al. (2022) discussed
 6 the literature findings on the analgesic efficacy of IFC therapy. Authors concluded that
 7 according to the literature, IFC therapy shows significant analgesic effects in patients with
 8 neck pain, low back pain, knee osteoarthritis and post-operative knee pain. Most of the IFC
 9 parameters seem not to influence its analgesic effects. We encourage further studies to
 10 investigate the mechanism of action of IFC therapy.

11
 12 Chen et al. (2022) conducted a systematic review and meta-analysis to assess the
 13 effectiveness of interferential current therapy (IFC) in patients with knee osteoarthritis. Ten
 14 RCTs with 493 patients met the inclusion criteria. Nine RCTs were included in the meta-
 15 analysis. The IFC groups exhibited significant improvements relative to the control groups
 16 for short-term pain scores, long-term pain scores, and short-term Western Ontario and
 17 McMaster Universities Osteoarthritis Index scores. All included studies did not observe
 18 any obvious adverse effects of IFC. IFC can be recommended as a treatment for knee
 19 osteoarthritis because it improves short- and long-term pain and short-term function.
 20 However, large-scale and high-quality RCTs with longer follow-up are required to
 21 establish an appropriate standardized treatment.

22
 23 Rampazo et al. (2023) investigated the effectiveness of IFC in patients with chronic non-
 24 specific low back pain. Thirteen RCTs were considered eligible for this systematic review
 25 (pooled n = 1367). Main results showed moderate-quality evidence and moderate effect
 26 sizes that IFC probably reduces pain intensity and disability compared to placebo
 27 immediately post-treatment, but not at intermediate-term follow-up. Low-quality evidence
 28 with small effect size showed that IFC may reduce pain intensity compared to TENS
 29 immediately post-treatment, but not for disability. There is very low-quality evidence that
 30 IC combined with other interventions (massage or exercises) may not further reduce pain
 31 intensity and disability compared to the other interventions provided in isolation
 32 immediately post-treatment. Authors concluded that moderate-quality evidence shows that
 33 IFC is probably better than placebo for reducing pain intensity and disability immediately
 34 post-treatment in patients with chronic non-specific low back pain.

35 36 **High Volt Galvanic Stimulation (HVGS)**

37 The few studies identified in the literature addressing HVGS were mostly randomized
 38 clinical trials and case studies published before (1997) with small patient populations and
 39 short-term follow-up. Patient selection criteria were lacking. More recently, Snyder et al.
 40 (2010) systematically reviewed the basic-science literature regarding the effects of high-
 41 voltage pulsed stimulation (HVPS) for edema control. Included studies investigated HVPS
 42 and its effect on acute edema formation and included outcome measures specific to edema.

1 Eleven studies met the inclusion criteria. Studies were critiqued by electrical stimulation
 2 treatment parameters: mode of stimulation, polarity, frequency, duration of treatment,
 3 voltage, intensity, number of treatments, and overall time of treatments. According to
 4 Snyder et al., (2010), the available evidence indicates that HVPS administered using
 5 negative polarity, pulse frequency of 120 pulses/s, and intensity of 90% visual motor
 6 contraction may be effective at curbing edema formation. In addition, according to authors,
 7 evidence suggests that treatment should be administered in either four 30-min treatment
 8 sessions (30-min treatment, 30-min rest cycle for 4 h) or a single, continuous 180-min
 9 session to achieve the edema-suppressing effects. Often such treatment occurs in an athletic
 10 training room for college athletes and may not be feasible in an outpatient clinical setting.
 11 Authors suggest that findings supported by the basic science research provides a general
 12 list of treatment parameters that may successfully manage the formation of edema after
 13 acute injury in animal subjects They believe this should facilitate further research related
 14 to HVPS and the effects on edema in humans. At this time, there is insufficient evidence
 15 in the published peer reviewed scientific literature to support the safety and efficacy of
 16 HVG/HVPS stimulation.

17 **PENS and PNT**

18 There is insufficient evidence in the published peer-reviewed literature to support the safety
 19 and effectiveness of PENS or PNT as a treatment option for chronic pain. Overall, studies
 20 have included small patient populations and short-term follow-ups. For low back pain,
 21 most of the literature is of poor quality with all trials evaluating chronic low back pain. In
 22 a technology brief, Hayes (2017) investigated the effectiveness of PENS for the treatment
 23 of low back pain (LBP). Three randomized controlled trials ($n=34$ to 200) evaluated the
 24 efficacy and safety of PENS for chronic LBP (CLBP) in adults and one study evaluated
 25 PNT for subacute radiating LBP. Hayes rated the studies as very low-quality of evidence.
 26 There was no clinically significant improvement with the use of PENS. When compared
 27 with other therapies, PENS monotherapy was favored over treatment with PENS followed
 28 by TENS or TENS alone at one month; however, the difference was not maintained at two
 29 months. Another study reported no difference in outcomes with PENS vs. sham. There is
 30 insufficient evidence to support PENS for the treatment of LBP. Weiner et al. (2008)
 31 conducted a randomized controlled trial ($n=200$) to evaluate the efficacy of PENS in adults
 32 with chronic low back pain. Patients were randomized to either 1) PENS, 2) brief electrical
 33 stimulation to control for treatment expectance (control-PENS), 3) PENS plus general
 34 conditioning and aerobic exercise (GCAE) or to 4) control-PENS plus GCAE. Treatment
 35 was delivered twice a week for 6 weeks to the 50 participants in each group. All groups
 36 reported significantly reduced pain (McGill Pain Questionnaire short form) and disability
 37 and improved gait velocity, which was sustained at 6 months. Significantly fewer fear
 38 avoidance beliefs were reported in the CGAE group compared to the non-CGAE group.
 39 Comparable reduced pain and function were reported by the PENS and control-PENS
 40 group, whether delivered for five minutes or 30 minutes. Thus, the exact dose of electrical
 41 stimulation needed for analgesia could not be determined. PENS and GCAE were more
 42

1 effective than PENS alone in reducing fear avoidance beliefs, but not in reducing pain or
 2 in improving physical function. There was a statistically significant improvement in chair
 3 rise time in the control-PENS plus CGAE compared to control-PENS alone. The overall
 4 drop-out rate was 8%. In the Agency for Healthcare Research and Quality (AHRQ)
 5 publication “Noninvasive Treatments for Low Back Pain” by Chou et al. (2016), the two
 6 studies on PENS that were of fair quality contradicted one another, as one found that PENS
 7 plus exercise was superior to sham plus exercise, while the other did not. Some studies
 8 looked at LBP with radicular signs while others did not or were unclear. Overall, the
 9 literature doesn’t support PENS for treatment of chronic low back pain without radicular
 10 symptoms. There was insufficient evidence to determine effects of PENS versus sham,
 11 PENS plus exercise versus exercise alone, or PENS versus other interventions (TENS),
 12 due to methodological limitations and imprecision. Harms were poorly reported in trials of
 13 PENS.

14
 15 Kang et al. (2007) conducted a single-blinded, randomized study of 63 patients with knee
 16 pain secondary to osteoarthritis. Twenty-eight patients were randomly assigned to the sham
 17 group and 35 to the live treatment group. The study investigated the efficacy of PNT in
 18 reducing knee pain and medication consumption during the first week following treatment.
 19 Pain levels were rated on a 100-mm visual analog pain scale. The live group had greater
 20 efficacy than the sham group in all time periods; however, only in the immediate post-
 21 treatment period did it reach statistical significance ($p=0.0361$). The overall median pain
 22 intensity difference over all periods was 14.5 for the live group and 6.5 for the sham group
 23 and reached statistical significance. At one week follow-up, the live group reported
 24 significantly less medication use than the sham group. Plaza-Manzano et al. (2020)
 25 evaluated the effects of percutaneous electrical stimulation (PENS) alone or as an adjunct
 26 with other interventions on pain and related disability in musculoskeletal pain conditions.
 27 Sixteen studies were included and included heterogeneous musculoskeletal conditions with
 28 short- or midterm follow-ups. The risk of bias was generally low; but the heterogeneity of
 29 the results downgraded the level of evidence. Authors concluded that there is low level of
 30 evidence suggesting the effects of PENS alone or in combination for pain, but not related
 31 disability, in musculoskeletal pain.

32
 33 Beltran-Alacreu et al. (2022) aimed to determine if the use of PENS was more effective
 34 and should be recommended when compared to TENS for the reduction of musculoskeletal
 35 pain intensity. Studies published (2020), comparing the effectiveness of PENS and TENS,
 36 were considered. The main outcome was pain assessed with a visual analog scale or
 37 numerical pain rating scale. Nine RCTs were included in the qualitative analysis, with
 38 seven of them in the quantitative analysis ($n = 527$). The overall effect of PENS on pain
 39 was statistically but not clinically superior to TENS with a high level of heterogeneity.
 40 When only studies with a lower risk of bias ($n = 3$) were analyzed, no difference was
 41 observed between TENS and PENS with a moderate recommendation level according to
 42 GRADE. There were no data concerning adverse effects. There was low-quality of

1 evidence for more pain intensity reduction with PENS, but the difference was not clinically
 2 significant. However, when only studies with low risk of bias are meta-analyzed, there was
 3 a moderate quality of evidence that there is no difference when TENS or PENS is applied
 4 for pain intensity.

5
 6 According to National Institute for Health and Care Excellence (NICE), regarding PENS:

- 7 ▪ PENS versus sham PENS
 - 8 ○ Quality of life
 - 9 ▪ Low quality evidence from 1 study with 89 participants showed a
 - 10 clinically important benefit of PENS compared to sham PENS at ≤ 3
 - 11 months.
 - 12 ▪ Very low to low quality evidence from 1 study with 24 participants
 - 13 showed a clinically important benefit of PENS compared to usual
 - 14 care at ≤ 3 months.
 - 15 ○ Pain reduction
 - 16 ▪ Low quality evidence from 1 study with 89 participants showed a
 - 17 clinically important benefit of PENS compared to sham PENS at ≤ 3
 - 18 months.
 - 19 ▪ Low quality evidence from 1 study with 24 participants showed a
 - 20 clinically important benefit of PENS compared to usual care at ≤ 3
 - 21 months.

22 23 **NMES and FES**

24 **Orthopedic Conditions**

25 Electric stimulated muscle contraction/neuromuscular electric stimulation (NMES) has
 26 been found to enhance muscle function post surgically. Patients who have received an ACL
 27 reconstruction have demonstrated accelerated recovery and greater muscle function when
 28 NMES is used in combination with exercise; however, the impact on functional outcomes
 29 is inconsistent (Cameron, 2017). Similar results were noted with knee OA patients and for
 30 other inflammatory conditions of the knee. Most research studied the use of NMES on the
 31 quadriceps muscle, however clinically NMES may be used for other joints and muscle
 32 groups (Cameron, 2017). NMES has been shown to be part of an effective rehabilitative
 33 regimen for patients following ligament/knee surgery. It may help prevent muscle atrophy
 34 associated with knee immobilization, may enable patients to ambulate sooner, and may
 35 reduce the use of pain medication as well as length of hospital stay (Arvidsson, 1986; Lake,
 36 1992; Gotlin et al, 1994; Snyder-Mackler et al, 1991 and 1995). Bax et al (2005)
 37 systematically reviewed the available evidence for the use of NMES in increasing strength
 38 of the quadriceps femoris. The authors concluded that limited evidence suggests that
 39 NMES can improve strength in comparison with no exercise, but volitional exercises
 40 appear more effective in most situations. The authors' cautious conclusions reflect the
 41 general poor quality of the included studies. It is also important to understand that at the
 42 time NMES is used, it is to re-education the neuromuscular system and engage more motor

1 units with muscle contraction. Given this, the mechanism of strength increase is likely due
2 to improved neuromuscular action vs. a true strength increase of the muscle.

3
4 Monaghan et al. (2010) completed a Cochrane review regarding the effectiveness of NMES
5 as a means of increasing quadriceps strength in patients before and after total knee
6 replacement. Only two studies were identified for inclusion in the review. No significant
7 differences were reported in either study for maximum voluntary isometric torque or
8 endurance between the NMES group and the control group, but significantly better
9 quadriceps muscle activation was reported in the exercise and neuromuscular stimulation
10 group compared with the exercise group alone in the second study. This difference was
11 significant at the mid training (6 week) time point but not at the twelfth week post training
12 time point. Both studies carried a high risk of bias. Mean values were not given for strength,
13 endurance, cross sectional area or quality of life. Pain outcomes, patient satisfaction or
14 adverse effects were not reported in either study. The results were presented as percentage
15 improvements from baseline and the number of subjects in each group was unclear.
16 Authors concluded that the studies found in this review do not permit any conclusions to
17 be made about the application of neuromuscular stimulation for the purposes of quadriceps
18 strengthening before or after total knee replacement. At that time the evidence for the use
19 of neuromuscular stimulation for the purposes of quadriceps strengthening in this patient
20 group is unclear.

21
22 Kim et al. (2010) performed a systematic review of RCTs assessing the effects of NMES
23 on quadriceps strength, functional performance, and self-reported function after ACL
24 reconstruction. Eight randomized controlled trials were included. Authors concluded that
25 NMES combined with exercise may be more effective in improving quadriceps strength
26 than exercise alone, whereas its effect on functional performance and patient-oriented
27 outcomes is inconclusive. Inconsistencies were noted in the NMES parameters and
28 application of NMES. Imoto et al. (2011) systematically evaluated the effectiveness of
29 electrical stimulation on rehabilitation after ligament and meniscal injuries. Seventeen
30 studies evaluating ES after anterior cruciate ligament reconstruction and two studies
31 evaluating ES after meniscectomy were included. There was a statistically significant
32 improvement in quadriceps strength through ES and in functional outcomes 6 to 8 weeks
33 after surgical reconstruction of the anterior cruciate ligament. Authors concluded that there
34 is evidence that ES coupled with conventional rehabilitation exercises may be effective in
35 improving muscle strength and function two months after surgery. Maddocks et al. (2013)
36 evaluated the effectiveness of NMES for improving muscle strength in adults with
37 advanced disease and to examine the acceptability and safety of NMES, and changes in
38 muscle function (strength or endurance), muscle mass, exercise capacity, breathlessness
39 and health-related quality of life. They included randomized controlled trials (RCTs) in
40 adults with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure,
41 cancer or human immunodeficiency virus/acquired immunodeficiency syndrome
42 (HIV/AIDS) comparing a program of NMES as a sole or adjunct intervention to no

1 treatment, placebo NMES or an active control. Eleven studies involving a total of 218
2 participants met the inclusion criteria across COPD, chronic heart failure and thoracic
3 cancer. Authors concluded NMES appears an effective means of improving muscle
4 weakness in adults with progressive diseases such as COPD, chronic heart failure and
5 cancer. Further research is needed to confirm findings and determine most effective
6 parameters.

7
8 Bemner et al. (2016) completed a critically appraised topic on the effectiveness of
9 neuromuscular electrical stimulation in improving voluntary activation of the quadriceps.
10 Four randomized controlled trials (RCTs) met the inclusion criteria and were included. Of
11 the included studies, one reported statistically significant improvements in quadriceps
12 voluntary activation in the intervention group relative to a comparison group, but the
13 statistical significance was not true for another study consisting of the same sample of
14 participants with a different follow-up period. One study reported a trend in the NMES
15 group, but the between group differences were not statistically significant in three of the
16 four RCTs. Current evidence does not support the use of NMES for the purpose of
17 enhancing quadriceps voluntary activation in patients with orthopedic knee conditions.
18 There is level B evidence that the use of NMES alone, or in conjunction with therapeutic
19 exercise, does not enhance quadriceps voluntary activation in patients with orthopedic knee
20 conditions (e.g., anterior cruciate ligament injuries, osteoarthritis, total knee arthroplasty).

21
22 Jones et al. (2016) updated a Cochrane Database review on the effectiveness of
23 neuromuscular electrical stimulation for quadriceps muscle weakness in adults with
24 advanced disease. Programs of NMES appear to be acceptable to patients and have led to
25 improvements in muscle function, exercise capacity, and quality of life. However,
26 estimates regarding the effectiveness of NMES based on individual studies lack power and
27 precision. Randomized controlled trials in adults with advanced chronic respiratory
28 disease, chronic heart failure, cancer, or HIV/AIDS comparing a program of NMES as a
29 sole or adjunct intervention to no treatment placebo NMES, or an active control were
30 included. Eighteen studies (20 reports) involving a total of 933 participants with COPD,
31 chronic respiratory disease, chronic heart failure, and/or thoracic cancer met the inclusion
32 criteria for this update, an additional seven studies since the previous version of this review.
33 All but one study that compared NMES to resistance training compared a program of
34 NMES to no treatment or placebo NMES. Most studies were conducted in a single center
35 and had a risk of bias arising from a lack of participant or assessor blinding and small study
36 size. The quality of the evidence using GRADE comparing NMES to control was low for
37 quadriceps muscle strength, moderate for occurrence of adverse events, and very low to
38 low for all other secondary outcomes. The included studies reported no serious adverse
39 events and a low incidence of muscle soreness following NMES. NMES led to a
40 statistically significant improvement in quadriceps muscle strength. An increase in muscle
41 mass was also observed following NMES, though the observable effect appeared
42 dependent on the assessment modality used. Across tests of exercise performance, mean

1 differences compared to control were statistically significant for the 6-minute walk, but not
2 for the incremental shuttle walk, endurance shuttle walk, or for cardiopulmonary exercise
3 testing with cycle ergometry. Authors concluded that NMES may be an effective treatment
4 for muscle weakness in adults with advanced progressive disease and could be considered
5 as an exercise treatment for use within rehabilitation programs. Further research is very
6 likely to have an important impact on the confidence in the estimate of effect and may
7 change the estimate. Further research to understand the role of NMES as a component of,
8 and in relation to, existing rehabilitation approaches is needed.

9
10 Gatewood et al. (2017) aimed to investigate the efficacy of device modalities used
11 following arthroscopic knee surgery. Outcome measures included: muscle strength, range
12 of motion, swelling, blood loss, pain relief, narcotic use, knee function evaluation and
13 scores, patient satisfaction and length of hospital stay. Twenty-five studies were included
14 in this systematic review, nineteen of which found a significant difference in outcomes.
15 Authors concluded that NMES improve quadriceps strength and overall knee functional
16 outcomes following knee surgery. Yue et al. (2018) assessed the evidence relative to the
17 comparative effectiveness of neuromuscular electrical stimulation (NMES),
18 transcutaneous electrical nerve stimulation (TENS), and electroacupuncture (EA) for
19 improving patient rehabilitation following total knee arthroplasty (TKA). Data were
20 analyzed from 17 randomized controlled trials involving 1,285 procedures: 8 NMES
21 studies (608 procedures), 7 TENS studies (560 procedures), and 2 EA studies (117
22 procedures). Qualitative analysis suggested that NMES was associated with higher
23 quadriceps strength and functional recovery after TKA. Recovery benefits were maximal
24 when the stimulation was performed once or twice a day for 4-6 weeks at an intensity of
25 100-120 mA and frequency of 30-100 Hz. The electrode should be sufficiently large (100-
26 200 cm²) to reduce discomfort. TENS at an intensity of 15-40 mA and frequency of 70-
27 150 Hz provided effective analgesia after TKA. EA at an intensity of 2 mA and frequency
28 of 2 Hz may also provide postoperative analgesia of TKA. Authors concluded that as
29 adjunct modalities, NMES and TENS can effectively improve rehabilitation after TKA
30 without triggering significant intolerance, and maximal benefits depend on optimized
31 parameters and intervention protocols. EA may be an effective adjunct modality for
32 analgesia after TKA.

33
34 Novak et al. (2020) sought to provide guidelines for treatment parameters regarding
35 electrical stimulation by investigating its efficacy in improving muscle strength and
36 decreasing pain in patients with knee osteoarthritis. Nine randomized control trials were
37 included in the review. First, the review confirmed that neuromuscular electrical
38 stimulation is the most effective electrical stimulation treatment in the management of knee
39 OA, and its efficiency is higher when combined with a strengthening program. Second,
40 frequency of at least 50 Hz and no more than 75 Hz with a pulse duration between 200 and
41 400 μ s and a treatment duration of 20 mins is necessary for successful treatment. Peng et
42 al. (2021) evaluated the effect of neuromuscular electrical stimulation (NMES) on

1 quadriceps muscle strength, pain, and function outcomes following total knee arthroplasty
2 (TKA). Nine RCTs that involved 691 patients were included in the meta-analysis. Pooled
3 analysis showed that NMES improved quadriceps muscle strength after TKA within 1
4 month, 1-2 months, 3-4 months, and 12-13 months; pain between 1 and 2 months and
5 between 3 and 6 months, Western Ontario and McMaster Universities Osteoarthritis Index
6 (WOMAC) between 3 and 4 months, timed up and go test (TUG) within 1 month, 3 minute
7 walk test between 3 and 6 months, and SF-36 MCS between 3 and 6 months after TKA.
8 Authors concluded that as a supplementary treatment after TKA, postoperative NMES
9 could improve the short-term to long-term quadriceps muscle strength, mid-term pain, and
10 mid-term function following TKA. However, many outcomes failed to achieve statistically
11 meaningful changes and minimal clinically important difference (MCID), thus the clinical
12 benefits remained to be confirmed.

13
14 Labanca et al. (2022) investigated whether adding NMES to TKA rehabilitation leads to a
15 better quadriceps strength recovery in comparison with standardized rehabilitation. A
16 second aim was to investigate which are the most commonly used NMES pulse settings
17 and their effectiveness. Intervention studies evaluating the effects of a rehabilitation
18 intervention based on quadriceps NMES in patients undergoing TKA were retrieved. Four
19 studies met the inclusion criteria. Due to the limited number and the heterogeneity of the
20 selected studies, it was not appropriate to carry out a meta-analysis. All the studies reported
21 higher quadriceps strength in patients undergoing quadriceps NMES, particularly early
22 after TKA. The addition of NMES or traditional strength training shows similar long-term
23 effects. Short duration and low-intensity NMES have limited effects on quadriceps
24 strength. Heterogeneity was found on NMES methodologies and pulse settings. In
25 conclusion, NMES is effective for quadriceps strength recovery following TKA. NMES
26 intensity and duration are essential for good NMES outcomes on quadriceps strength.
27 Further studies on NMES methodologies, pulse features and settings are required to address
28 the gaps in knowledge on NMES following TKA.

29
30 Culvenor et al. (2022) synthesized the evidence for effectiveness of rehabilitation
31 interventions following ACL and/or meniscal tear on symptomatic, functional, clinical,
32 psychosocial, quality of life and reinjury outcomes. Authors included 22 systematic
33 reviews (142 trials of mostly men) evaluating ACL-injured individuals and none evaluating
34 isolated meniscal injuries. Authors synthesized data from 16 reviews evaluating 12
35 different interventions. Moderate-certainty evidence was observed for: (1) neuromuscular
36 electrical stimulation to improve quadriceps strength; (2) open versus closed kinetic chain
37 exercises to be similarly effective for quadriceps strength and self-reported function; (3)
38 structured home-based versus structured in-person rehabilitation to be similarly effective
39 for quadriceps and hamstring strength and self-reported function; and (4) postoperative
40 knee bracing being ineffective for physical function and laxity. There was low-certainty
41 evidence that: (1) preoperative exercise therapy improves self-reported and physical
42 function postoperatively; (2) cryotherapy reduces pain and analgesic use; (3) psychological

1 interventions improve anxiety/fear; and (4) whole body vibration improves quadriceps
2 strength. There was very low-certainty evidence that: (1) protein-based supplements
3 improve quadriceps size; (2) blood flow restriction training improves quadriceps size; (3)
4 neuromuscular control exercises improve quadriceps and hamstring strength and self-
5 reported function; and (4) continuous passive motion has no effect on range of motion.
6 Authors concluded that the general level of evidence for rehabilitation after ACL or
7 meniscal tear was low. Moderate-certainty evidence indicates that several rehabilitation
8 types can improve quadriceps strength, while brace use has no effect on knee
9 function/laxity.

10
11 According to a 2024 manuscript by Arhos et al., using NMES to augment quadriceps
12 strength training in patients after knee injury and surgery is critical to improving functional
13 outcomes and reducing the risk of reinjury. Setting up NMES with appropriate parameters
14 and dosage to maximum tolerance at each visit is essential for ensuring patients are
15 achieving the optimal treatment effect. With the use of NMES at an early postinjury
16 timepoint, clinicians can attenuate the detrimental long-term effects of quadriceps
17 weakness and inhibition in patients after knee injuries.

18
19 Carvalho et al. (2024) examined the effectiveness of neuromuscular electrical stimulation
20 (NMES) added to the exercise or superimposed on voluntary contractions on patient-
21 reported outcomes measures (PROMs) in people with knee osteoarthritis (KOA). Authors
22 described the effects of intervention according to each PROMs (scores for Pain; Self-
23 reported functional ability; Symptoms (hear clicking, swelling, catching, restricted range
24 of motion, and stiffness); Daily living function; Sports function; and Quality of life) to
25 examine the impact of NMES plus exercise on pain compared with exercise in people with
26 knee OA. Six RCTs (n = 367) were included. In the qualitative synthesis, the systematic
27 literature analysis showed improvement in pain after NMES plus exercise compared with
28 exercise alone in three studies. The other three studies revealed no difference between
29 groups in pain, although similar improvement after treatments. In the meta-analysis, NMES
30 at a specific joint angle combined with exercise was not superior to exercise alone in pain
31 management. There was no additional effect of NMES on exercise on self-reported
32 functional ability, stiffness, and physical function compared with exercise alone. In only
33 one study, symptoms, activities of daily living, sports function, and quality of life improved
34 after whole-body electrostimulation combined with exercise. Authors concluded that this
35 review found insufficient evidence for the effectiveness of NMES combined with exercise
36 in treating knee OA considering PROMs. While pain relief was observed in some studies,
37 more high-quality clinical trials are needed to support the use of NMES added to the
38 exercise in clinical practice.

39
40 Moezy et al. (2024) assessed the effectiveness of NMES and exercise therapy, for
41 improving pain, muscle weakness and function among patients with KOA. A randomized
42 controlled trial was conducted with 75 female patients diagnosed with KOA. Participants

1 were divided into three intervention groups: NMES-only, exercise therapy (Exs) alone, and
2 a combination of NMES and exercise (NMES + Exs). All patients underwent 12 supervised
3 treatment sessions, three times a week. Outcome measures included pain intensity
4 measured by visual analog scale (VAS), knee flexion range of motion (FROM), thigh
5 muscle girth (TG), thickness of the Vastus Medialis Oblique (VMO), timed up and go test
6 (TUG), six-minute walk test (6MWT), and WOMAC scores. Statistical analyses (ANOVA
7 and Kruskal-Wallis) methods were done to compare the amounts at the baseline,
8 immediately after treatment and after 12 weeks. The NMES group exhibited a significant
9 reduction in pain at the 12-week follow-up compared to the other groups. The NMES +
10 Exs group showed better outcomes in terms of FROM, TG, and VMO thickness post-
11 intervention and at the 12-week follow-up. Additionally, NMES was superior in improving
12 TUG and 6MWT post-intervention and during the follow-up assessments. The NMES +
13 Exs group achieved better WOMAC stiffness scores at both post-intervention and follow-
14 up evaluations. Furthermore, at the 12-week follow-up, NMES + Exs group outperformed
15 the others in WOMAC pain and function subscales ($p = 0.003$, $p = 0.017$, respectively),
16 while the NMES group demonstrated better WOMAC total scores compared to the other
17 groups. Authors concluded that the combination of NMES and exercise seems to be an
18 efficient approach for managing KOA, as it enhances knee flexion range and TG, increases
19 VMO thickness, and improves WOMAC scores. On the other hand, NMES alone was
20 found to be effective in improving the physical function of KOA patients.

21 22 **Neurological Conditions**

23 The main goal of stroke rehabilitation is to improve function to allow patients greater
24 independence in their activities of daily living, resulting in an improvement in quality of
25 life. Typical treatment techniques of stroke rehabilitation comprise various combination of
26 range of motion (ROM) and muscle strengthening exercises, mobilization activities, and
27 compensatory techniques. Other key therapies include neurophysiological and/or
28 developmental based methods in which the treatment program incorporates neuromuscular
29 re-education techniques. It is in these situations that FES is used for stroke rehabilitation.
30 It has been utilized to manage contracture of joints, maintain ROM, facilitate voluntary
31 motor control, and reduce spasticity. However, there is insufficient evidence that FES is
32 effective as a rehabilitative tool for patients who suffered strokes. In particular, there are
33 little data supporting the long-term effectiveness of this modality for stroke rehabilitation
34 and other neurologic conditions. In a Cochrane review, Price and Pandyan (2000)
35 ascertained the effectiveness of any form of surface electric stimulation in the prevention
36 and/or treatment of pain around the shoulder at any time after stroke. These investigators
37 concluded that the evidence from randomized controlled studies so far does not confirm or
38 refute that ES around the shoulder after stroke influences reports of pain, but there do
39 appear to be benefits for passive humeral lateral rotation. A possible mechanism is through
40 the reduction of glenohumeral subluxation. The authors stated that further studies are
41 needed. Van Peppen et al (2004) determined the evidence for physical therapy
42 interventions aimed at improving functional outcome after stroke. 151 studies were

1 included in this systematic review; 123 were randomized controlled trials (RCTs) and 28
2 controlled clinical trials (CCTs). Researchers reported that while strong evidence was
3 found regarding use of NMES for glenohumeral subluxation, no or insufficient evidence
4 in terms of functional outcome was found for FES and NMES aimed at improving dexterity
5 or gait performance. Furthermore, in a review on therapeutic orthosis and electric
6 stimulation for upper extremity hemiplegia after stroke, Aoyagi and Tsubahara (2004)
7 stated that despite a number of studies suggesting the effectiveness of electrical stimulation
8 for reducing shoulder subluxation or improving the function of wrist and finger extensors
9 in the short term, the long-term effectiveness after discontinuation as well as the motor
10 recovery mechanism remains unclear. More research is needed to determine the evidence-
11 based effectiveness of electrical stimulation for stroke survivors. Koyuncu et al. (2010)
12 conducted a randomized controlled trial to evaluate FES for the treatment of 50 hemiplegic
13 patients with shoulder subluxation and pain secondary to stroke. All patients received
14 conventional rehabilitation and the study group also received FES stimulation to the
15 supraspinatus and posterior deltoid muscles on the hemiplegic side, five times a day, one
16 hour each for four weeks. Comparison of the resting AROM vs. PROM VAS value changes
17 showed no significant difference between the groups. There was a significant difference
18 between the two groups for the amount of change in shoulder subluxation in favor of the
19 study group, indicating increased stability of the shoulder. Authors suggest that that
20 applying FES treatment to the supraspinatus and posterior deltoid muscles in addition to
21 conventional treatment when treating the subluxation in hemiplegic patients is more
22 beneficial than conventional treatment by itself.

23
24 Morawietz and Moffat (2013) provided an overview of, and evaluate the current evidence
25 on, locomotor training approaches for gait rehabilitation in individuals with incomplete
26 spinal cord injury to identify the most effective therapies. Only randomized controlled trials
27 evaluating locomotor therapies after incomplete spinal cord injury in an adult population
28 were included. Eight articles were included in this review. Five compared body-weight-
29 supported treadmill training (BWSTT) or robotic-assisted BWSTT with conventional gait
30 training in acute/subacute subjects (≤ 1 y postinjury). The remaining studies each compared
31 3 or 4 different locomotor interventions in chronic participants (> 1 y postinjury). Sample
32 sizes were small, and study designs differed considerably impeding comparison. Only
33 minor differences in outcomes measures were found between groups. Gait parameters
34 improved slightly more after BWSTT and robotic gait training for acute participants. For
35 chronic participants, improvements were greater after BWSTT with functional electrical
36 stimulation and overground training with functional electrical stimulation/body-weight
37 support compared with BWSTT with manual assistance, robotic gait training, or
38 conventional physiotherapy. Authors concluded that evidence on the effectiveness of
39 locomotor therapy is limited. All approaches show some potential for improvement of
40 ambulatory function without superiority of 1 approach over another. More research on this
41 topic is required.

1 Gu and Ran (2016) reviewed the evidence for the effect of functional electrical stimulation
2 (FES) on shoulder subluxation, pain, upper arm motor function, daily function, and quality
3 of life in patients with stroke when added to conventional therapy. The results of this meta-
4 analysis showed a significant difference in shoulder subluxation between the FES group
5 and the placebo group, only if FES was applied early after stroke. And a significant
6 difference was observed posttreatment in the Fugl-Meyer Motor Assessment between the
7 FES group and the placebo group. No effects were found on pain, upper arm motor
8 function, daily function, and quality of life outcomes. Authors concluded that FES can be
9 used to prevent or reduce shoulder subluxation early after stroke. However, findings did
10 not support the efficacy of use of FES for pain reduction, improvement in arm strength,
11 movement, functional use, daily function, or quality of life after stroke.

12
13 FES has been proposed for improving ambulation in patients with gait disorders such as
14 drop foot, hemiplegia due to stroke, cerebral injury, or incomplete spinal cord injury. As
15 an example, FES can be applied to the anterior tibialis muscle to assist in dorsiflexion
16 during gait for patients with foot drop. Several small studies support the integration of FES
17 for patients with spinal cord injury or who have sustained a stroke for various activities.
18 As long as the peripheral nervous system is intact, any patients with central nervous system
19 dysfunction may benefit from FES use. Effectiveness of FES may be likely due to the direct
20 effect of muscle strengthening in addition to increased excitability of the motor neuron
21 pool produced by the motor level electrical stimulation (Cameron, 2022). Yan and
22 colleagues (2005) evaluated whether FES was more effective in promoting motor recovery
23 of the lower extremity and walking ability than standard rehabilitation alone. A total of 46
24 patients were assigned randomly to one of three groups receiving standard rehabilitation
25 with FES or placebo stimulation or alone (control). They received treatment for 3 weeks,
26 starting shortly after having the stroke. Outcome measurements included composite
27 spasticity score, maximum isometric voluntary contraction of ankle dorsi-flexors and
28 planter-flexors and walking ability. After 3 weeks of treatment, those receiving FES plus
29 standard rehabilitation did better on several measures of lower limb functioning compared
30 to the other 2 groups. All patients in the FES group were able to walk after treatment, and
31 84.6 % of them returned home, in comparison with the placebo (53.3 %) and control (46.2
32 %) groups. However, these authors stated that generalization of the results from this study
33 should be performed with caution because of subject selection criteria, which did not cover
34 all stroke categories or subjects aged younger than 45 or older than 85 years. Randomized
35 controlled trials and case series have primarily included small patient populations ($n=14-$
36 64) with short-term follow-ups and heterogeneous treatment regimens and outcome
37 measures (Esnour, et al., 2010; Nooijen, et al., 2009; Everaert, et al., 2010; Stein, et al.,
38 2010; Barrett, et al., 2010; Postans, et al., 2004).

39
40 In a Cochrane review on electrostimulation for promoting recovery of movement or
41 functional ability after stroke, Pomeroy et al (2006) sought to find out whether
42 electrostimulation improved functional motor ability to do activities of daily living.

1 Twenty-four trials were included in the review. Authors reported that electrostimulation
2 improved some aspects of functional motor ability and some aspects of motor impairment
3 and normality of movement over no treatment. For electrostimulation compared with
4 placebo, this review found that electrostimulation improved an aspect of functional motor
5 ability. For electrostimulation compared with conventional physical therapy, they found
6 that electrostimulation improved an aspect of motor impairment. There were no statistically
7 significant differences between electrostimulation and control treatment for all other
8 outcomes. Authors caution that these results need to be interpreted with reference to the
9 following: (1) the majority of analyses only contained one trial; (2) variation was found
10 between included trials in time after stroke, level of functional deficit, and dose of
11 electrostimulation; and (3) the possibility of selection and detection bias in the majority of
12 included trials. Researchers conclude that data were insufficient to inform clinical use of
13 electrostimulation for neuromuscular re-training. Research is needed to address specific
14 questions about the type of electrostimulation that might be most effective, in what dose
15 and at what time after stroke. Pereira et al. (2012) conducted a systematic review of
16 randomized controlled trials to evaluate the effectiveness of FES in improving lower limb
17 function in chronic stroke patients (mean time since stroke ≥ 6 mos.). Seven RCTs
18 including a pooled sample size of 231 participants met inclusion criteria. Analysis revealed
19 a small but significant treatment effect in favor of FES on the 6-minute walk test. Authors
20 conclude that FES may be an effective intervention in the chronic phase post stroke.
21 However, its therapeutic value in improving lower extremity function and advantage over
22 other gait training approaches remains uncertain.

23
24 More recently, Howlett et al. (2015) conducted a systematic review and meta-analysis to
25 investigate the effectiveness of FES in improving activity following a stroke and to
26 determine if FES is more effective than training alone. Eighteen randomized and non-
27 randomized comparisons studies ($n=485$) met inclusion criteria. One study had three arms
28 which was counted as a separate comparison group ($n=19$ comparisons). Because of
29 incomplete data, all trials were not included in the meta-analysis. Only measures that
30 reflected the International Classification of Function domain of activity performance were
31 used in analyses. In some trials only one measure was available and in trials with more than
32 one measure the reviewers chose the measure that most closely reflected the task being
33 trained. Various outcome measures were used for lower-limb and upper-limb activity
34 assessments. FES had a small to moderate effect on activity compared to no FES or placebo
35 and had a moderate effect on activity compared to training alone. However, due to the lack
36 of available data, the authors were unable determine if FES improved subject participation
37 or if the benefits of FES are long-term. Author-noted limitations of the studies included:
38 the lack of blinding of therapist and participants; the potential of small trial bias with 25
39 being the average number of participants per trial; and combining data for the meta-analysis
40 that was collected using different outcome measures. There was also heterogeneity of
41 subject characteristics including time after stroke, the limb that was trained, and the
42 severity of stroke. In a randomized controlled study, Bethoux et al. (2015) compared

1 changes in gait quality and function between FES and ankle-foot orthoses (AFOs) in
2 individuals with foot drop post-stroke over a 12-month period. They completed a follow-
3 up analysis on a multi-center unblinded RCT that had been conducted at 30 rehabilitation
4 centers. Subjects continued to wear their randomized device for all home and community
5 ambulation for another 6 months to final 12-month assessments. Primary outcomes were
6 the 10 Meter Walk Test (10MWT) and device-related serious adverse event rate. Secondary
7 outcome measures were the 6-Minute Walk Test (6MWT), GaitRite Functional
8 Ambulation Profile, and the Modified Emory Functional Ambulation Profile (mEFAP). A
9 total of 495 subjects were randomized, and 384 completed the 12-month follow-up. Both
10 FES and AFO groups showed statistically and clinically significant improvement for
11 10MWT. No significant between group differences were found. At 12 months, both FES
12 and AFOs continue to demonstrate equivalent gains in gait speed. Results suggest that
13 long-term FES use may lead to additional improvements in walking endurance and
14 functional ambulation; further research is needed to confirm these findings.

15
16 Prenton et al. (2016) conducted a systematic review and meta-analysis of randomized
17 controlled trials to compare the effects of FES and ankle foot orthoses (AFO) for foot drop
18 of central neurological origin. Five synthesized randomized controlled trials ($n=815$) were
19 included. Orthotics included customized and off the shelf AFOs. Meta-analysis of the
20 outcomes of the 10-meter (m) walking speed (5 trials) ($n=789$) and functional exercise
21 capacity (3 trials) ($n=761$) showed between group comparable improvements which were
22 not significant ($p=0.79$; $p=0.31$, respectively). There were no significant differences in
23 meta-analysis for the 10-meter (m) walk test using data at short- (4 trials; $n=771$) and
24 longer-term (3 trials; $n=713$) time-points for FES vs. AFO. There was a significant
25 difference ($p=0.04$) in favor of the AFO for the medium-term 10-m test. Analyses revealed
26 between group comparable improvements in functional exercise capacity. The timed up-
27 and-go test was reported in two studies, and both reported between-group comparable
28 improvements ($p=0.812$ and $p=0.539$). The mobility domain of the Stroke Impact Scale
29 (SIS) was reported by three trials ($n=701$) and showed comparable between-group
30 improvements ($p=0.80$). This meta-analysis indicates that AFOs have positive combined-
31 orthotic effects on walking that are equivalent to FES for foot-drop caused by stroke
32 regardless of length of use. The fact that the reviewed trials only included subjects age 18
33 years and older who had experienced a stroke prevents the results from being generalized
34 to other populations. Other limitations of the analysis included the risk of bias in the studies
35 and the heterogeneity of the AFO and FES devices used.

36
37 Stein et al. (2015) conducted a systematic review ($n=29$ studies; 940 subjects) and meta-
38 analysis ($n=14$ studies; 383 subjects) of randomized controlled trials to evaluate the effect
39 of NMES on spastic muscles after stroke. The primary outcome was spasticity, assessed
40 by the Modified Ashworth Scale. The secondary outcome was range of motion ($n=13$
41 studies), assessed by a goniometer. Outcomes were conflicting. Some studies reported an
42 improvement in spasticity ($n=12$ studies) and range of motion ($n=13$ studies) with NMES

1 when used as an adjunctive therapy and some studies did not. Based on sensitivity analysis,
2 no effects on spasticity and range of motion were seen on wrists and no effect on spasticity
3 of elbows. The degree of spasticity and the criteria for spasticity assessment varied. Most
4 studies showed evidence of bias. Other study limitations included: heterogeneity of
5 outcome measures; time of treatment following stroke (1.5 months to more than 12
6 months); various degrees of chronic tissue changes; heterogeneity of conventional
7 therapies used (e.g., active leg cycling, occupational therapy, stretching, Botulinum Toxin
8 A), missing data; and heterogeneity of stimulation frequency and pulse duration. Large
9 scale and high-quality randomized controlled trials are needed to establish the true efficacy
10 NMES in this patient population. Sharififar et al. (2018) aimed to determine the effect on
11 motor function of extremities of adding an electrical sensory modality without motor
12 recruitment before or with routine rehabilitation for hemiparesis after stroke by a
13 comprehensive systematic review and meta-analysis. Authors concluded that electrical
14 sensory input could contribute to routine rehabilitation to improve early post-stroke lower-
15 extremity impairment and late motor function, with no change in spasticity. Prolonged
16 periods of sensory stimulation such as TENS combined with activity can have beneficial
17 effects on impairment and function after stroke.

18
19 Kristensen et al. (2021) sought to determine the effectiveness of neuromuscular electrical
20 stimulation (NMES) toward improving activities of daily living (ADL) and functional
21 motor ability post stroke and to investigate the influence of paresis severity and the timing
22 of treatment initiation for the effectiveness of NMES. The inclusion criteria were
23 randomized controlled trials exploring the effect of NMES toward improving ADL or
24 functional motor ability in survivors of stroke. The search identified 6,064 potential articles
25 with 20 being included. Data from 428 and 659 participants (mean age, 62.4 years; 54%
26 male) for outcomes of ADL and functional motor ability, respectively, were pooled in a
27 random-effect meta-analysis. The analysis revealed a significant positive effect of NMES
28 toward ADL, whereas no effect on functional motor ability was evident. Subgroup analyses
29 showed that application of NMES in the subacute stage and in the upper extremity
30 improved ADL, whereas a beneficial effect was observed for functional motor abilities in
31 patients with severe paresis. Authors concluded that the results of the present meta-analysis
32 are indicative of potential beneficial effects of NMES toward improving ADL post stroke,
33 whereas the potential for improving functional motor ability appears less clear.
34 Furthermore, subgroup analyses indicated that NMES application in the subacute stage and
35 targeted at the upper extremity is efficacious for ADL rehabilitation and that functional
36 motor abilities can be positively affected in patients with severe paresis.

37
38 Loh et al. (2022) summarized the effect size of CCFES through measures of upper
39 extremity motor recovery compared with that of neuromuscular electrical stimulation
40 (NMES). Six RCTs were selected, and 267 participants were included. The Upper
41 Extremity Fugl-Meyer assessment (UEFMA) was included in all studies, the Box and
42 Blocks test (BBT) and active range of motion (AROM) were included in 3 and 4 studies,

1 respectively. The modified Barthel Index (mBI) and Arm Motor Abilities Test (AMAT)
2 were included in 2 and 3 studies, respectively. The CCFES group demonstrated greater
3 improvement than the NMES did in UEFMA, AROM, and mBI. However, the results for
4 AMAT did not differ significantly. Authors concluded that contralaterally controlled
5 functional electrical stimulation produced greater improvements in upper extremity
6 hemiplegia in people with stroke than NMES did.

7
8 Johnston et al. (2021) provided evidence to guide clinical decision-making for the use of
9 either ankle-foot orthosis (AFO) or functional electrical stimulation (FES) as an
10 intervention to improve body function and structure, activity, and participation as defined
11 by the International Classification of Functioning, Disability and Health (ICF) for
12 individuals with poststroke hemiplegia with decreased lower extremity motor control
13 within this clinical practice guideline. A review of literature published through November
14 2019 was performed across 7 databases for all studies involving stroke and AFO or FES.
15 Data extracted included time post-stroke, participant characteristics, device types,
16 outcomes assessed, and intervention parameters. Outcomes were examined upon initial
17 application and after training. Recommendations were determined on the basis of the
18 strength of the evidence and the potential benefits, harm, risks, or costs of providing AFO
19 or FES. One-hundred twenty-two meta-analyses, systematic reviews, randomized
20 controlled trials, and cohort studies were included. Strong evidence exists that AFO and
21 FES can each increase gait speed, mobility, and dynamic balance. Moderate evidence exists
22 that AFO and FES increase quality of life, walking endurance, and muscle activation, and
23 weak evidence exists for improving gait kinematics. AFO or FES should not be used to
24 decrease plantar flexor spasticity. Studies that directly compare AFO and FES do not
25 indicate overall superiority of one over the other. But evidence suggests that AFO may lead
26 to more compensatory effects while FES may lead to more therapeutic effects. Due to the
27 potential for gains at any phase post-stroke, the most appropriate device for an individual
28 may change, and reassessments should be completed to ensure the device is meeting the
29 individual's needs. It is important to note that this CPG cannot address the effects of one
30 type of AFO over another for the majority of outcomes, as studies used a variety of AFO
31 types and rarely differentiated effects. The recommendations also do not address the
32 severity of hemiparesis, and most studies included participants with varied baseline
33 ambulation ability. Authors summarize that this CPG suggests that AFO and FES both lead
34 to improvements post-stroke. Future studies should examine timing of provision, device
35 types, intervention duration and delivery, longer term follow-up, responders versus
36 nonresponders, and individuals with greater impairments.

37
38 van der Scheer et al. (2021) summarized and appraise evidence on functional electrical
39 stimulation (FES) cycling exercise after spinal cord injury (SCI), in order to inform the
40 development of evidence-based clinical practice guidelines. Ninety-two studies met the
41 eligibility criteria, comprising 999 adults with SCI representing all age, sex, time since
42 injury, lesion level and lesion completeness strata. For muscle health (e.g., muscle mass,

1 fiber type composition), significant improvements were found in 3 out of 4 Level 1-2
2 studies, and 27 out of 32 Level 3-4 studies (GRADE rating: 'High'). Although lacking Level
3 1-2 studies, significant improvements were also found in nearly all of 35 Level 3-4 studies
4 on power output and aerobic fitness (e.g., peak power and oxygen uptake during an FES
5 cycling test) (GRADE ratings: 'Low'). Authors concluded that the evidence indicates that
6 FES cycling exercise improves lower-body muscle health of adults with SCI and may
7 increase power output and aerobic fitness. Mahmoudi et al. (2021) systematically reviewed
8 the effect of functional electrical stimulation (FES) on balance as compared to conventional
9 therapy alone in post-stroke. Nine papers were included in this review. The total number
10 of participants in this review study was 255. The age of participants ranged from 20 to 80
11 years. Stroke patients were in chronic phase ($n = 5$) and in subacute phase ($n = 4$). Various
12 parameters, including the target muscles, the treatment time per session (20 min-2 h),
13 number of treatment sessions (12-48) and FES frequency (25-40 Hz), were assessed.
14 Among the studies, significant between-group improvement favoring FES in combination
15 with conventional therapy was found on the Berg Balance Scale ($n = 7$) and Timed Up and
16 Go Scale ($n = 4$) when compared to conventional therapy alone. There was no adverse
17 effect reported by any studies. Authors concluded that FES was reported to be more
18 beneficial in balance improvement among stroke patients when combined with
19 conventional balance therapy. The studies were limited by low-powered, small sample
20 sizes ranging from 9 to 48, and lack of blinding, and reporting of missing data.

21
22 Ye et al. (2021) comprehensively and critically appraised the clinical benefits and
23 engineering designs of functional electrical stimulation (FES)-rowing for management of
24 individuals with spinal cord injury (SCI). Comparison of peak oxygen consumption
25 ($\dot{V}O_{2peak}$) rates showed that $\dot{V}O_{2peak}$ during FES-rowing was significantly higher than
26 arm-only exercise; FES-rowing training improved $\dot{V}O_{2peak}$ by 11.2% on average, with a
27 4.1% increase in $\dot{V}O_{2peak}$ per month of training. FES-rowing training reduced bone
28 density loss with increased time postinjury. The rowing ergometer used in 2 studies
29 provided motor assistance during rowing. Studies preferred manual stimulation control
30 ($n=20$) over automatic ($n=4$). Authors concluded that results suggest FES-rowing is a
31 viable exercise for individuals with SCI that can improve cardiovascular performance and
32 reduce bone density loss. Further randomized controlled trials are needed to better
33 understand the optimal set-up for FES-rowing that maximizes the rehabilitation outcomes.
34 Karamian et al. (2022) summarized the various forms of electrical stimulation technology
35 that exist and their applications for SCI. With regards to FES and NMES, authors report
36 positive findings for improvement in muscle function and functional activities.

37
38 Chiu et al. (2014) conducted a systematic review to determine the effectiveness of FES vs.
39 activity training alone in children with cerebral palsy. Five randomized controlled trials
40 met inclusion criteria. The experimental group had to receive FES while performing an
41 activity such as walking. The studies used outcome measures of activity that best reflected
42 the activity used in the study. When continuous data (e.g., walking speed) were not

1 available, ordinal data (e.g., Gross Motor Function Measurement) were used. A statistically
2 significant between-group difference in activity in the FES groups was reported for the
3 three studies that compared FES with no FES. Improvements were seen immediately after
4 the intervention period, but long-term follow-up was not reported. The two studies
5 investigating the effects of FES vs. activity training reported no significant differences
6 between the groups. The results reported that FES is better than no FES, but that FES is
7 not more effective than activity training. Outcomes could not be pooled for meta-analysis
8 due to incomplete data and the large difference in baseline scores. Due to the inability to
9 conduct a meta-analysis, the authors stated that firm conclusions could not be made.
10 Limitations of the studies included the heterogeneous patient populations and the variations
11 in the frequency, intensity and duration of the interventions. Bosques et al. (2016)
12 discussed the potential clinical applicability, while clarifying the differences in electrical
13 stimulation (ES) treatments and the theory behind potential benefits to remediate functional
14 impairments in youth in a comprehensive review. The synthesis of the literature suggests
15 that improvements in various impairments may be possible with the integration of ES. Most
16 studies were completed on children with cerebral palsy (CP). Electrical stimulation may
17 improve muscle mass and strength, spasticity, passive range of motion (PROM), upper
18 extremity function, walking speed, and positioning of the foot and ankle kinematics during
19 walking. Sitting posture and static/dynamic sitting balance may be improved with ES to
20 trunk musculature. Bone mineral density may be positively affected with the use of
21 Functional Electrical Stimulation (FES) ergometry. ES may also be useful in the
22 management of urinary tract dysfunction and chronic constipation. Among all reviewed
23 studies, reports of direct adverse reactions to electrical stimulation were rare. In conclusion,
24 NMES and FES appear to be safe and well tolerated in children with various disabilities.
25 Authors suggested that psychiatrists and other healthcare providers better understand the
26 indications and parameters in order to utilize these tools effectively in the pediatric
27 population.

28
29 Springer and Khamis (2017) completed a systematic review on the orthotic and therapeutic
30 effects of functional electrical stimulation on gait in people with multiple sclerosis (MS).
31 Twelve relevant studies were reviewed. Eleven studies reported the effects of peroneal
32 stimulation. Most found a significant orthotic effect (measured during stimulation), mainly
33 on walking speed. Only three assessed the therapeutic effect (carry-over), which was not
34 significant. Authors concluded that the evidence suggests that FES has a positive orthotic
35 effect on walking in patients with MS. Yet, more robust trials are needed to substantiate
36 this finding. Therapeutic efficacy of FES was not demonstrated.

37
38 Ou et al. (2022) assessed the effects of neuromuscular electrical stimulation on the upper
39 limbs of patients with cerebral palsy. Eight randomized controlled trials (N = 294) were
40 included in the meta-analysis. Compared with traditional physical therapy, sensorimotor
41 training and task-oriented training, constraint-induced movement therapy, dynamic
42 bracing, and conventional robot-assisted therapy, neuromuscular electrical stimulation in

1 combination with these therapies resulted in significantly greater functional scale scores,
2 muscle strength of upper limbs, and spasticity of upper limbs but did not improve the wrist
3 range of motion. In addition, the effect of neuromuscular electrical stimulation on
4 functional scale scores remained after 3-mo follow-up. Authors concluded that
5 neuromuscular electrical stimulation effectively improved hand function, muscle strength,
6 and spasticity in patients with cerebral palsy.

7
8 Chen et al. (2023) investigated whether neuromuscular electrical stimulation improves
9 mobility in children with spastic cerebral palsy. A total of 14 randomized controlled trials
10 (2 crossover studies and 12 parallel studies including 421 patients) were included in this
11 meta-analysis. Compared with the control group (conventional physical therapy), the
12 treatment group exhibited greater improvement in walking speed and the standing,
13 walking, running, and jumping dimension of the Gross Motor Function Measure. Authors
14 concluded that neuromuscular electrical stimulation improved mobility in children with
15 spastic cerebral palsy, particularly in standing, running, and jumping function, and it is safe
16 for children with spastic cerebral palsy.

17
18 Zhu et al. (2022) summarized and analyzed the relationship between functional electrical
19 stimulation treatment and gait parameter changes in children with cerebral palsy. Nine
20 papers were included in the analysis, with a total of 282 children with cerebral palsy,
21 including 142 patients in the functional electrical stimulation treatment group and 140
22 patients in the comfort treatment, general nursing, or other physical therapy. The results
23 showed that functional electrical stimulation could increase the walking speed of children
24 with cerebral palsy and increase the walking step length of children with cerebral palsy.
25 Authors concluded that functional nerve stimulation treatment could increase the gait speed
26 and step length of children with cerebral palsy, which could improve the walking of
27 children with cerebral palsy. Furthermore, this study needs more research data to support
28 the authors' findings.

29
30 Tenberg et al. (2023) investigated the comparative effectiveness of various exercise
31 interventions of the upper limb for individuals with an acute or subacute stroke. The
32 primary outcome was upper limb motor function, secondary outcomes were activities of
33 daily living and social participation, both assessed at post-intervention and follow-up.
34 Nonspecific/multimodal active upper limb therapy was the standard comparator. This
35 review involved 145 randomized controlled trial on 6,432 participants and 45 different
36 treatment categories. The network meta-analysis analyzed 119 randomized controlled trials
37 on 5,553 participants and 41 different treatment categories. Electrical stimulation
38 combined with task-specific training, high-volume constraint-induced movement therapy,
39 and strength training were the most effective interventions. Authors concluded that
40 electrical stimulation combined with task-specific training (low evidence), high-volume
41 constraint-induced movement therapy (moderate evidence), and strength training (low
42 evidence) were the most effective interventions in improving upper limb motor function in

1 individuals with a stroke. As the results were sensitive against a high risk of bias, likewise,
2 these interventions should receive more attention in research and practice. Due to the
3 heterogeneous use, electrical stimulation in combination with task-specific training should
4 be further investigated in well-designed studies alongside other successful interventions
5 (e.g., constraint-induced movement therapy).

6
7 Wu et al. (2023) analyzed and discussed the efficacy of various electrical stimulation
8 therapy (EST) treatments in alleviating pain among MS patients. Ten RCTs containing 315
9 participants were included. The pooled data from 8 trials including 267 participants showed
10 that the EST was superior in alleviating pain evaluated by the visual analog scale. In
11 subgroup analysis, medium-term EST treatment showed the highest effect size compared
12 to short-term and long-term treatment. However, no significant differences were found in
13 terms of pain-related quality of life, depression, fatigue, and pain-related disability. No
14 adverse events related to EST were reported. A high risk of bias was identified in three of
15 the ten included studies. Authors concluded that EST is effective and safe for alleviating
16 pain in MS, but it should be noted that limited sample sizes and methodological issues were
17 present in the included studies. More robust assessment criteria and high-quality RCTs are
18 required for patients with MS.

19
20 Hwang and Song (2023) summarized the rehabilitative effects of electrical stimulation
21 therapy on gait performance in stroke patients. This review included randomized controlled
22 trials (RCT) investigating the therapeutic effects of electrical stimulation in stroke patients
23 throughout five databases. This review qualitatively synthesized 20 studies and
24 quantitatively analyzed 11 RCTs. Functional electrical stimulation (FES) was the most
25 commonly used electrical stimulation type to improve postural stability and gait
26 performance in stroke patients. The clinical measurement tools commonly used in the three
27 studies to assess the therapeutic effects of FES were Berg balance scale (BBS), 10-meter
28 walk test (10MWT), 6-minute walk test (6mWT), and gait velocity. The BBS score and
29 gait velocity had positive effects in the FES group compared with the control group, but
30 the 10MWT and 6mWT showed the same effects between the two groups. The
31 heterogeneity of BBS scores was also high. Authors concluded that the results of this
32 review suggest that electrical stimulation shows little evidence of postural stability and gait
33 performance in stroke patients, although some electrical stimulations showed positive
34 effects on postural stability and gait performance.

35
36 Máté et al. (2023) examined the evidence regarding the potential of hybrid functional
37 electrical stimulation (FES) cycling for improving cardiorespiratory fitness for people with
38 a mobility disability related to a central nervous system (CNS) disorder. From a total of
39 280 articles, 13 were studies included. During acute bouts of exercise, hybrid FES cycling
40 was moderately more effective than arm crank exercise (ACE) in increasing $\dot{V}o_{2peak}$ from
41 rest. There was a large effect on the increase of $\dot{V}o_{2peak}$ from rest for hybrid FES cycling
42 compared with FES cycling. Longitudinal training with hybrid FES cycling showed a

1 significant improvement in $\dot{V}O_{2peak}$ from pre to post intervention with a large, pooled
 2 effect size of 0.83. Authors concluded that hybrid FES cycling produced higher $\dot{V}O_{2peak}$
 3 compared with ACE or FES cycling during acute bouts of exercise. Hybrid FES cycling
 4 can improve cardiorespiratory fitness in people with SCI. Additionally, there is emerging
 5 evidence that hybrid FES cycling might increase aerobic fitness in people with mobility
 6 disability related to CNS disorders.

7
 8 Andreopoulou et al. (2023) conducted an umbrella review of systematic reviews on
 9 functional electrical stimulation (FES) to improve walking in adults with an upper motor
 10 neuron lesion. The methodological quality of the 24 eligible reviews (stroke, n = 16; spinal
 11 cord injury (SCI), n = 5; multiple sclerosis (MS); n = 2; mixed population, n = 1) ranged
 12 from critically low to high. Stroke reviews concluded that FES improved walking speed
 13 through an orthotic (immediate) effect and had a therapeutic benefit (i.e., over time)
 14 compared to usual care (low certainty evidence). There was low-to-moderate certainty
 15 evidence that FES was no better or worse than an Ankle Foot Orthosis regarding walking
 16 speed post 6 months. MS reviews concluded that FES had an orthotic but no therapeutic
 17 effect on walking. SCI reviews concluded that FES with or without treadmill training
 18 improved speed but combined with an orthosis was no better than orthosis alone. FES may
 19 improve quality of life and reduce falls in MS and stroke populations. Authors concluded
 20 that FES has orthotic and therapeutic benefits. Certainty of evidence was low-to-moderate,
 21 mostly due to high risk of bias, low sample sizes, and wide variation in outcome measures.
 22 Future trials must be of higher quality, use agreed outcome measures, including measures
 23 other than walking speed, and examine the effects of FES for adults with cerebral palsy,
 24 traumatic and acquired brain injury, and Parkinson's disease.

25
 26 Ibitoye et al. (2023) examined the effectiveness of leg exercises on bone mineral density
 27 and muscle cross-sectional area based on their clinical efficacy in persons with SCI. The
 28 primary outcome targeted was the change in muscle mass/volume and bone mineral density
 29 as measured by CT, MRI and similar devices. Relevant studies indicated that persons with
 30 SCI that undertook FES- and frame-supported leg exercise exhibited better improvement
 31 in muscle and bone health preservation in comparison to those who were confined to frame-
 32 assisted leg exercise only. However, this observation is only valid for exercise initiated
 33 early (i.e., within 3 months after injury) and for ≥ 30 min/day for \geq thrice a week and for
 34 up to 24 months or as long as desired and/or tolerable. Consequently, apart from the
 35 positive psychological effects on the users, leg exercise may reduce fracture rate and its
 36 effectiveness may be improved if augmented with FES.

37 **Dysphagia**

38 Electrical stimulation (ES) has been examined for the treatment of dysphagia. However,
 39 there is currently insufficient evidence to support the effectiveness of ES in treating this
 40 condition. No peer-reviewed literature was found for DPNS specifically, but rather is
 41 limited to electrical stimulation, FES, or NMES. In a non-concurrent cohort study,
 42

1 Blumenfeld et al. (2006) assessed the effectiveness of ES in treating persons with
2 dysphagia and aspiration. The charts of 40 consecutive subjects undergoing ES and 40
3 consecutive persons undergoing traditional dysphagia therapy (TDT) were reviewed. The
4 swallow severity scale improved from 0.50 to 1.48 in the TDT group ($p < 0.05$) and from
5 0.28 to 3.23 in the ES group ($p < 0.001$). After adjusting for potential confounding factors,
6 persons receiving ES did significantly better in regard to improvement in their swallowing
7 function than persons receiving TDT ($p = 0.003$). The authors concluded that the findings
8 suggested that dysphagia therapy with transcutaneous ES is superior to traditional
9 dysphagia therapy alone in individuals in a long-term acute care facility. They also stated
10 that confirmation of these findings with a prospective, placebo-controlled, randomized
11 clinical trial is needed before a definitive determination regarding the effectiveness of ES
12 dysphagia therapy can be made. Kiger et al. (2006) compared the outcomes using
13 transcutaneous neuromuscular electrical stimulation (VitalStim[®] therapy) to outcomes
14 using traditional swallowing therapy for deglutition disorders. A total of 22 patients had an
15 initial and a follow-up video-fluoroscopic swallowing study or fiberoptic endoscopic
16 evaluation of swallowing and were divided into an experimental group that received
17 VitalStim[®] treatments and a control group that received traditional swallowing therapy.
18 Outcomes were analyzed for changes in oral and pharyngeal phase dysphagia severity,
19 dietary consistency restrictions, and progression from non-oral to oral intake. Results of
20 chi-square analysis showed no statistically significant difference in outcomes between the
21 experimental and control groups.

22
23 Huckabee and Doeltgen (2007) reviewed NMES as an emerging modality in an attempt to
24 advise the New Zealand medical community about the application of it as a treatment for
25 pharyngeal swallowing impairment (dysphagia). Authors conclude that there are potential
26 benefits of the use of this treatment but key concerns for patient safety and long-term
27 outcomes exist. Shaw et al. (2007) sought to evaluate the effectiveness of VitalStim[®]
28 therapy in a heterogeneous group of dysphagic patients. They performed a retrospective
29 analysis of 18 patients who received this therapy at an urban tertiary referral center. All
30 patients underwent pre-therapy evaluation by speech-language pathologists, including
31 modified barium swallow and/or functional endoscopic evaluation of swallowing and
32 clinical evaluation of swallowing that included assessment of laryngeal elevation, diet
33 tolerance, and swallowing delay, and were then assigned an overall dysphagia severity
34 score. After therapy, all patients underwent the same assessments. Twelve of the 18 also
35 underwent a functional swallowing telephone survey months (range, 1 to 21 months) after
36 their therapy to assess whether the improvement was worthwhile and sustained. Eleven of
37 the 18 patients (61%) demonstrated some improvement in their swallowing. 6 of the 18
38 patients (33%) were improved enough to no longer require a feeding tube. However, of the
39 5 patients categorized as having “severe dysphagia” before therapy, only 2 showed any
40 improvement, and these patients still required a feeding tube for adequate nutrition.
41 Telephone surveys did confirm that those who improved with their therapy seemed to
42 maintain their progress and that most patients were satisfied with their therapy. Authors

1 concluded that VitalStim[®] therapy seems to help those with mild to moderate dysphagia.
2 However, the patients with the most severe dysphagia in the study did not gain
3 independence from their feeding tubes but could potential help those with mild to moderate
4 dysphagia. Carnaby-Mann and Crary (2007) examined the evidence on neuromuscular
5 electrical stimulation for swallowing rehabilitation. A total of 81 studies were reviewed.
6 Seven were accepted for analysis. A significant summary effect size was identified for the
7 application of NMES for swallowing. Best-evidence synthesis showed indicative findings
8 in favor of NMES for swallowing. The analysis revealed a small but significant summary
9 effect size for NMES for swallowing. Because of the small number of studies and low
10 methodological grading for these studies, caution should be taken in interpreting this
11 finding. These results support the need for more rigorous research in this area. This is in
12 agreement with the observation of Steele et al (2007) who noted that although ES
13 approaches to the restoration and rehabilitation of swallowing is an exciting area of
14 research which holds promise for future clinically relevant technology and/or therapy,
15 implementation of ES in clinical swallowing rehabilitation settings still remains pre-
16 mature.

17
18 Clark et al. (2009) systematically reviewed the literature examining the effects of NMES
19 on swallowing and neural activation. The review was conducted as part of a series
20 examining the effects of oral motor exercises (OMEs) on speech, swallowing, and neural
21 activation. Out of 899 citations initially identified for the broad review of OMEs, 14 articles
22 relating to NMES qualified for inclusion. Most of the studies (10/14) were considered
23 exploratory research, and many had significant methodological limitations. Authors
24 concluded that the review revealed that surface NMES to the neck has been most
25 extensively studied with promising findings, yet high-quality controlled trials are needed
26 to provide evidence of efficacy. Surface NMES to the palate, faucial pillars, and pharynx
27 has been explored in Phase I research, but no evidence of efficacy is currently available.
28 Intramuscular NMES has been investigated in a single Phase I exploratory study.
29 Additional research is needed to document the effects of such protocols on swallowing
30 performance. Christiaanse et al. (2011) compared the change in swallowing function in
31 pediatric patients with dysphagia who received neuromuscular electrical stimulation
32 (NMES) to a control group who received usual oral motor training and dietary
33 manipulations without NMES. Children were classified into two groups based on the
34 etiology of their dysphagia (primary vs. acquired). Only the treatment group who had
35 acquired dysphagia improved more than the similar subgroup of control children. Authors
36 concluded that NMES treatment of anterior neck muscles in a heterogeneous group of
37 pediatric patients with dysphagia did not improve the swallow function more than that seen
38 in patients who did not receive NMES treatment. However, there may be subgroups of
39 children that will improve with NMES treatment. Geeganage et al. (2012) assessed the
40 effectiveness of interventions for the treatment of dysphagia and nutritional and fluid
41 supplementation in patients with acute and subacute stroke. Authors included 33 studies
42 involving 6,779 participants. Swallowing therapies included the following: acupuncture,

1 drug therapy, neuromuscular electrical stimulation, pharyngeal electrical stimulation,
2 physical stimulation (thermal, tactile), transcranial direct current stimulation, and
3 transcranial magnetic stimulation. Authors conclude that there remains insufficient data on
4 the effect of swallowing therapy, feeding, and nutritional and fluid supplementation on
5 functional outcome and death in dysphagic patients with acute or subacute stroke.
6 Behavioural interventions and acupuncture reduced dysphagia, and pharyngeal electrical
7 stimulation reduced pharyngeal transit time.

8
9 Tan et al. (2013) assessed the overall efficacy by comparing the two treatment protocols in
10 a meta-analysis. Studies that compared the efficacy of treatment and clinical outcomes of
11 NMES versus traditional treatment (TT) in dysphagia rehabilitation were assessed. Seven
12 studies were eligible for inclusion, including 291 patients, 175 of whom received NMES
13 and 116 of whom received TT. Of the seven studies, there were two randomized controlled
14 trials, one multicenter randomized controlled trial and four clinical controlled trials. The
15 change scores on the Swallowing Function Scale of patients with dysphagia treated with
16 NMES were significantly higher compared with patients treated with TT. However,
17 subgroup analysis according to etiology showed that there were no differences between
18 NMES and TT in dysphagia post-stroke. No studies reported complications of NMES.
19 Authors concluded that NMES is more effective for treatment of adult dysphagia patients
20 of variable etiologies than TT. However, in patients with dysphagia post-stroke, the
21 effectiveness was comparable. Miller et al (2014) performed a systematic review of the
22 literature on the use of neuromuscular electrostimulation (NMES) in otorhinolaryngology
23 that have been published in German or English. The search identified 180 studies. These
24 were evaluated and relevant studies were included in the further evaluation. The authors
25 concluded that the evidence collected to date is encouraging; particularly for the treatment
26 of certain forms of dysphagia and laryngeal paresis. Terré and Mearin (2015) evaluated the
27 effectiveness of neuromuscular electrical stimulation (NMES) treatment in patients with
28 oropharyngeal dysphagia secondary to acquired brain injury. Twenty patients with
29 neurological oropharyngeal dysphagia (14 stroke and 6 severe traumatic brain injury) were
30 enrolled in a prospective randomized study, with patients and assessors blinded (to group
31 allocation): Ten patients underwent NMES, and conventional swallowing therapy and 10
32 patients underwent sham electrical stimulation (SES) and conventional swallowing
33 therapy. Both groups completed 20 sessions. Feeding swallowing capacity was evaluated
34 using the functional oral intake scale (FOIS). After treatment, the NMES group increased
35 by 2.6 points (4.5 points) compared with only 1 point (3.1 points) for the SES group. At 3
36 months of follow-up, mean scores were 5.3 and 4.6 respectively; thus, both groups
37 improved similarly. At that time point (3 months), tracheal aspiration persisted in 6 patients
38 in each group. However, a significant improvement in relation to the bolus viscosity at
39 which aspiration appeared was found in the NMES group versus the SES group. Also, a
40 significant increase in pharyngeal amplitude contraction was observed at the end of
41 treatment (1 month) in the NMES group compared with the SES group. Authors concluded

1 that NMES significantly accelerated swallowing function improvement in patients with
2 oropharyngeal dysphagia secondary to acquired brain injury.

3
4 Chen et al. (2016) evaluated whether swallow treatment with neuromuscular electrical
5 stimulation is superior to that without neuromuscular electrical stimulation, and whether
6 neuromuscular electrical stimulation alone is superior to swallow therapy. Eight studies
7 were identified. Authors concluded that swallow treatment with neuromuscular electrical
8 stimulation seems to be more effective than that without neuromuscular electrical
9 stimulation for post-stroke dysphagia in the short-term considering the limited number of
10 studies available. Evidence was insufficient to indicate that neuromuscular electrical
11 stimulation alone was superior to swallow therapy. Alamer et al. (2020) summarized the
12 latest best scientific evidence on the efficacy of neuromuscular electrical stimulation on
13 swallowing function in dysphagic stroke patients. Evidence of overall quality was graded
14 from moderate to high. Eleven RCTs involving 784 patients were analyzed. The primary
15 outcome measures of this review were functional dysphagia scale (FDS) and standard
16 swallowing assessment. This review found neuromuscular electrical stimulation (NMES)
17 coupled with traditional swallowing therapy could be an optional intervention to improve
18 swallowing function after stroke in rehabilitation department.

19
20 Liang et al. (2021) explored the clinical efficacy of VitalStim® electrical stimulation
21 combined with swallowing function training for patients with dysphagia following an acute
22 stroke. Seventy-two patients with dysphagia following an acute stroke were admitted to the
23 hospital and were further divided into two groups using prospective research methods.
24 There were 36 cases in each group according to the random number table method. The
25 control group received conventional medical treatment and swallowing function training
26 while the experimental group received conventional medical treatment and VitalStim®
27 electrical stimulation combined with swallowing function training. The overall response
28 rate of the experimental group (94.44%) was higher than that of the control group
29 (77.78%), and the difference was statistically significant. Compared with before treatment,
30 the upward and forward movement speeds of the hyoid bone, anterior movement speed,
31 the grading score of the Kubota drinking water test, Caiteng's grading score, serum
32 superoxide dismutase, 5-hydroxytryptamine, and norepinephrine levels, Fugl-Meyer
33 Assessment score, and multiple quality of life scores of the two groups showed
34 improvement after treatment. While the standard swallowing assessment score, serum
35 malondialdehyde level, and National Institutes of Health Stroke Scale score decreased, the
36 aforementioned indices showed a significant improvement in the experimental group.
37 Authors concluded that the results of this study indicate that VitalStim® electrical
38 stimulation combined with swallowing function is effective for treating dysphagia
39 following an acute stroke. It can effectively improve swallowing, neurological, and limb
40 motor functions, reduce complications, promote physical recovery, and improve overall
41 quality of life of patients.

1 Propp et al. (2022) aimed to determine the effectiveness of neuromuscular electrical
2 stimulation (NMES) for treatment of oropharyngeal dysphagia in children. Studies of
3 children (≤ 18 years) diagnosed with oropharyngeal dysphagia using NMES in the
4 throat/neck region were included. A meta-analysis was not conducted due to clinical
5 heterogeneity in studies. Ten studies were included (5 RCTs, 4 case series, 1 cohort study;
6 including 393 children, mean or median age below 7 years, including children with
7 neurologic impairments). In all studies, swallowing function improved after NMES
8 treatment. Eight of 10 studies reported on the child's feeding ability, and, with one
9 exception, there was improvement in feeding ability. The studies demonstrated moderate
10 to high risk of bias. Authors concluded that NMES treatment may be beneficial in
11 improving swallowing function for children with dysphagia, however, given the quality of
12 the studies, inadequate outcome reporting, and short follow-up duration, uncertainty
13 remains. Well-designed RCTs are needed to establish its effectiveness before its adoption
14 in clinical practice.

15
16 Miller et al. (2022) evaluated recent studies regarding a potential effectiveness of
17 transcutaneous NMES applied to the anterior neck as a treatment for dysphagia. Eighteen
18 studies were identified with varying patient groups, stimulation protocols, electrode
19 placement and therapy settings. However, 16 studies have reported of beneficial outcomes
20 in relation with NMES. It could generally be concluded that there is a considerable amount
21 of level 2 studies which suggest that NMES is an effective treatment option, especially
22 when combined with traditional dysphagia therapy for patients with dysphagia after stroke
23 and patients with Parkinson's disease, or with different kinds of brain injuries. Further
24 research is still necessary in order to clarify which stimulation protocols, parameters and
25 therapy settings are most beneficial for certain patient groups and degrees of impairment.

26
27 Wang et al. (2024) evaluated the impact of NMES on dysphagia in stroke patients.
28 Research outcomes included Swallowing Quality of Life (SWAL-QoL), Penetration-
29 Aspiration Scale (PAS), Functional Oral Intake Scale (FOIS), Dysphagia Outcomes and
30 Severity Scale (DOSS), the Repeat Salivary Swallowing Test (RSST), and Water
31 Swallowing Test (WST). Nine randomized controlled trials (RCTs) and quasi-RCTs were
32 included, and remarkable differences were found between patients treated with or without
33 NMES in respect of FOIS scores, PAS scores, and SWAL-QoL scores. No significant
34 difference was manifested in WST, RSST, and DOSS. Evidence suggests that NMES is
35 more effective for post-stroke dysphagia patients than treatment without NMES.

36 37 **Heart Conditions**

38 Literature does not support the use of NMES for the treatment of heart failure (Arena et
39 al., 2010) conducted a systematic review of the literature to evaluate the evidence
40 supporting NMES and inspiratory muscle training (IMT) for the treatment of systolic heart
41 failure. Thirteen NMES studies met inclusion criteria, ten were randomized controlled
42 trials. Although the studies reported improvement in aerobic capacity, peak oxygen uptake

1 and strength and endurance of muscle groups, the studies were limited by patient
 2 population (i.e., mostly males), diverse NMES training protocols, variation in the type of
 3 muscle contraction elicited (i.e., titanic vs. twitch), the use of different muscle groups and
 4 different comparators. The percent improvement in peak oxygen uptake was consistently
 5 greater with conventional therapy (i.e., bicycle/treadmill). Sillen et al. (2009) conducted a
 6 systematic review of randomized controlled trials to analyze the role of NMES in strength,
 7 exercise capacity, and disease-specific health status in patients with congestive heart failure
 8 ($n=9$ studies) and chronic obstructive pulmonary disease ($n=5$ studies) with disabling
 9 dyspnea, fatigue, and exercise intolerance. The limited number of studies, heterogeneous
 10 patient populations and variability in NMES methodology prohibited the use of meta-
 11 analysis. Although some of the studies reported significant improvements with NMES
 12 compared to no exercise or usual care, outcomes, including adverse events, were
 13 conflicting. Additional studies are indicated to provide sufficient evidence to establish the
 14 clinical utility of NMES in this patient population.

15 **Pelvic Floor Stimulation (electric or electromagnetic)**

16 Stewart et al. (2017) assessed the effects of electrical stimulation with non-implanted
 17 devices, alone or in combination with other treatment, for managing stress urinary
 18 incontinence or stress-predominant mixed urinary incontinence in women. Eligible trials
 19 ($n=56$) included adult women with SUI or stress-predominant mixed urinary incontinence
 20 (MUI). Authors concluded that electrical stimulation (ES) probably improves
 21 incontinence-specific quality of life (QoL) compared to no treatment but there may be little
 22 or no difference between electrical stimulation and pelvic floor muscle training (PFMT).
 23 Consistent with other reviews, it is uncertain whether adding electrical stimulation to
 24 PFMT makes any difference in terms of quality of life, compared with PFMT alone. The
 25 impact of electrical stimulation on subjective cure/improvement and incontinence-specific
 26 QoL, compared with vaginal cones, PFMT plus vaginal cones, or drug therapy, is
 27 uncertain. Comparisons of different types of ES to each other and of ES plus surgery to
 28 surgery are also inconclusive in terms of subjective cure/improvement and incontinence-
 29 specific QoL. Authors concluded that the current evidence base indicated that electrical
 30 stimulation is probably more effective than no active or sham treatment, but it is not
 31 possible to say whether ES is similar to PFMT or other active treatments in effectiveness
 32 or not. Overall, the quality of the evidence was too low to provide reliable results. Pan et
 33 al. (2018) evaluated the value of magnetic stimulation (MS) in patients with pelvic floor
 34 dysfunction (PFD). A total of 20 studies including 1019 patients were eligible for inclusion
 35 whose level of evidence for the included studies was low. Meta-analysis of four trials
 36 comparing MS with sham intervention showed that MS was not associated with significant
 37 improvement in outcomes or QoL, or number of leakages. Narrative review showed that
 38 there were no convincing evidence that MS was effective for chronic pelvic floor pain,
 39 detrusor overactivity, or overactive bladder. Authors concluded that there is no convincing
 40 evidence to support the benefits of using MS in the management of PFD. The applicability
 41 of MS in the treatment of PFD remains uncertain, so larger, well-designed trials with longer
 42

1 follow-up periods adopted relevant and comparable outcomes are needed to be further
2 explored to provide a definitive conclusion.

3
4 Ignácio et al. (2022) sought to determine what the effect is of an intravaginal electrical
5 stimulation regimen on their ability to contract the pelvic floor muscles and on self-reported
6 urinary incontinence in women who are unable to contract their pelvic floor muscles
7 voluntarily. Sixty-four women with pelvic floor muscle function assessed by bi-digital
8 palpation to be grade 0 or 1 on the Modified Oxford Scale. For 8 weeks, participants
9 randomized to the experimental group received weekly 20-minute sessions of intravaginal
10 electrical stimulation with instructions to attempt pelvic floor muscle contractions during
11 the bursts of electrical stimulation in the final 10 minutes of each session. The control group
12 received no intervention. The primary outcome was ability to voluntarily contract the
13 pelvic floor muscles, evaluated through vaginal palpation using the Modified Oxford Scale.
14 Secondary outcomes were prevalence and severity of urinary incontinence symptoms
15 assessed by the International Consultation on Incontinence Questionnaire on Urinary
16 Incontinence-Short Form (ICIQ-UI-SF) score from 0 to 21. Sixty-one participants provided
17 outcome data. After the intervention, the ability to contract the pelvic floor muscles was
18 acquired by 36% of the experimental group and 12% of the control. The experimental
19 group also improved by a mean of 2 points more than the control group on the ICIQ-UI-
20 SF score. Authors concluded that in women who are unable to contract their pelvic floor
21 muscles voluntarily, 8 weeks of intravaginal electrical stimulation with voluntary
22 contraction attempts improved their ability to contract their pelvic floor muscles and
23 reduced the overall severity and impact of urinary incontinence on quality of life. Although
24 the main estimates of these effects indicate that the effects are large enough to be
25 worthwhile, the precision of these estimates was low, so it is not possible to confirm
26 whether the effects are trivial or worthwhile.

27
28 Zhu et al. (2022) evaluated the efficacy and safety of pelvic floor muscle training (PFMT)
29 combined with biofeedback (BF), electrical stimulation (ES) therapy, or both for
30 postpartum lower urinary tract symptoms (LUTS). Seventeen studies were included. The
31 results of the meta-analysis showed that PFMT plus ES with or without BF was more
32 effective than PFMT alone. Patients receiving PFMT plus ES and BF achieved greater
33 improvement than controls receiving PFMT alone in incontinence quality of life scores,
34 pelvic floor muscle strength, and urodynamic parameters (maximum urethral closure
35 pressure, abdominal leak point pressure, and maximum urinary flow rate), and 1-h urine
36 leakage also decreased. Authors concluded that PFMT plus ES with or without BF
37 exhibited better efficacy and safety for early postpartum LUTS than PFMT alone.

38
39 Ali et al. (2022) sought to determine the effects of nonsurgical, minimally or noninvasive
40 therapies on urge urinary incontinence (UUI) symptoms and quality of life (QoL) in
41 individuals with neurogenic bladder (NGB). Randomized controlled trials that compared
42 therapies such as intravaginal electrical stimulation (IVES), transcutaneous electrical nerve

1 stimulation (TENS), neuromuscular electrical stimulation (NMES), transcutaneous tibial
2 nerve stimulation (TTNS), pelvic floor muscle training (PFMT), and behavioral therapy
3 (BT) to control were included. Meta-analyses revealed a significant effect of electrical
4 stimulation on UII due to multiple sclerosis and stroke. The pooled analyses of TTNS and
5 revealed significant effects of these interventions on QoL in people with Parkinson's
6 disease. However, meta-analyses revealed nonsignificant effects for PFMT and BT on UII
7 due to Parkinson's disease. Authors concluded that their meta-analyses found electrical
8 stimulation to be beneficial for improving the symptoms of UII among people with
9 multiple sclerosis and those with stroke. The review also revealed that TTNS and BT might
10 improve QoL for people with NGB due to Parkinson's disease, although the effects of
11 PFMT and BT on UII warrant further investigation.

12
13 Sarmiento et al. (2022) perform an updated and comprehensive literature review focused
14 on the effects of pelvic floor electrical stimulation. Regarding the studied populations, the
15 results demonstrated heterogeneity between human and animal populations. Articles
16 comprised studies that investigated the therapeutic effects of electrical stimulation on
17 pelvic floor dysfunctions in humans, totaling 1,303 participants. From these, only the
18 research performed by 25 included men in the study population, which investigated 96
19 patients with urinary incontinence post-radical prostatectomy. Authors concluded that non-
20 invasive electrical stimulation has shown promise in the clinical improvement of disorders
21 associated with pelvic floor fragility. The vast majority of studies addressed in this review
22 showed that electrostimulation improves urination control and sexual quality, in addition
23 to providing greater collagen production and maintaining the effectiveness of sphincter
24 contraction.

25
26 Learnardo et al. (2022) compared biofeedback-assisted pelvic muscle floor training
27 (PFMT) and pelvic electrical stimulation (ES) as an intervention group, with PFMT or
28 bladder training (BT) as the control group, in women with an overactive bladder (OAB) in
29 a meta-analysis. Eight studies involving 562 patients (comprising 204 patients with
30 biofeedback-assisted PFMT, 108 patients with pelvic ES, and 250 patients who received
31 PFMT alone or BT and lifestyle recommendations only, as the control group) were
32 included. The ES group showed significant differences in terms of changes to QoL,
33 episodes of incontinence, and the number of participants cured or improved, while the
34 biofeedback group resulted in nonsignificant changes in QoL, episodes of incontinence,
35 and the number of participants cured or improved, both compared to the control group
36 respectively. Authors concluded that this meta-analysis shows that low-frequency pelvic
37 ES appears to be sufficient and effective as an additional intervention for women with OAB
38 in clinical practice according to improvements in the subjects' QoL and reduction of
39 symptoms. Meanwhile, biofeedback-assisted PFMT does not appear to be a significant
40 adjuvant for conservative OAB therapy.

1 Todhunter-Brown et al. (2022) summarized Cochrane Reviews that assessed the effects of
2 conservative interventions for treating urinary incontinence (UI) in women. The common
3 types of UI are stress (SUI), urgency (UUI) and mixed (MUI). A wide range of
4 interventions can be delivered to reduce the symptoms of UI in women. Conservative
5 interventions are generally recommended as the first line of treatment. Authors included
6 reviews that compared a conservative intervention with 'control' (which included placebo,
7 no treatment or usual care), another conservative intervention or another active, but non-
8 conservative, intervention. They included 29 relevant Cochrane Reviews. Seven focused
9 on physical therapies; five on education, behavioral and lifestyle advice; one on mechanical
10 devices; one on acupuncture and one on yoga. Fourteen focused on non-conservative
11 interventions but had a comparison with a conservative intervention. There were 112
12 unique trials (including 8,975 women) that had primary outcome data included in at least
13 one analysis. For UUI, (five reviews): Conservative intervention versus control: there was
14 moderate to high-certainty evidence demonstrating that PFMT plus feedback, PFMT plus
15 biofeedback, electrical stimulation and bladder training were more beneficial than control
16 for curing or improving UI. Women using electrical stimulation plus PFMT had higher
17 quality of life than women in the control group. One conservative intervention versus
18 another conservative intervention: for cure or improvement, there was moderate certainty
19 evidence that electrical stimulation was more effective than laseropuncture. There was high
20 or moderate certainty evidence that PFMT resulted in higher quality of life than electrical
21 stimulation and electrical stimulation plus PFMT resulted in better cure or improvement
22 and higher quality of life than PFMT alone. For all types of urinary incontinence (13
23 reviews): Conservative intervention versus control: there was moderate to high certainty
24 evidence of better cure or improvement with PFMT, electrical stimulation, weight loss and
25 cones compared to control. Specific to electrical stimulation and exercise, authors
26 concluded that there is high certainty that PFMT is more beneficial than control for all
27 types of UI for outcomes of cure or improvement and quality of life and electrical
28 stimulation is beneficial for women with UUI. Most evidence within the included Cochrane
29 Reviews is of low certainty.

30
31 Stania et al. (2022) sought to determine the therapeutic efficacy of intravaginal electrical
32 stimulation (ES) in women with SUI. Of the 686 records identified, a total of 10 articles
33 met the inclusion criteria. A meta-analysis revealed significant differences between the ES
34 and no active treatment groups in the pooled objective cure rates and subjective cure or
35 improvement rates. No significant differences were found in the pooled number of
36 incontinence episodes per 24 h, the pooled Incontinence Quality of Life Questionnaire
37 scores or the pooled number of adverse effects between the ES and other conservative
38 treatment groups. Authors concluded that there was insufficient evidence for or against the
39 use of intravaginal ES therapy for women with SUI, partly due to the variability in the
40 interventions of the included trials and the small number of trials included.

1 Fernández-Pérez et al. (2023) evaluated the effectiveness of physical therapy interventions
2 for the treatment of female dyspareunia. Of the 19 articles selected, six applied multimodal
3 physiotherapy treatments; five, electrotherapy; three, Thiele's massage; two,
4 interdisciplinary interventions or pelvic floor muscle training; and one, extracorporeal
5 shockwave therapy. The meta-analysis showed significant results for the variables pain and
6 quality of life with the interventions based on electrotherapy and electrotherapy combined
7 with pelvic floor muscle training. These interventions did not show significant results for
8 the improvement of sexual function. Authors concluded that physiotherapy techniques are
9 effective and procedures have been identified with reliable results in improving pain and
10 quality of life in patients with dyspareunia. One of the most important aspects is the
11 strengthening of the perineal musculature and the application of Transcutaneous Electrical
12 Nerve Stimulation. Furthermore, manual trigger point release therapy and Thiele massage,
13 optimize and guarantee the reduction of pain intensity.

14
15 Huang et al. (2023) investigated the comparative efficacy of neuromodulation technologies
16 for overactive bladder (OAB) syndrome in adults. The search selected clinical trials with
17 random allocation to percutaneous tibial nerve stimulation (PTNS), transcutaneous tibial
18 nerve stimulation (TTNS), vaginal electrical stimulation (VES), sacral neuromodulation
19 (SNM), parasacral stimulation (PS), pudendal neuromodulation, or placebo. The main
20 outcomes were the voiding diary, OAB-related quality of life, and positive response rate.
21 The study included 21 randomized controlled trials involving 1433 participants, and all
22 trials were used for the meta-analysis. In the network meta-analyses, five of six
23 neuromodulation technologies, including PTNS, TTNS, VES, SNM, and PS, were related
24 to higher efficacy than the placebo. Ranking probability showed that SNM was the most
25 efficacious therapy for improving OAB-related quality of life, urinary episodes, and
26 urinary frequency. For urgency incontinence episodes and the number of pads, PTNS and
27 TTNS were the most efficacious modalities, respectively. Authors concluded that
28 neuromodulation technologies, including PTNS, TTNS, VES, SNM, and PS, may be
29 effective and safe solutions for OAB syndrome in adults. Moreover, SNM is the most
30 efficacious regimen for OAB-related quality of life, urinary episodes, and urinary
31 frequency. PTNS and TTNS are the most efficacious modalities for reducing urgency
32 incontinence episodes and the number of pads, respectively. Future studies should pay
33 more attention to the quality of study design and report, patients who may benefit the most
34 from neuromodulation, and the long-term effect, cost-effectiveness, and satisfaction of
35 neuromodulation.

36
37 Zhang et al. (2023) described and synthesized non-pharmacological and nonsurgical
38 interventions for male urinary incontinence from the existing literature. A total of 4602
39 studies were identified, of which 87 studies were included. Approximately 78% were
40 randomized controlled trials. More than 88% of the participants were men with prostate
41 cancer. Exercising pelvic floor muscles 30 times per day for 12 weeks was the most
42 frequently reported. Parameters of electrical stimulation were typically set up to 50 Hz and

1 300 μ s for frequency and width of pulse, respectively, and lasted for 15 min. Pure pelvic
 2 floor muscle training, Pilates, Yoga, whole body vibration, diaphragm/abdominal muscle
 3 training, micturition interruption exercise, acupuncture, and auriculotherapy showed
 4 positive effects on reducing urinary incontinence. Authors concluded that findings suggest
 5 implementing pelvic floor muscle training alone before or after surgery can both prompt
 6 the recovery of continence in men after prostate cancer surgery. The decision to use
 7 biofeedback or electrical stimulation to enhance the therapeutic effect of pelvic floor
 8 muscle training should be approached with caution. More rigorous designed studies are
 9 needed to validate the effectiveness of Traditional Chinese Medicine techniques and
 10 diverse novel methods.

11
 12 Jiang et al. (2024) assessed the efficacy of transcutaneous electrical nerve stimulation
 13 (TENS) for neurogenic bladder after spinal cord injury (SCI). The primary outcomes were
 14 maximum cystometric capacity (MCC) and residual urine volume (RUV). Secondary
 15 outcomes included maximum detrusor pressure, flow rate, and bladder diary. Eleven trials
 16 involving 881 participants were included. Meta-analysis showed that TENS in addition to
 17 conventional treatment had larger MCC and lower RUV than did conventional treatment
 18 only. Compared with magnetic stimulation, no differences were observed with TENS for
 19 MCC and RUV. There also were no differences in MCC and when compared with
 20 solifenacin succinate and pelvic floor biofeedback, respectively. Authors concluded that
 21 TENS may be an effective treatment option for neurogenic bladder after SCI.

22 23 **Threshold Electrical Stimulation (TES)**

24 Dali et al. (2002) sought to determine whether a group of stable children with cerebral palsy
 25 would improve their motor skills after 12 months of TES. Two thirds received active and
 26 one third received inactive stimulators. Fifty seven of 82 outpatients who were able to walk
 27 at least with a walker, completed all 12 months of treatment. Results demonstrated that
 28 there was no significant difference between active and placebo treatment in any of the
 29 tested groups, nor combined. Authors concluded that TES in these patients did not have
 30 any significant clinical effect during the test period. Kerr et al. (2006) investigated the
 31 efficacy of NMES and TES in strengthening the quadriceps muscles of both legs in children
 32 with cerebral palsy (CP). Sixty children were randomized to one of the following groups:
 33 NMES (n=18), TES (n=20), or placebo (n=22). Thirty-four children walked unaided, 17
 34 used posterior walkers, six used crutches, and the remaining three used sticks for mobility.
 35 Peak torque of the left and right quadriceps muscles, gross motor function, and impact of
 36 disability were assessed at baseline and end of treatment (16wks), and at a 6-week follow-
 37 up visit. No statistically significant difference was demonstrated between NMES or TES
 38 versus placebo for strength or function. Statistically significant differences were observed
 39 between NMES and TES versus placebo for impact of disability at the end of treatment,
 40 but only between TES and placebo at the 6-week follow-up. In conclusion, further evidence
 41 is required to show whether NMES and/or TES may be useful as an adjunct to therapy in
 42 ambulatory children with diplegia who find resistive strengthening programs difficult.

Neufit Neubie device

There is a paucity of published literature to support the use of the Neufit Neubie device for electrical stimulation and therefore conclusions about the safety and efficacy of the device of combination units cannot be made.

RST-SANEXAS neoGEN® Electric cell-Signaling Treatments (EcST)

There is no peer reviewed published literature to support the use of the RST-SANEXAS neoGEN® Electric cell-Signaling Treatment (EcST) and therefore conclusions about the safety, and efficacy cannot be made.

Hako-Med

There is insufficient evidence in the published peer reviewed scientific literature to support the efficacy of Hako-Med treatments.

Transcutaneous electrical modulation pain reprocessing (TEMPR) (e.g., Scrambler therapy, Calmare®)

There is insufficient evidence in the published peer reviewed scientific literature to support the efficacy of TEMPR. Studies comparing TEMPR to conventional treatment options and to sham therapy are lacking. Available studies are primarily in the form of case series with small, heterogeneous patient populations and short-term follow-ups investigating TEMPR for the treatment of various types of pain including cancer pain. In some cases, pain relief was not maintained following therapy (Ricci, et al., 2019; Lee, et al., 2016; Notaro, et al., 2016; Coyne, et al., 2013; Ricci, et al., 2011; Smith, et al., 2020; Sabato, et al., 2005; Marineo, et al., 2003).

Marineo et al. (2012) conducted a randomized controlled trial to compare the effects of Scrambler therapy (n=26) to guideline-based drug management (n=26) (control group) for the treatment of pain (i.e., postsurgical neuropathic pain, postherpetic neuralgia or spinal canal stenosis). Scrambler therapy included one 45-minute session a day for ten days at the maximally tolerated stimulus. The primary outcome was change in visual analogue scale (VAS) pain scores at one month. Secondary outcomes included VAS pain scores at two and three months, pain medication usage and allodynia. At the one-month, two-month and three-month follow-up visits, there was a significant reduction in the mean VAS score for the treatment group compared to the control group ($p < 0.0001$, each). More relapses occurred in patients with polyradicular pain than monoradicular pain. Relapses in the test group were significant ($p < 0.001$) but not in the control group ($p > 0.05$). No adverse effects were observed. Compared to the control group, allodynia significantly reduced in the Scrambler group at one, two and three months ($p = 0.0017$, $p = 0.0094$, $p = 0.0644$, respectively). Scrambler therapy was also associated with significant pain medication reduction and dosage variation was statistically significant ($p < 0.0001$). Author-noted limitations included: lack of a sham comparator, the type of treatment provided to the control group, and the small sample size. Other limitations are the short-term follow-up and heterogeneity of the patient population.

1 Hou et al. 2018 conducted a systematic review of the literature to assess the safety and
2 efficacy of medical and pharmacological therapies for the treatment of chemotherapy-
3 induced peripheral neuropathy (CIPN). Studies with adult subjects (age \geq 18 years) were
4 included if they were randomized controlled trials (RCTs), prospective non-randomized
5 studies, case-control, cohort, cross-over or retrospective. Case reports, case series,
6 abstracts, review articles, letters to the editor, and animal studies were excluded. In total,
7 13 RCTs, 18 prospective studies, and four retrospective studies met the inclusion criteria.
8 The studies investigated the use of pharmacotherapy and other numerous modalities
9 including laser therapy, scrambler therapy, magnetic field therapy, dietary therapy, long-
10 wave diathermy therapy, and acupuncture. The primary outcome measures were highly
11 variable across the included studies. The authors' focus was pain relief and change in the
12 severity of CIPN symptoms. Due to the low quality of the studies and the paucity of
13 evidence no recommendation could be made for acupuncture-like transcutaneous nerve
14 stimulation (ALTENS), electro-acupuncture, percutaneous auricular neurostimulation,
15 interferential therapy, low-frequency magnetic field therapy and scrambler therapy. The
16 limitations of this systematic review included: heterogeneity of the studies with variations
17 in timing of treatment, primary outcomes, and chemotherapeutic agents. Most of the
18 included studies had small sample sizes and short-term follow-up periods.

19
20 Hayes (2020) evaluated Scrambler/Calmare for the treatment of chronic nonmalignant
21 pain. Nine studies including three randomized controlled trials, one repeated-measure time
22 series (observational studies), three pretest/posttest study and two retrospective reviews
23 were included in the Brief. Outcomes were measured using visual analog scale (VAS),
24 numeric rating scale (NRS), and the Brief Pain Inventory (BPI). No adverse events were
25 reported. Although limited evidence suggested improvement in pain, “substantial
26 uncertainty” remains due to the lack of well-designed comparative studies. The overall
27 quality of the evidence was rated low to very low and Hayes concluded that there was
28 insufficient evidence to assess the impact of Scrambler/Calmare on health outcomes or
29 patient management.

30
31 Hayes (2020) also evaluated the literature on Scrambler/Calmare for the management of
32 chronic pain related to cancer or cancer treatment. There was a paucity of “very-low-
33 quality” evidence for cancer-related pain in adult patients. Twelve studies including two
34 randomized controlled trials, nine single arm studies, and one retrospective review meet
35 the inclusion criteria. It is proposed that Scrambler Therapy (ST) may be used as an adjunct
36 to conventional treatments. The long-term durability of relief of pain using ST is unclear.
37 Limitations of the studies included: small patient populations (n=11-83), short term follow-
38 ups, lack of a control group, limited reporting of outcomes, lack of statistical rigor and
39 analyses, lack of blinding, and substantial attrition. There is insufficient evidence to support
40 the safety and effectiveness of Scrambler/Calmare for pain related to cancer and cancer
41 treatment.

1 Kashyap and Bhatnagar (2020) aimed to detect possible gaps in the literature regarding the
2 efficacy of ST for cancer pain and formulate recommendations for research through a
3 systematic review of the literature. Twenty-seven studies were retrieved. Ten were articles
4 that were categorized as literature reviews, including 7 general literature reviews not
5 following a specific review methodology, 1 editorial, and 2 systematic reviews. Seventeen
6 were original studies, including 2 single-arm trials, 1 randomized controlled trial, 4 pilot
7 trials, 4 case reports, 2 retrospective studies, and 4 prospective studies. By and large, the
8 available literature supports the use of ST as an effective therapy for the management of
9 refractory cancer pain. However, the level of evidence for its application to cancer pain is
10 not particularly strong, and improvement in pain with ST may even be owing to a placebo
11 effect. Authors concluded that methodologically sound, large randomized control trials are
12 needed in this area.

13
14 Wang et al. (2022) aimed to summarize the evidence regarding 4 major types of
15 neuromodulation devices for the treatment of painful diabetic neuropathy (PDN). They
16 focused on spinal cord stimulators (SCS), peripheral nerve stimulators (PNS),
17 transcutaneous electrical nerve stimulators (TENS), and scrambler therapy devices (ST)
18 because they are often used for refractory neuropathic pain. Seventeen studies met
19 inclusion criteria, 10 of which were regarding SCS. Only 3 of the 10 were randomized
20 controlled trials. We found no studies assessing contemporary PNS. Four studies assessed
21 TENS, but the devices varied widely in voltages and waveforms. Two case reports
22 described ST. Authors concluded that the evidence for neuromodulation devices for the
23 treatment of PDN mostly comprises open-label prospective trials or case reports. SCS has
24 the most volume of evidence for efficacy. Studies regarding TENS show mixed results,
25 possibly due to numerous device varieties. PNS and ST may hold promise based on their
26 proposed mechanisms of action, but prospective controlled trials are needed.

27
28 Jin et al. (2022) aimed to investigate the efficacy of scrambler therapy (ST) for the
29 management of chronic pain in a meta-analysis. Out of 348 studies, a total of 7 RCTs (n =
30 287 patients) that met the inclusion criteria were included in the final analysis. Overall, ST
31 marginally decreased pain scores after the end of the treatment compared with the control
32 group, with substantial heterogeneity. A subgroup meta-analysis found that the use of ST
33 significantly reduced analgesic consumption compared to the control group. However, no
34 significant efficacy was observed in the subgroup meta-analyses by methodological
35 quality, type of diseases causing pain, and follow-up period. The included trials have a
36 small sample size and low methodological quality. Authors concluded that ST seems to be
37 effective in the management of patients with chronic pain. However, further, large RCTs
38 are warranted to confirm our findings.

39
40 Karri et al. (2023) performed a systematic review based on the use of Scrambler Therapy
41 (ST) in treating chronic pain syndromes. Primary outcome parameters collected were
42 analgesic benefit, adverse effects, and other metrics such as sensorimotor testing. A total

1 of 21 studies met the final criteria for study inclusion and comprised randomized controlled
 2 trials (n = 8), prospective observational studies (n = 10), and retrospective cohort studies
 3 (n = 3). Nearly all the reported studies explored the use of ST for the treatment of
 4 neuropathic pain, with chemotherapy-induced peripheral neuropathy being the most
 5 studied condition. Most studies were limited by small cohorts but reported ST being safe,
 6 well tolerated, and providing clinically meaningful pain reduction. The duration of
 7 posttreatment follow-up ranged from ten to 14 days (concordant with completion of typical
 8 ST protocols) to three months. Secondary benefits such as medication reduction and
 9 improvement of sensory and motor symptoms were noted by some studies. Authors
 10 concluded that ST is regarded as a safe intervention with potential for significant analgesic
 11 benefit for neuropathic pain conditions. Although the available evidence is most robust for
 12 treating chemotherapy-induced peripheral neuropathy, ST has also been shown to be
 13 effective in treating other neuropathic pain syndromes. Evidence for ST use in nociceptive
 14 pain conditions is limited but appears promising. The favorable safety profile and
 15 increasing evidence basis for ST warrant more extensive recognition and consideration for
 16 use in clinical care.

17 **PRACTITIONER SCOPE AND TRAINING**

18 Practitioners should practice only in the areas in which they are competent based on their
 19 education, training, and experience. Levels of education, experience, and proficiency may
 20 vary among individual practitioners. It is ethically and legally incumbent on a practitioner
 21 to determine where they have the knowledge and skills necessary to perform such services
 22 and whether the services are within their scope of practice.
 23

24
 25 It is best practice for the practitioner to appropriately render services to a member only if
 26 they are trained, equally skilled, and adequately competent to deliver a service compared
 27 to others trained to perform the same procedure. If the service would be most competently
 28 delivered by another health care practitioner who has more skill and training, it would be
 29 best practice to refer the member to the more expert practitioner.
 30

31 Best practice can be defined as a clinical, scientific, or professional technique, method, or
 32 process that is typically evidence-based and consensus driven and is recognized by a
 33 majority of professionals in a particular field as more effective at delivering a particular
 34 outcome than any other practice (Joint Commission International Accreditation Standards
 35 for Hospitals, 2013).
 36

37 Depending on the practitioner's scope of practice, training, and experience, a member's
 38 condition and/or symptoms during examination or the course of treatment may indicate the
 39 need for referral to another practitioner or even emergency care. In such cases it is prudent
 40 for the practitioner to refer the member for appropriate co-management (e.g., to their
 41 primary care physician) or if immediate emergency care is warranted, to contact 911 as
 42 appropriate. See policy *Managing Medical Emergencies (CPG 159 – S)* for information.

1 **REFERENCES**

2 Ahmed I, Mustafaoglu R, Rossi S, et al. Non-invasive Brain Stimulation Techniques for
3 the Improvement of Upper Limb Motor Function and Performance in Activities of
4 Daily Living After Stroke: A Systematic Review and Network Meta-analysis. Arch
5 Phys Med Rehabil. 2023;104(10):1683-1697. doi:10.1016/j.apmr.2023.04.027

6
7 Ali MU, Fong KN, Kannan P, Bello UM, Kranz G. Effects of nonsurgical, minimally or
8 noninvasive therapies for urinary incontinence due to neurogenic bladder: a systematic
9 review and meta-analysis. Ther Adv Chronic Dis. 2022;13:20406223211063059.
10 Published 2022 Mar 18

11
12 Alamer A, Melese H, Nigussie F. Effectiveness of Neuromuscular Electrical Stimulation
13 on Post-Stroke Dysphagia: A Systematic Review of Randomized Controlled Trials.
14 Clin Interv Aging. 2020 Sep 3;15:1521-1531. Doi: 10.2147/CIA.S262596

15
16 Ali MU, Fong KN, Kannan P, Bello UM, Kranz G. Effects of nonsurgical, minimally or
17 noninvasive therapies for urinary incontinence due to neurogenic bladder: a systematic
18 review and meta-analysis. Ther Adv Chronic Dis. 2022;13:20406223211063059.
19 Published 2022 Mar 18

20
21 Allen CB, Williamson TK, Norwood SM, Gupta A. Do Electrical Stimulation Devices
22 Reduce Pain and Improve Function?-A Comparative Review. Pain Ther. 2023
23 Dec;12(6):1339-1354

24
25 Almeida CC, Silva VZMD, Júnior GC, Liebano RE, Durigan JLQ. Transcutaneous
26 electrical nerve stimulation and interferential current demonstrate similar effects in
27 relieving acute and chronic pain: a systematic review with meta-analysis. Braz J Phys
28 Ther. 2018 Sep — Oct;22(5):347-354

29
30 American College of Occupational and Environmental Medicine (ACOEM); 2nd ed. Elk
31 Grove Village (IL); 2007. Low back disorders. Occupational medicine practice
32 guidelines: evaluation and management of common health problems and functional
33 recovery in workers. 366 [1310 references]

34
35 American Society of Anesthesiologists Task Force on Chronic Pain Management;
36 American Society of Regional Anesthesia and Pain Medicine. Practice Guidelines for
37 Chronic Pain Management: An Updated Report by the American Society of
38 Anesthesiologists Task Force on Chronic Pain Management and the American Society
39 of Regional Anesthesia and Pain Medicine. Anesthesiology 2010; 112(4):810-833

- 1 Andreopoulou G, Busselli G, Street T, et al. Is functional electrical stimulation effective in
2 improving walking in adults with lower limb impairment due to an upper motor neuron
3 lesion? An umbrella review. *Artif Organs*. 2024;48(3):210-231. doi:10.1111/aor.14563
4
- 5 Aoyagi Y, Tsubahara A. Therapeutic orthosis and electrical stimulation for upper extremity
6 hemiplegia after stroke: a review of effectiveness based on evidence. *Top Stroke
7 Rehabil*. 2004 Summer;11(3):9-15
8
- 9 Arena R, Pinkstaff S, Wheeler E, Peberdy MA, Guazzi M, Myers J. Neuromuscular
10 electrical stimulation and inspiratory muscle training as potential adjunctive
11 rehabilitation options for patients with heart failure. *J Cardiopulm Rehabil Prev*. 2010
12 Jul-Aug;30(4):209-23
13
- 14 Arhos EK, Ito N, Hunter-Giordano A, Nolan TP, Snyder-Mackler L, Silbernagel KG.
15 Who's Afraid of Electrical Stimulation? Let's Revisit the Application of NMES at the
16 Knee. *J Orthop Sports Phys Ther*. 2024;54(2):1-6. doi:10.2519/jospt.2023.12028
17
- 18 Arvidsson I, Arvidsson H, Eriksson E, Jansson E. Prevention of quadriceps wasting after
19 immobilization: An evaluation of the effect of electrical stimulation. *Orthopedics*.
20 1986;9(11):1519-1528
21
- 22 Barrett C, Taylor P. The effects of the odstock drop foot stimulator on perceived quality of
23 life for people with stroke and multiple sclerosis. *Neuromodulation*. 2010 Jan;13(1):58-
24 64
25
- 26 Bax L, Staes F, Verhagen A. Does neuromuscular electrical stimulation strengthen the
27 quadriceps femoris: A systematic review of 66 randomized controlled trials. *Sports
28 Med*. 2005;35(3):191-212
29
- 30 Beltran-Alacreu H, Serrano-Muñoz D, Martín-Caro Álvarez D, Fernández-Pérez JJ,
31 Gómez-Soriano J, Avendaño-Coy J. Percutaneous Versus Transcutaneous Electrical
32 Nerve Stimulation for the Treatment of Musculoskeletal Pain. A Systematic Review
33 and Meta-Analysis. *Pain Med*. 2022;23(8):1387-1400. doi:10.1093/pm/pnac027
34
- 35 Bergman S. Management of musculoskeletal pain. *Best Pract Res Clin Rheumatol*.
36 2007;21:153-166
37
- 38 Bethoux F, Rogers HL, Nolan KJ, Abrams GM, Annaswamy T, Brandstater M, Browne B,
39 Burnfield JM, Feng W, Freed MJ, Geis C, Greenberg J, Gudesblatt M, Ikramuddin F,
40 Jayaraman A, Kautz SA, Lutsep HL, Madhavan S, Meilahn J, Pease WS, Rao N,
41 Seetharama S, Sethi P, Turk MA, Wallis RA, Kufta C. Long-Term Follow-up to a
42 Randomized Controlled Trial Comparing Peroneal Nerve Functional Electrical

- 1 Stimulation to an Ankle Foot Orthosis for Patients With Chronic Stroke. *Neurorehabil*
 2 *Neural Repair*. 2015 Nov-Dec;29(10):911-22
 3
- 4 Blum K, Chen AL, Chen TJ, Prihoda TJ, Schoolfield J, DiNubile N, Waite RL, Arcuri V,
 5 Kerner M, Braverman ER, Rhoades P, Tung H. The H-Wave device is an effective and
 6 safe non-pharmacological analgesic for chronic pain: a meta-analysis. *Adv Ther*. 2008
 7 Jul;25(7):644-57
 8
- 9 Blum K, Ho CK, Chen AL, Fulton M, Fulton B, Westcott WL, Reinl G, Braverman ER,
 10 DiNubile N, Chen TJ. The H-Wave(I) Device Induces NODependent Augmented
 11 Microcirculation and Angiogenesis, Providing Both Analgesia and Tissue Healing in
 12 Sports Injuries. *Phys Sportsmed*. 2008 Dec;36(1):103-14
 13
- 14 Blumenfeld L, Hahn Y, Lepage A, Leonard R, Belafsky PC. Transcutaneous electrical
 15 stimulation versus traditional dysphagia therapy: a nonconcurrent cohort study.
 16 *Otolaryngol Head Neck Surg*. 2006;135(5):754-757. doi:10.1016/j.otohns.2006.04.016
 17
- 18 Bogduk N. Management of chronic low back pain *Med J Aust* 2004; 180 (10): 542-544
 19
- 20 Bosques G, Martin R, McGee L, Sadowsky C. Does therapeutic electrical stimulation
 21 improve function in children with disabilities? A comprehensive literature review. *J*
 22 *Pediatr Rehabil Med*. 2016 May 31;9(2):83-99
 23
- 24 Bremner CB, Holcomb WR, Brown CD, Perreault ME. The Effectiveness of
 25 Neuromuscular Electrical Stimulation in Improving Voluntary Activation of the
 26 Quadriceps: A Critically Appraised Topic. *J Sport Rehabil*. 2016 Nov 11:1-21
 27
- 28 California Technology Assessment Forum. Interferential Stimulation For The Treatment
 29 Of Musculoskeletal Pain. 2005. Retrieved on July 3, 2024 from
 30 [https://www.scribd.com/document/15028105/Interferential-Stimulation-for-the-](https://www.scribd.com/document/15028105/Interferential-Stimulation-for-the-Treatment-of-Musculoskeletal-Pain)
 31 [Treatment-of-Musculoskeletal-Pain](https://www.scribd.com/document/15028105/Interferential-Stimulation-for-the-Treatment-of-Musculoskeletal-Pain)
 32
- 33 Cameron, M. *Physical Agents in Rehabilitation: An Evidence-Based Approach to Practice*.
 34 6th edition. Saunders; 2022
 35
- 36 Carnaby-Mann GD, Crary MA. Examining the evidence on neuromuscular electrical
 37 stimulation for swallowing: a meta-analysis. *Arch Otolaryngol Head Neck Surg*. 2007
 38 Jun;133(6):564-71
 39
- 40 Carvalho MTX, Guesser Pinheiro VH, Alberton CL. Effectiveness of neuromuscular
 41 electrical stimulation training combined with exercise on patient-reported outcomes

1 measures in people with knee osteoarthritis: A systematic review and meta-analysis.
2 Physiother Res Int. 2024;29(1):e2062. doi:10.1002/pri.2062

3
4 Castel LD, Freburger JK, Holmes GM, Scheinman RP, Jackman AM, Carey TS. Spine and
5 pain clinics serving North Carolina patients with back and neck pain: what do they do,
6 and are they multidisciplinary? Spine 2009;34:615-622

7
8 Centers for Medicare and Medicaid Services. National Coverage Determination (NCD):
9 Electrotherapy for Treatment of Facial Nerve Paralysis (Bell’s Palsy) (160.15).
10 Retrieved on July 3, 2024 from [https://www.cms.gov/medicare-coverage-](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=94&ncdver=1&bc=AAAAGAAAAAAA&)
11 [database/details/ncd-details.aspx?NCDId=94&ncdver=1&bc=AAAAGAAAAAAA&](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=94&ncdver=1&bc=AAAAGAAAAAAA&)

12
13 Centers for Medicare and Medicaid Services. Local Coverage Determination (LCD):
14 Outpatient Physical and Occupational Therapy Services (L33631). Retrieved on July
15 3, 2024 from [https://www.cms.gov/medicare-coverage-database/details/lcd-](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33631&ver=51&NCDId=72&ncdver=1&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCD%7cTA&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=---%7c5%7c6%7c66%7c67%7c9%7c38%7c63%7c41%7c64%7c65%7c44&KeyWord=laser+procedures&KeyWordLookUp=Doc&KeyWordSearchType=And&kq=true&bc=IAAABAAAAAAA&)
16 [details.aspx?LCDId=33631&ver=51&NCDId=72&ncdver=1&SearchType=Advance](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33631&ver=51&NCDId=72&ncdver=1&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCD%7cTA&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=---%7c5%7c6%7c66%7c67%7c9%7c38%7c63%7c41%7c64%7c65%7c44&KeyWord=laser+procedures&KeyWordLookUp=Doc&KeyWordSearchType=And&kq=true&bc=IAAABAAAAAAA&)
17 [d&CoverageSelection=Both&NCSelection=NCD%7cTA&ArticleType=Ed%7cKey](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33631&ver=51&NCDId=72&ncdver=1&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCD%7cTA&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=---%7c5%7c6%7c66%7c67%7c9%7c38%7c63%7c41%7c64%7c65%7c44&KeyWord=laser+procedures&KeyWordLookUp=Doc&KeyWordSearchType=And&kq=true&bc=IAAABAAAAAAA&)
18 [%7cSAD%7cFAQ&PolicyType=Final&s=---](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33631&ver=51&NCDId=72&ncdver=1&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCD%7cTA&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=---%7c5%7c6%7c66%7c67%7c9%7c38%7c63%7c41%7c64%7c65%7c44&KeyWord=laser+procedures&KeyWordLookUp=Doc&KeyWordSearchType=And&kq=true&bc=IAAABAAAAAAA&)
19 [%7c5%7c6%7c66%7c67%7c9%7c38%7c63%7c41%7c64%7c65%7c44&KeyWord=](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33631&ver=51&NCDId=72&ncdver=1&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCD%7cTA&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=---%7c5%7c6%7c66%7c67%7c9%7c38%7c63%7c41%7c64%7c65%7c44&KeyWord=laser+procedures&KeyWordLookUp=Doc&KeyWordSearchType=And&kq=true&bc=IAAABAAAAAAA&)
20 [laser+procedures&KeyWordLookUp=Doc&KeyWordSearchType=And&kq=true&b](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33631&ver=51&NCDId=72&ncdver=1&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCD%7cTA&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=---%7c5%7c6%7c66%7c67%7c9%7c38%7c63%7c41%7c64%7c65%7c44&KeyWord=laser+procedures&KeyWordLookUp=Doc&KeyWordSearchType=And&kq=true&bc=IAAABAAAAAAA&)
21 [c=IAAABAAAAAAA&](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33631&ver=51&NCDId=72&ncdver=1&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCD%7cTA&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=---%7c5%7c6%7c66%7c67%7c9%7c38%7c63%7c41%7c64%7c65%7c44&KeyWord=laser+procedures&KeyWordLookUp=Doc&KeyWordSearchType=And&kq=true&bc=IAAABAAAAAAA&)

22
23 Centers for Medicare and Medicaid Services. National Coverage Determination (NCD):
24 Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative Pain
25 (10.2). Retrieved on July 3, 2024 from [https://www.cms.gov/medicare-coverage-](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=145&ncdver=2&bc=AAAAGAAAAAAA&)
26 [database/details/ncd-](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=145&ncdver=2&bc=AAAAGAAAAAAA&)
27 [details.aspx?NCDId=145&ncdver=2&bc=AAAAGAAAAAAA&](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=145&ncdver=2&bc=AAAAGAAAAAAA&)

28
29 Centers for Medicare and Medicaid Services. National Coverage Determination (NCD):
30 Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low Back Pain
31 (CLBP) (160.27). Retrieved on July 3, 2024 from [https://www.cms.gov/medicare-](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=354&ncdver=1&bc=AAAAGAAAAAAA&)
32 [coverage-database/details/ncd-](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=354&ncdver=1&bc=AAAAGAAAAAAA&)
33 [details.aspx?NCDId=354&ncdver=1&bc=AAAAGAAAAAAA&](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=354&ncdver=1&bc=AAAAGAAAAAAA&)

34
35 Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for
36 Treatment of Motor Function Disorders with Electric Nerve Stimulation (160.2).
37 Retrieved on July 3, 2024 from [https://www.cms.gov/medicare-coverage-](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?ncdid=22)
38 [database/details/ncd-details.aspx?ncdid=22](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?ncdid=22)

39
40 Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for
41 Non-Implantable Pelvic Floor Electrical Stimulator (230.8) Retrieved on July 3, 2024
42 from <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=231>

- 1 Cetin N, Aytar A, Atalay A, Akman MN. Comparing hot pack, short-wave diathermy,
2 ultrasound, and TENS on isokinetic strength, pain, and functional status of women with
3 osteoarthritic knees: A single-blind, randomized, controlled trial. *Am J Phys Med
4 Rehabil.* 2008;87:443-451
5
- 6 Chen HL, Yang FA, Lee TH, Liou TH, Escorpizo R, Chen HC. Effectiveness of
7 interferential current therapy in patients with knee osteoarthritis: a systematic review
8 and meta-analysis of randomized controlled trials. *Sci Rep.* 2022;12(1):9694.
9 Published 2022 Jun 11. doi:10.1038/s41598-022-13478-6
10
- 11 Chen YH, Wang HY, Liao CD, Liou TH, Escorpizo R, Chen HC. Effectiveness of
12 neuromuscular electrical stimulation in improving mobility in children with cerebral
13 palsy: A systematic review and meta-analysis of randomized controlled trials. *Clin
14 Rehabil.* 2023;37(1):3-16. doi:10.1177/02692155221109661
15
- 16 Chen YW, Chang KH, Chen HC, Liang WM, Wang YH, Lin YN. The effects of surface
17 neuromuscular electrical stimulation on post-stroke dysphagia: a systemic review and
18 meta-analysis. *Clin Rehabil.* 2016 Jan;30(1):24-35
19
- 20 Chiu HC, Ada L. Effect of functional electrical stimulation on activity in children with
21 cerebral palsy: a systematic review. *Pediatr Phys Ther.* 2014 Fall;26(3):283-8.
22
- 23 Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, Fu R, Dana T, Kraegel P,
24 Griffin J, Grusing S, Brodt E. Noninvasive Treatments for Low Back Pain.
25 Comparative Effectiveness Review No. 169. (Prepared by the Pacific Northwest
26 Evidence-based Practice Center under Contract No. 290-2012-00014-I.) AHRQ
27 Publication No. 16-EHC004-EF. Rockville, MD: Agency for Healthcare Research and
28 Quality; February 2016
29
- 30 Chou R and Hoyt Huffman LH. Nonpharmacologic therapies for acute and chronic low
31 back pain: A review of the evidence for an American Pain Society/American College
32 of Physicians Clinical Practice Guideline. *Annals of Internal Medicine.*
33 2007;147(7):492-504
34
- 35 Chou R, Qaseem A, Snow V, Casey D, Cross Jr T, Shekelle P, Owens DK. Diagnosis and
36 treatment of low back pain: A joint clinical practice guideline from the American
37 College of Physicians and the American Pain Society. *Annals of Internal Medicine.*
38 2007;147(7):478-490
39
- 40 Christiaanse ME, Mabe B, Russell G, Simeone TL, Fortunato J, Rubin B. Neuromuscular
41 electrical stimulation is no more effective than usual care for the treatment of primary
42 dysphagia in children. *Pediatr Pulmonol.* 2011 Jun;46(6):559-65

- 1 Clark H, Lazarus C, Arvedson J, Schooling T, Frymark T. Evidence-based systematic
2 review: effects of neuromuscular electrical stimulation on swallowing and neural
3 activation. *Am J Speech Lang Pathol.* 2009 Nov;18(4):361-75
4
- 5 Coyne PJ, Wan W, Dodson P, Swainey C, Smith TJ. A trial of Scrambler therapy in the
6 treatment of cancer pain syndromes and chronic chemotherapy-induced peripheral
7 neuropathy. *J Pain Palliat Care Pharmacother.* 2013 Dec;27(4):359-64.
8
- 9 Culvenor AG, Girdwood MA, Juhl CB, et al. Rehabilitation after anterior cruciate ligament
10 and meniscal injuries: a best-evidence synthesis of systematic reviews for the
11 OPTIKNEE consensus. *Br J Sports Med.* 2022;56(24):1445-1453.
12 doi:10.1136/bjsports-2022-105495
13
- 14 Dali Cí, Hansen FJ, Pedersen SA, Skov L, Hilden J, Bjørnskov I, Strandberg C, Christensen
15 J, Haugsted U, Herbst G, Lyskjaer U. Threshold electrical stimulation (TES) in
16 ambulant children with CP: a randomized double-blind placebo-controlled clinical
17 trial. *Dev Med Child Neurol.* 2002 Jun;44(6):364-9.
18
- 19 Davison P, Wilkinson R, Miller J, Auais M. A systematic review of using electrical
20 stimulation to improve clinical outcomes after hip fractures. *Physiother Theory Pract.*
21 2022;38(12):1857-1875. doi:10.1080/09593985.2021.1894620
22
- 23 DeJesus BM, Rodrigues IKL, Azevedo-Santos IF, DeSantana JM. Effect of
24 Transcutaneous Electrical Nerve Stimulation on Pain-related Quantitative Sensory
25 Tests in Chronic Musculoskeletal Pain and Acute Experimental Pain: Systematic
26 Review and Meta-analysis. *J Pain.* 2023;24(8):1337-1382.
27 doi:10.1016/j.jpain.2023.03.014
28
- 29 Dias LV, Cordeiro MA, Schmidt de Sales R, et al. Immediate analgesic effect of
30 transcutaneous electrical nerve stimulation (TENS) and interferential current (IFC) on
31 chronic low back pain: Randomised placebo-controlled trial. *J Bodyw Mov Ther.*
32 2021;27:181-190
33
- 34 Dissanayaka TD, Pallegama RW, Suraweera HJ, Johnson MI, Kariyawasam AP.
35 Comparison of the Effectiveness of Transcutaneous Electrical Nerve Stimulation and
36 Interferential Therapy on the Upper Trapezius in Myofascial Pain Syndrome: A
37 Randomized Controlled Study. *Am J Phys Med Rehabil.* 2016 Sep;95(9):663-72
38
- 39 Dubinsky RM, Miyasaki J, American Academy of Neurology, Efficacy of transcutaneous
40 electrical nerve stimulation in the treatment of pain in neurologic disorders (an
41 evidence-based review), *Neurology®* 2010; 74: 173-176

- 1 ELECTROPHYSICAL AGENTS - Contraindications And Precautions: An Evidence-
 2 Based Approach To Clinical Decision Making In Physical Therapy. *Physiother Can.*
 3 2010;62(5):1-80. Doi:10.3138/ptc.62.5
 4
- 5 Esnouf JE, Taylor PN, Mann GE, Barrett CL. Impact on activities of daily living using a
 6 functional electrical stimulation device to improve dropped foot in people with multiple
 7 sclerosis, measured by the Canadian Occupational Performance Measure. *Mult Scler.*
 8 2010 Sep;16(9):1141-7
 9
- 10 Evans AG, Horrar AN, Ibrahim MM, et al. Outcomes of transcutaneous nerve stimulation
 11 for migraine headaches: a systematic review and meta-analysis. *J Neurol.*
 12 2022;269(8):4021-4029. doi:10.1007/s00415-022-11059-1
 13
- 14 Everaert DG, Stein RB, Abrams GM, Dromerick AW, Francisco GE, Hafner BJ, Huskey
 15 TN, Munin MC, Nolan KJ, Kufta CV. Effect of a foot-drop stimulator and ankle-foot
 16 orthosis on walking performance after stroke: a multicenter randomized controlled
 17 trial. *Neurorehabil Neural Repair.* 2013 Sep;27(7):579-91
 18
- 19 Facci LM, Nowotny JP, Tormem F, Trevisani VF. Effects of transcutaneous electrical
 20 nerve stimulation (TENS) and interferential currents (IFC) in patients with nonspecific
 21 chronic low back pain: randomized clinical trial. *Sao Paulo Med J.* 2011;129(4):206-
 22 16
 23
- 24 Fernández-Pérez P, Leirós-Rodríguez R, Marqués-Sánchez MP, Martínez-Fernández MC,
 25 de Carvalho FO, Maciel LYS. Effectiveness of physical therapy interventions in
 26 women with dyspareunia: a systematic review and meta-analysis. *BMC Womens*
 27 *Health.* 2023;23(1):387. Published 2023 Jul 24. doi:10.1186/s12905-023-02532-8
 28
- 29 Fertout A, Manière-Ezvan A, Lupi L, Ehrmann E. Management of temporomandibular
 30 disorders with transcutaneous electrical nerve stimulation: A systematic review.
 31 *Cranio.* 2022;40(3):217-228. doi:10.1080/08869634.2019.1687986
 32
- 33 Frequency Specific Microcurrent. Retrieved on July 3, 2024 from
 34 <http://frequencyspecific.com/microcurrent-experimental-results-5407/about/>
 35
- 36 Fuentes JP, Armijo Olivo S, Magee DJ, Gross DP. Effectiveness of interferential current
 37 therapy in the management of musculoskeletal pain: a systematic review and meta-
 38 analysis. *Phys Ther.* 2010 Sep;90(9):1219-38
 39
- 40 Gatewood CT, Tran AA, Dragoo JL. The efficacy of post-operative devices following knee
 41 arthroscopic surgery: a systematic review. *Knee Surg Sports Traumatol Arthrosc.* 2017
 42 Feb;25(2):501-516

- 1 Gikaro JM, Bigambo FM, Minde VM, Swai EA. Efficacy of electrophysical agents in
2 fibromyalgia: A systematic review and network meta-analysis. *Clin Rehabil.*
3 2023;37(10):1295-1310. doi:10.1177/02692155231170450
4
- 5 Geeganage C, Beavan J, Ellender S, Bath PM. Interventions for dysphagia and nutritional
6 support in acute and subacute stroke. *Cochrane Database Syst Rev.* 2012 Oct
7 17;10:CD000323
8
- 9 Gibson W, Wand BM, Meads C, Catley MJ, O'Connell NE. Transcutaneous electrical
10 nerve stimulation (TENS) for chronic pain – an overview of Cochrane Reviews.
11 *Cochrane Database Syst Rev.* 2019 Apr 3;4(4):CD011890. Doi:
12 10.1002/14651858.CD011890.pub3
- 13 Gotlin RS, Hershkowitz S, Juris PM, et al. Electrical stimulation effect on extensor lag and
14 length of hospital stay after total knee arthroplasty. *Arch Phys Med Rehabil.*
15 1994;75(9):957-959
16
- 17 Graham N, Gross AR, Carlesso LC, Santaguida PL, Macdermid JC, Walton D, Ho E;
18 ICON. An ICON Overview on Physical Modalities for Neck Pain and Associated
19 Disorders. *Open Orthop J.* 2013 Sep 20;7:440-60
20
- 21 Gross AR, Goldsmith C, Hoving JL, Haines T, Peloso P, Aker P, et al. Conservative
22 management of mechanical neck disorders: a systematic review. *J Rheumatol* 2007;
23 34:1083-1102
24
- 25 Gu P, Ran JJ. Electrical Stimulation for Hemiplegic Shoulder Function: A Systematic
26 Review and Meta-Analysis of 15 Randomized Controlled Trials. *Arch Phys Med*
27 *Rehabil.* 2016 Sep;97(9):1588-94
28
- 29 Guzman J, Haldeman S, Carroll LJ, Carragee EJ, Hurwitz EL, Peloso P, et al. Clinical
30 practice implications of the Bone and Joint Decade 2000-2010 Task Force on Neck
31 Pain and Its Associated Disorders: from concepts and findings to recommendations.
32 *Spine* 2008;33:S199-S213
33
- 34 Haldeman S, Dagenais S. What have we learned about the evidence-informed management
35 of chronic low back pain? *Spine J.* 2008 Jan-Feb;8(1):266-77
36
- 37 Hako-Med. Retrieved on June 15, 2023 June 27, 2024 from <https://hakomed.net/>
38
- 39 Hawk C, Whalen W, Farabaugh RJ, Daniels CJ, Minkalis AL, Taylor DN, Anderson D,
40 Anderson K, Crivelli LS, Cark M, Barlow E, Paris D, Sarnat R, Weeks J. Best Practices
41 for Chiropractic Management of Patients with Chronic Musculoskeletal Pain: A

- 1 Clinical Practice Guideline. *J Altern Complement Med.* 2020 Oct;26(10):884-901. Doi:
2 10.1089/acm.2020.0181
3
- 4 Hayes Inc. Health technology assessment. Scrambler/Calmare pain therapy (Calmare
5 Therapeutics Inc.) for the management of pain not related to cancer. Lansdale, PA:
6 Hayes, Inc. Apr 6, 2020.
7
- 8 Hayes Inc. Health technology assessment. Scrambler/Calmare pain therapy (Calmare
9 Therapeutics Inc.) for the management of chronic pain related to cancer or cancer
10 treatment. Lansdale, PA: Hayes, Inc. Mar 30, 2020.
11
- 12 Hayes Inc. Hayes Brief. Percutaneous electrical nerve stimulation for treatment of low back
13 pain. Lansdale, PA: Hayes, Inc. Feb 9, 2017
14
- 15 Houghton PE. Clinical Trials Involving Biphasic Pulsed Current, MicroCurrent, and/or
16 Low-Intensity Direct Current. *Adv Wound Care (New Rochelle).* 2014 Feb1;3(2):166-
17 183
18
- 19 Howlett OA, Lannin NA, Ada L, McKinstry C. Functional electrical stimulation improves
20 activity after stroke: a systematic review with meta-analysis. *Arch Phys Med Rehabil.*
21 2015 May;96(5):934-43
22
- 23 Hsueh TC, Cheng PT, Kuan TS, Hong CZ. The immediate effectiveness of electrical nerve
24 stimulation and electrical muscle stimulation on myofascial trigger points. *Am J Phys*
25 *Med Rehabil* 1997;76:471-476
26
- 27 Huang J, Fan Y, Zhao K, et al. Comparative Efficacy of Neuromodulation Technologies
28 for Overactive Bladder in Adults: A Network Meta-Analysis of Randomized
29 Controlled Trials. *Neuromodulation.* 2023;26(8):1535-1548.
30 doi:10.1016/j.neurom.2022.06.004
31
- 32 Huckabee ML, Doeltgen S. Emerging modalities in dysphagia rehabilitation:
33 neuromuscular electrical stimulation. *N Z Med J.* 2007 Oct 12;120(1263):U2744
34
- 35 Hurlow A, Bennett MI, Robb KA, Johnson MI, Simpson KH, Oxberry SG. Transcutaneous
36 electric nerve stimulation (TENS) for cancer pain in adults. *Cochrane Database of*
37 *Systematic Reviews* 2012, Issue 3. Art. No.: CD006276
38
- 39 Hurwitz EL, Carragee EJ, van d, V, Carroll LJ, Nordin M, Guzman J, et al. Treatment of
40 neck pain: noninvasive interventions: results of the Bone and Joint Decade 2000-2010
41 Task Force on Neck Pain and Its Associated Disorders. *J Manipulative Physiol Ther*
42 2009;32:S141-S175

- 1 Hussein HM, Alshammari RS, Al-Barak SS, Alshammari ND, Alajlan SN, Althomali OW.
 2 A Systematic Review and Meta-analysis Investigating the Pain-Relieving Effect of
 3 Interferential Current on Musculoskeletal Pain. *Am J Phys Med Rehabil.*
 4 2022;101(7):624-633. doi:10.1097/PHM.0000000000001870
 5
- 6 Hwang S, Song CS. Rehabilitative effects of electrical stimulation on gait performance in
 7 stroke patients: A systematic review with meta-analysis. *NeuroRehabilitation.*
 8 2024;54(2):185-197. doi:10.3233/NRE-230360
 9
- 10 Ibitoye MO, Hamzaid NA, Ahmed YK. Effectiveness of FES-supported leg exercise for
 11 promotion of paralysed lower limb muscle and bone health-a systematic review.
 12 *Biomed Tech (Berl).* 2023;68(4):329-350. Published 2023 Mar 1. doi:10.1515/bmt-
 13 2021-0195
 14
- 15 Ignácio Antônio F, Bø K, Pena CC, et al. Intravaginal electrical stimulation increases
 16 voluntarily pelvic floor muscle contractions in women who are unable to voluntarily
 17 contract their pelvic floor muscles: a randomised trial. *J Physiother.* 2022;68(1):37-42
 18
- 19 Iijima H, Takahashi M. Microcurrent Therapy as a Therapeutic Modality for
 20 Musculoskeletal Pain: A Systematic Review Accelerating the Translation From
 21 Clinical Trials to Patient Care. *Arch Rehabil Res Clin Transl.* 2021;3(3):100145.
 22 Published 2021 Jul 21
 23
- 24 Imoto AM, Peccin S, Almeida GJ, Saconato H, Atallah ÁN. Effectiveness of electrical
 25 stimulation on rehabilitation after ligament and meniscal injuries: a systematic review.
 26 *Sao Paulo Med J.* 2011 Dec;129(6):414-23
 27
- 28 Jamtvedt G, Dahm KT, Christie A, et al. Physical therapy interventions for patients with
 29 osteoarthritis of the knee: An overview of systematic reviews. *Phys Ther.* 2008;88:123-
 30 136
 31
- 32 Jauregui JJ, Cherian JJ, Gwam CU, Chughtai M, Mistry JB, Elmallah RK, Harwin SF,
 33 Bhave A, Mont MA. A Meta-Analysis of Transcutaneous Electrical Nerve Stimulation
 34 for Chronic Low Back Pain. *Surg Technol Int.* 2016 Apr;28:296-30
 35
- 36 Jiang Y, Li X, Guo S, et al. Transcutaneous Electrical Stimulation for Neurogenic Bladder
 37 After Spinal Cord Injury: A Systematic Review and Meta-Analysis. *Neuromodulation.*
 38 2024;27(4):604-613. doi:10.1016/j.neurom.2023.06.002
 39
- 40 Jin DM, Xu Y, Geng DF, Yan TB. Effect of transcutaneous electrical nerve stimulation on
 41 symptomatic diabetic peripheral neuropathy: a meta-analysis of randomized controlled
 42 trials. *Diabetes Res Clin Pract.* 2010 Jul;89(1):10-5

- 1 Jin Y, Kim D, Hur J, Myung SK. Efficacy of Scrambler Therapy for Management of
 2 Chronic Pain: A Meta-Analysis of Randomized Controlled Trials. *Pain Physician*.
 3 2022;25(7):E931-E939.
 4
- 5 Johnson M, Martinson M. Efficacy of electrical nerve stimulation for chronic
 6 musculoskeletal pain: A meta-analysis of randomized controlled trials. *Pain*.
 7 2007;130:157-165
 8
- 9 Johnson MI, Jones G. Transcutaneous electrical nerve stimulation: current status of
 10 evidence. *Pain Manag*. 2017 Jan;7(1):1-4
 11
- 12 Johnson MI, Paley CA, Howe TE, Sluka KA. Transcutaneous electrical nerve stimulation
 13 for acute pain. *Cochrane Database Syst Rev*. 2015 Jun 15;6:CD006142
 14
- 15 Johnson MI, Paley CA, Jones G, Mulvey MR, Wittkopf PG. Efficacy and safety of
 16 transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults:
 17 a systematic review and meta-analysis of 381 studies (the meta-TENS study). *BMJ*
 18 *Open*. 2022;12(2):e051073. Published 2022 Feb 10
 19
- 20 Johnston TE, Keller S, Denzer-Weiler C, Brown L. A Clinical Practice Guideline for the
 21 Use of Ankle-Foot Orthoses and Functional Electrical Stimulation Post-Stroke. *J*
 22 *Neurol Phys Ther*. 2021;45(2):112-196
 23
- 24 Jones S, Man WD, Gao W, Higginson IJ, Wilcock A, Maddocks M. Neuromuscular
 25 electrical stimulation for muscle weakness in adults with advanced disease. *Cochrane*
 26 *Database Syst Rev*. 2016 Oct 17;10:CD009419
 27
- 28 Kadı MR, Hepgüler S, Atamaz FC, et al. Is interferential current effective in the
 29 management of pain, range of motion, and edema following total knee arthroplasty
 30 surgery? A randomized double-blind controlled trial. *Clin Rehabil*. 2019; 33(6):1027-
 31 1034
 32
- 33 Kang RW, Lewis PB, Kramer A, Hayden JK, Cole BJ. Prospective randomized single-
 34 blinded controlled clinical trial of percutaneous neuromodulation pain therapy device
 35 versus sham for the osteoarthritic knee: a pilot study. *Orthopedics*. 2007 Jun;30(6):439-
 36 45
 37
- 38 Karamian BA, Siegel N, Nourie B, et al. The role of electrical stimulation for rehabilitation
 39 and regeneration after spinal cord injury. *J Orthop Traumatol*. 2022;23(1):2. Published
 40 2022 Jan 6

- 1 Karri J, Marathe A, Smith TJ, Wang EJ. The Use of Scrambler Therapy in Treating Chronic
2 Pain Syndromes: A Systematic Review. *Neuromodulation*. 2023;26(8):1499-1509.
3 doi:10.1016/j.neurom.2022.04.045
4
- 5 Kashyap K, Bhatnagar S. Evidence for the Efficacy of Scrambler Therapy for Cancer Pain:
6 A Systematic Review. *Pain Physician*. 2020;23(4):349-364.
7
- 8 Kerr C, McDowell B, Cosgrove A, Walsh D, Bradbury I, McDonough S. Electrical
9 stimulation in cerebral palsy: a randomized controlled trial. *Dev Med Child Neurol*.
10 2006 Nov;48(11):870-6.
11
- 12 Khadilkar A, Milne S, Brosseau L, Robinson V, Saginur M, Shea B, Tugwell P, Wells G.
13 Transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain.
14 *Cochrane Database Syst Rev*. 2005 Jul 20;(3):CD003008. Review. Update in:
15 *Cochrane Database Syst Rev*. 2008;(4):CD003008
16
- 17 Khadilkar A, Odebiyi DO, Brosseau L, Wells GA. Transcutaneous electrical nerve
18 stimulation (TENS) versus placebo for chronic low-back pain. *Cochrane Database Syst*
19 *Rev*. 2008 Oct 8;(4):CD003008
20
- 21 Kiger M, Brown CS, Watkins L. Dysphagia management: an analysis of patient outcomes
22 using VitalStim therapy compared to traditional swallow therapy. *Dysphagia*. 2006
23 Oct;21(4):243-53
24
- 25 Kim KM, Croy T, Hertel J, Saliba S. Effects of neuromuscular electrical stimulation after
26 anterior cruciate ligament reconstruction on quadriceps strength, function, and patient-
27 oriented outcomes: a systematic review. *J Orthop Sports Phys Ther*. 2010
28 Jul;40(7):383-91
29
- 30 Koyuncu E, Nakipoğlu-Yüzer GF, Doğan A, Ozgirgin N. The effectiveness of functional
31 electrical stimulation for the treatment of shoulder subluxation and shoulder pain in
32 hemiplegic patients: A randomized controlled trial. *Disabil Rehabil*. 2010;32(7):560-6
33
- 34 Kristensen MGH, Busk H, Wienecke T. Neuromuscular Electrical Stimulation Improves
35 Activities of Daily Living Post Stroke: A Systematic Review and Meta-analysis. *Arch*
36 *Rehabil Res Clin Transl*. 2021;4(1):100167. Published 2021 Nov 12
37
- 38 Labanca L, Bonsanto F, Raffa D, Orlandi Magli A, Benedetti MG. Does adding
39 neuromuscular electrical stimulation to rehabilitation following total knee arthroplasty
40 lead to a better quadriceps muscle strength recovery? A systematic review. *Int J Rehabil*
41 *Res*. 2022;45(2):118-125. doi:10.1097/MRR.0000000000000525

- 1 Lee SC, Park KS, Moon JY, Kim EJ, Kim YC, Seo H, Sung JK, Lee da J. An exploratory
2 study on the effectiveness of "Calmare therapy" in patients with cancer-related
3 neuropathic pain: A pilot study. *Eur J Oncol Nurs*. 2016 Apr;21:1-7.
4
- 5 Leonardo K, Seno DH, Mirza H, Afriansyah A. Biofeedback-assisted pelvic floor muscle
6 training and pelvic electrical stimulation in women with overactive bladder: A
7 systematic review and meta-analysis of randomized controlled trials. *Neurourol*
8 *Urodyn*. 2022;41(6):1258-1269. doi:10.1002/nau.24984
9
- 10 Leemans L, Polli A, Nijs J, Wideman T, den Bandt H, Beckwée D. It Hurts to Move!
11 Intervention Effects and Assessment Methods for Movement-Evoked Pain in Patients
12 With Musculoskeletal Pain: A Systematic Review with Meta-analysis. *J Orthop Sports*
13 *Phys Ther*. 2022;52(6):345-374. doi:10.2519/jospt.2022.10527
14
- 15 Liang Y, Lin J, Wang H, et al. Evaluating the Efficacy of VitalStim Electrical Stimulation
16 Combined with Swallowing Function Training for Treating Dysphagia following an
17 Acute Stroke. *Clinics (Sao Paulo)*. 2021;76:e3069. Published 2021 Nov 8.
18 doi:10.6061/clinics/2021/e3069
19
- 20 Loh MS, Kuan YC, Wu CW, Liao CD, Hong JP, Chen HC. Upper Extremity
21 Contralaterally Controlled Functional Electrical Stimulation Versus Neuromuscular
22 Electrical Stimulation in Post-Stroke Individuals: A Meta-Analysis of Randomized
23 Controlled Trials. *Neurorehabil Neural Repair*. 2022;36(7):472-482.
24 doi:10.1177/15459683221092647
25
- 26 Maddocks M, Gao W, Higginson IJ, Wilcock A. Neuromuscular electrical stimulation for
27 muscle weakness in adults with advanced disease. *Cochrane Database Syst Rev*. 2013
28 Jan 31;1:CD009419
29
- 30 Mahmoudi Z, Mohammadi R, Sadeghi T, Kalbasi G. The Effects of Electrical Stimulation
31 of Lower Extremity Muscles on Balance in Stroke Patients: A Systematic Review of
32 Literatures. *J Stroke Cerebrovasc Dis*. 2021;30(8):105793
33
- 34 Marineo G, Iorno V, Gandini C, Moschini V, Smith TJ. Scrambler therapy may relieve
35 chronic neuropathic pain more effectively than guideline-based drug management:
36 results of a pilot, randomized, controlled trial. *J Pain Symptom Manage*. 2012
37 Jan;43(1):87-95. doi: 10.1016/j.jpainsymman.2011.03.015.
38
- 39 Máté S, Sinan-Fornusek C, Dhopte P, Singh MF, Hackett D, Fornusek C. Effects of
40 Functional Electrical Stimulation Cycling Combined With Arm Cranking Exercise on
41 Cardiorespiratory Fitness in People With Central Nervous System Disorders: A

- 1 Systematic Review and Meta-analysis. *Arch Phys Med Rehabil.* 2023;104(11):1928-
2 1940. doi:10.1016/j.apmr.2023.03.026
3
- 4 Miller S, Kühn D, Jungheim M, Schwemmle C, Ptok M. Neuromuskuläre
5 Elektrostimulationsverfahren in der HNO-Heilkunde [Neuromuscular electric
6 stimulation therapy in otorhinolaryngology]. *HNO.* 2014;62(2):131-140.
7 doi:10.1007/s00106-013-2810-4
- 8 Miller S, Peters K, Ptok M. Review of the effectiveness of neuromuscular electrical
9 stimulation in the treatment of dysphagia - an update. *Ger Med Sci.* 2022;20:Doc08.
10 Published 2022 Jun 14. doi:10.3205/000310
11
- 12 Moezy A, Masoudi S, Nazari A, Abasi A. A controlled randomized trial with a 12-week
13 follow-up investigating the effects of medium-frequency neuromuscular electrical
14 stimulation on pain, VMO thickness, and functionality in patients with knee
15 osteoarthritis. *BMC Musculoskelet Disord.* 2024;25(1):158. Published 2024 Feb 20.
16 doi:10.1186/s12891-024-07266-8
17
- 18 Monaghan B, Caulfield B, O’Mathúna DP. Surface neuromuscular electrical stimulation
19 for quadriceps strengthening pre and post total knee replacement. *Cochrane Database*
20 *Syst Rev.* 2010 Jan 20;(1):CD007177
21
- 22 Morawietz C, Moffat F. Effects of locomotor training after incomplete spinal cord injury:
23 a systematic review. *Arch Phys Med Rehabil.* 2013;94(11):2297-2308.
24 doi:10.1016/j.apmr.2013.06.023
25
- 26 Mulvey MR, Bagnall AM, Johnson MI, Marchant PR. Transcutaneous electrical nerve
27 stimulation (TENS) for phantom pain and stump pain following amputation in adults.
28 *Cochrane Database of Systematic Reviews* 2010, Issue 5. Art. No.: CD007264
29
- 30 Nair HKR. Microcurrent as an adjunct therapy to accelerate chronic wound healing and
31 reduce patient pain. *J Wound Care.* 2018 May 2;27(5):296-306
32
- 33 National Guideline Centre (UK). Evidence review for electrical physical modalities for
34 chronic primary pain: Chronic pain (primary and secondary) in over 16s: assessment
35 of all chronic pain and management of chronic primary pain. London: National Institute
36 for Health and Care Excellence (NICE); April 2021
37
- 38 Nnoaham KE, Kumbang J. Transcutaneous electrical nerve stimulation (TENS) for chronic
39 pain. *Cochrane Database Syst Rev.* 2008:CD003222
40
- 41 Nooijen CF, Ter Hoeve N, Field-Fote EC. Gait quality is improved by locomotor training
42 in individuals with SCI regardless of training approach. *J Neuroeng Rehabil*

- 1 Notaro P, Dell'Agnola CA, Dell'Agnola AJ, Amatu A, Bencardino KB, Siena S. Pilot
2 evaluation of scrambler therapy for pain induced by bone and visceral metastases and
3 refractory to standard therapies. *Support Care Cancer*. 2016 Apr;24(4):1649-54.
4
- 5 Norwood SM, Han D, Gupta A. H-Wave® Device Stimulation for Chronic Low Back Pain:
6 A Patient-Reported Outcome Measures (PROMs) Study. *Pain Ther*. 2024
7 Feb;13(1):113-126
8
- 9 Novak S, Guerron G, Zou Z, Cheung G, Berteau JP. New Guidelines for Electrical
10 Stimulation Parameters in Adult Patients With Knee Osteoarthritis Based on a
11 Systematic Review of the Current Literature. *Am J Phys Med Rehabil*. 2020
12 Aug;99(8):682-68
13
- 14 Ottawa panel evidence-based clinical practice guidelines for electrotherapy and
15 thermotherapy interventions in the management of rheumatoid arthritis in adults. *Phys
16 Ther*. 2004;84:1016-1043
- 17 Ou CH, Shiue CC, Kuan YC, Liou TH, Chen HC, Kuo TJ. Neuromuscular Electrical
18 Stimulation of Upper Limbs in Patients With Cerebral Palsy: A Systematic Review and
19 Meta-analysis of Randomized Controlled Trials. *Am J Phys Med Rehabil*.
20 2023;102(2):151-158. doi:10.1097/PHM.0000000000002058
21
- 22 Page MJ, Green S, Mrocki MA, Surace SJ, Deitch J, McBain B, Lyttle N, Buchbinder R.
23 Electrotherapy modalities for rotator cuff disease. *Cochrane Database Syst Rev*. 2016
24 Jun 10;(6):CD012225
25
- 26 Paley CA, Wittkopf PG, Jones G, Johnson MI. Does TENS Reduce the Intensity of Acute
27 and Chronic Pain? A Comprehensive Appraisal of the Characteristics and Outcomes of
28 169 Reviews and 49 Meta-Analyses. *Medicina (Kaunas)*. 2021;57(10):1060. Published
29 2021 Oct 4. doi:10.3390/medicina57101060
30
- 31 Pan H, Bao Y, Cao H, Jin R, Wang P, Zhang J. The effectiveness of magnetic stimulation
32 for patients with pelvic floor dysfunction: A systematic review and meta-analysis.
33 *Neurourol Urodyn*. 2018 Nov;37(8):2368-2381
34
- 35 Peng L, Wang K, Zeng Y, Wu Y, Si H, Shen B. Effect of Neuromuscular Electrical
36 Stimulation After Total Knee Arthroplasty: A Systematic Review and Meta-Analysis
37 of Randomized Controlled Trials. *Front Med (Lausanne)*. 2021;8:779019. Published
38 2021 Dec 3
39
- 40 Pereira S, Mehta S, McIntyre A, Lobo L, Teasell RW. Functional electrical stimulation for
41 improving gait in persons with chronic stroke. *Top Stroke Rehabil*. 2012 Nov-
42 Dec;19(6):491-8

- 1 Philadelphia panel evidence-based clinical practice guidelines on selected rehabilitation
2 interventions for knee pain. *Phys Ther.* 2001;81:1675-1700
3
- 4 Philadelphia panel evidence-based clinical practice guidelines on selected rehabilitation
5 interventions for shoulder pain. *Phys Ther.* 2001;81:1719-1730
6
- 7 Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on
8 selected rehabilitation interventions for low back pain. *Phys Ther.* 2001;81(10):1641-
9 74
10
- 11 Pieber K, Herceg M, Paternostro-Sluga T. Electrotherapy for the treatment of painful
12 diabetic peripheral neuropathy: a review. *J Rehabil Med.* 2010 Apr;42(4):289-95
13
- 14 Pietrosimone B, Luc-Harkey BA, Harkey MS, Davis-Wilson HC, Pfeiffer SJ, Schwartz
15 TA, Nissman D, Padua DA, Blackburn JT, Spang JT. Using TENS to Enhance
16 Therapeutic Exercise in Individuals with Knee Osteoarthritis. *Med Sci Sports Exerc.*
17 2020 Oct;52(10):2086-2095
18
- 19 Pivec R, Stokes M, Chitnis AS, Paulino CB, Harwin SF, Mont MA. Clinical and economic
20 impact of TENS in patients with chronic low back pain: analysis of a nationwide
21 database. *Orthopedics.* 2013 Dec;36(12):922-8
22
- 23 Plaza-Manzano G, Gómez-Chiguano GF, Cleland JA, Ariás-Buría JL, Fernández-de-Las-
24 Peñas C, Navarro-Santana MJ. Effectiveness of percutaneous electrical nerve
25 stimulation for musculoskeletal pain: A systematic review and meta-analysis. *Eur J*
26 *Pain.* 2020 Jul;24(6):1023-1044
27
- 28 Poitras S, Brosseau L. Evidence-informed management of chronic low back pain with
29 transcutaneous electrical nerve stimulation, interferential current, electrical muscle
30 stimulation, ultrasound, and thermotherapy. *Spine J.* 2008 Jan-Feb;8(1):226-33
31
- 32 Pomeroy VM, King L, Pollock A, Baily-Hallam A, Langhorne P. Electrostimulation for
33 promoting recovery of movement or functional ability after stroke. *Cochrane Database*
34 *Syst Rev.* 2006 Apr 19;(2):CD003241
35
- 36 Postans NJ, Hasler JP, Granat MH, Maxwell DJ. Functional electric stimulation to augment
37 partial weight-bearing supported treadmill training for patients with acute incomplete
38 spinal cord injury: A pilot study. *Arch Phys Med Rehabil.* 2004 Apr;85(4):604-10
39
- 40 Prenton S, Hollands KL, Kenney LP. Functional electrical stimulation versus ankle foot
41 orthoses for foot-drop: A meta-analysis of orthotic effects. *J Rehabil Med.* 2016 Oct
42 5;48(8):646-656

- 1 Price CI, Pandyan AD. Electrical stimulation for preventing and treating post-stroke
2 shoulder pain. *Cochrane Database Syst Rev.* 2000;(4):CD001698
3
- 4 Propp R, Gill PJ, Marcus S, et al. Neuromuscular electrical stimulation for children with
5 dysphagia: a systematic review. *BMJ Open.* 2022;12(3):e055124. Published 2022 Mar
6 25. doi:10.1136/bmjopen-2021-055124
7
- 8 Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee of the
9 American College of Physicians. Noninvasive Treatments for Acute, Subacute, and
10 Chronic Low Back Pain: A Clinical Practice Guideline From the American College of
11 Physicians. *Ann Intern Med.* 2017 Apr 4;166(7):514-530
12
- 13 Rajpurohit B, Khatri SM, Metgud D, Bagewadi A. Effectiveness of transcutaneous
14 electrical nerve stimulation and microcurrent electrical nerve stimulation in bruxism
15 associated with masticatory muscle p—n--a comparative study. *Indian J Dent Res.*
16 2010 Jan-Mar;21(1):104-6
17
- 18 Rampazo ÉP, Martignago CCS, de Noronha M, Liebano RE. Transcutaneous electrical
19 stimulation in neck pain: A systematic review and meta-analysis. *Eur J Pain.*
20 2022;26(1):18-42
21
- 22 Rampazo ÉP, Liebano RE. Analgesic Effects of Interferential Current Therapy: A
23 Narrative Review. *Medicina (Kaunas).* 2022;58(1):141. Published 2022 Jan 17.
24 doi:10.3390/medicina58010141
25
- 26 Rampazo ÉP, Júnior MAL, Corrêa JB, et al. Effectiveness of interferential current in
27 patients with chronic non-specific low back pain: a systematic review with meta-
28 analysis. *Braz J Phys Ther.* 2023;27(5):100549. doi:10.1016/j.bjpt.2023.100549
29
- 30 Reichenbach S, Jüni P, Hincapié CA, et al. Effect of transcutaneous electrical nerve
31 stimulation (TENS) on knee pain and physical function in patients with symptomatic
32 knee osteoarthritis: the ETRELKA randomized clinical trial. *Osteoarthritis Cartilage.*
33 2022;30(3):426-435
34
- 35 Ricci M, Fabbri L, Pirotti S, Ruffilli N, Foca F, Maltoni M. Scrambler therapy: what's new
36 after 15 years? The results from 219 patients treated for chronic pain. *Medicine*
37 *(Baltimore).* 2019 Jan;98(2):e13895.
38
- 39 Ricci M, Pirotti S, Scarpi E, Burgio M, Maltoni M, Sansoni E, Amadori D. Managing
40 chronic pain: results from an open-label study using MC5-A Calmare® device. *Support*
41 *Care Cancer.* 2012 Feb;20(2):405-12. Epub 2011 Mar 11

- 1 RST-SANEXAS neoGEN® Electric cell-Signaling Treatments (EcST). Retrieved on June
2 15, 2023 from <https://www.rstsanexas.com/neogen/>
3
- 4 Robb K, Oxberry SG, Bennett MI, Johnson MI, Simpson KH, Searle RD. A Cochrane
5 systematic review of transcutaneous electrical nerve stimulation for cancer pain. *J Pain*
6 *Symptom Manage.* 2009 Apr;37(4):746-53
7
- 8 Rutjes AW, Nuesch E, Sterchi R, Kalichman L, Hendriks E, Osiri M, Brosseau L,
9 Reichenbach S, Jüni P. Transcutaneous electrostimulation for osteoarthritis of the knee.
10 *Cochrane Database Syst Rev.* 2009 Oct 7;(4):CD002823
11
- 12 Sabato AF, Marineo G, Gatti A. Scrambler therapy. *Minerva Anestesiol.* 2005 Jul-
13 Aug;71(7-8):479-82
14
- 15 Shaw GY, Sechtem PR, Searl J, Keller K, Rawi TA, Dowdy E. Transcutaneous
16 neuromuscular electrical stimulation (VitalStim) curative therapy for severe dysphagia:
17 myth or reality? *Ann Otol Rhinol Laryngol.* 2007 Jan;116(1):36-44
18
- 19 Sharififar S, Shuster JJ, Bishop MD. Adding electrical stimulation during standard
20 rehabilitation after stroke to improve motor function. A systematic review and meta-
21 analysis. *Ann Phys Rehabil Med.* 2018;61(5):339-344
22
- 23 Sillen MJ, Speksnijder CM, Eterman RM, Janssen PP, Wagers SS, Wouters EF, Uszko-
24 Lencer NH, Spruit MA. Effects of neuromuscular electrical stimulation of muscles of
25 ambulation in patients with chronic heart failure or COPD: a systematic review of the
26 English-language literature. *Chest.* 2009 Jul;136(1):44-61
27
- 28 Sluka KA, Bjordal JM, Marchand S, Rakel BA. What makes transcutaneous electrical
29 nerve stimulation work? Making sense of the mixed results in the clinical literature.
30 *Phys. Ther.* 2013;93(10):1397–1402
31
- 32 Sluka KA, Walsh D. Transcutaneous electrical nerve stimulation: Basic science
33 mechanisms and clinical effectiveness. *J Pain.* 2003;4:109-121
34
- 35 Smith TJ, Razzak AR, Blackford AL, et al. A pilot randomized sham-controlled trial of
36 mc5-a scrambler therapy in the treatment of chronic chemotherapy-induced peripheral
37 neuropathy (CIPN). *J Palliat Care.* 2020;35(1):53-58
38
- 39 Snyder-Mackler L, Delitto A, Bailey SL, Stralka SW. Strength of the quadriceps femoris
40 muscle and functional recovery after reconstruction of the anterior cruciate ligament.
41 A prospective, randomized clinical trial of electrical stimulation. *J Bone Joint Surg Am.*
42 1995;77(8):1166-1173

- 1 Snyder-Mackler L, Ladin Z, Schepsis AA, Young JC. Electrical stimulation of the thigh
2 muscles after reconstruction of the anterior cruciate ligament. *J Bone Joint Surg.*
3 1991;73(7):1025-1036
4
- 5 Springer S, Khamis S. Effects of functional electrical stimulation on gait in people with
6 multiple sclerosis - A systematic review. *Mult Scler Relat Disord.* 2017 Apr;13:4-12
7
- 8 Stania M, Niemiec B, Kamieniarz A, Chmielewska D. Intravaginal electrical stimulation
9 as a monotherapy for female stress urinary incontinence: A systematic review and
10 meta-analysis. *Complement Ther Clin Pract.* 2022;49:101624.
11 doi:10.1016/j.ctcp.2022.101624
12
- 13 Steele CM, Thrasher AT, Popovic MR. Electric stimulation approaches to the restoration
14 and rehabilitation of swallowing: a review. *Neurological Research.* 2007;29(1):9–15
15
- 16 Stein C, Fritsch CG, Robinson C, Sbruzzi G, Plentz RD. Effects of electrical stimulation
17 in spastic muscles after stroke: systematic review and meta-analysis of randomized
18 controlled trials. *Stroke.* 2015 Aug;46(8):2197-205
19
- 20 Stein RB, Everaert DG, Thompson AK, Chong SL, Whittaker M, Robertson J, Kuether G.
21 Long-term therapeutic and orthotic effects of a foot drop stimulator on walking
22 performance in progressive and nonprogressive neurological disorders. *Neurorehabil*
23 *Neural Repair.* 2010 Feb;24(2):152-67
24
- 25 Stewart F, Berghmans B, Bø K, Glazener CM. Electrical stimulation with non-implanted
26 devices for stress urinary incontinence in women. *Cochrane Database Syst Rev.* 2017
27 Dec 22;12:CD012390
28
- 29 Tan C, Liu Y, Li W, Liu J, Chen L. Transcutaneous neuromuscular electrical stimulation
30 can improve swallowing function in patients with dysphagia caused by non-stroke
31 diseases: a meta-analysis. *J Oral Rehabil.* 2013 Jun;40(6):472-80
32
- 33 Tenberg S, Mueller S, Vogt L, et al. Comparative Effectiveness of Upper Limb Exercise
34 Interventions in Individuals With Stroke: A Network Meta-Analysis. *Stroke.*
35 2023;54(7):1839-1853. doi:10.1161/STROKEAHA.123.043110
36
- 37 Teoli D, Dua A, An J. Transcutaneous Electrical Nerve Stimulation. [Updated 2024 Mar
38 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
39 Available from: <https://www.ncbi.nlm.nih.gov/books/NBK537188/>

- 1 Terré R, Mearin F. A randomized controlled study of neuromuscular electrical stimulation
2 in oropharyngeal dysphagia secondary to acquired brain injury. *Eur J Neurol.* 2015
3 Apr;22(4):687-e44
4
- 5 Todhunter-Brown A, Hazelton C, Campbell P, Elders A, Hagen S, McClurg D.
6 Conservative interventions for treating urinary incontinence in women: an Overview
7 of Cochrane systematic reviews. *Cochrane Database Syst Rev.* 2022;9(9):CD012337.
8 Published 2022 Sep 2. doi:10.1002/14651858.CD012337.pub2
9
- 10 van der Scheer JW, Goosey-Tolfrey VL, Valentino SE, Davis GM, Ho CH. Functional
11 electrical stimulation cycling exercise after spinal cord injury: a systematic review of
12 health and fitness-related outcomes. *J Neuroeng Rehabil.* 2021;18(1):99. Published
13 2021 Jun 12
14
- 15 Van Peppen RP, Kwakkel G, Wood-Dauphinee S, Hendriks HJ, Van der Wees PJ, Dekker
16 J. The impact of physical therapy on functional outcomes after stroke: what's the
17 evidence? *Clin Rehabil.* 2004 Dec;18(8):833-62
18
- 19 Vance CG, Dailey DL, Rakel BA, Sluka KA. Using TENS for pain control: the state of the
20 evidence. *Pain Manag.* 2014 May;4(3):197-209
21
- 22 Vance CGT, Dailey DL, Chimenti RL, Van Gorp BJ, Crofford LJ, Sluka KA. Using TENS
23 for Pain Control: Update on the State of the Evidence. *Medicina (Kaunas).*
24 2022;58(10):1332. Published 2022 Sep 22. doi:10.3390/medicina58101332
25
- 26 Verville L, Hincapié CA, Southerst D, et al. Systematic Review to Inform a World Health
27 Organization (WHO) Clinical Practice Guideline: Benefits and Harms of
28 Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Primary Low Back
29 Pain in Adults. *J Occup Rehabil.* 2023;33(4):651-660. doi:10.1007/s10926-023-10121-
30 7
31
- 32 Walsh DM. *TENS: Clinical Applications and Related Theory.* In. New York: Churchill
33 Livingston; 1997
34
- 35 Walsh NE, Brooks P, Hazes JM, et al. Standards of care for acute and chronic
36 musculoskeletal pain: The bone and joint decade (2000-2010). *Arch Phys Med Rehabil.*
37 2008;89:1830-1845
38
- 39 Wang EJ, Berninger LE, Komargodski O, Smith TJ. Painful Diabetic Neuropathy - Spinal
40 Cord Stimulation, Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve
41 Stimulation, and Scrambler Therapy: A Narrative Review. *Pain Physician.*
42 2022;25(8):E1163-E1173

- 1 Wang Z, Xiao Z, Shen Q, Zhao N, Zhang W. Neuromuscular Electrical Stimulation for
 2 Post-Stroke Dysphagia Treatment: A Systemic Evaluation and Meta-Analysis of
 3 Randomized Controlled Trials. *Dysphagia*. 2024;39(3):424-432. doi:10.1007/s00455-
 4 023-10626-6
- 5
- 6 Weiner DK, Perera S, Rudy TE, Glick RM, Shenoy S, Delitto A. Efficacy of percutaneous
 7 electrical nerve stimulation and therapeutic exercise for older adults with chronic low
 8 back pain: a randomized controlled trial. *Pain*. 2008 Nov 30;140(2):344-57
- 9
- 10 Welch V., Brosseau L, Saginur M, Shea B, Tugwell P, Wells G. Transcutaneous electrical
 11 nerve stimulation (TENS) for chronic low back pain. *Cochrane Database Syst Rev*.
 12 2001;(2):CD003008
- 13
- 14 Williamson TK, Rodriguez HC, Gonzaba A, Poddar N, Norwood SM, Gupta A. H-Wave®
 15 Device Stimulation: A Critical Review. *J Pers Med*. 2021;11(11):1134. Published 2021
 16 Nov 2
- 17
- 18 Wu Y, Zhu F, Chen W, Zhang M. Effects of transcutaneous electrical nerve stimulation
 19 (TENS) in people with knee osteoarthritis: A systematic review and meta-analysis. *Clin*
 20 *Rehabil*. 2022;36(4):472-485. doi:10.1177/02692155211065636
- 21
- 22 Wu F, Li X, Liang J, et al. Electrical stimulation therapy for pain and related symptoms in
 23 multiple sclerosis: A systematic review and meta-analysis. *Mult Scler Relat Disord*.
 24 2023;80:105114. doi:10.1016/j.msard.2023.105114
- 25
- 26 Yan T, Hui-Chan CW, Li LS. Functional electrical stimulation improves motor recovery
 27 of the lower extremity and walking ability of subjects with first acute stroke: a
 28 randomized placebo-controlled trial. *Stroke*. 2005 Jan;36(1):80-5
- 29
- 30 Yan D, Vassar R. Neuromuscular electrical stimulation for motor recovery in pediatric
 31 neurological conditions: a scoping review. *Dev Med Child Neurol*. 2021;63(12):1394-
 32 1401
- 33
- 34 Ye G, Grabke EP, Pakosh M, Furlan JC, Masani K. Clinical Benefits and System Design
 35 of FES-Rowing Exercise for Rehabilitation of Individuals with Spinal Cord Injury: A
 36 Systematic Review. *Arch Phys Med Rehabil*. 2021;102(8):1595-1605
- 37
- 38 Yue C, Zhang X, Zhu Y, Jia Y, Wang H, Liu Y. Systematic Review of Three Electrical
 39 Stimulation Techniques for Rehabilitation After Total Knee Arthroplasty. *J*
 40 *Arthroplasty*. 2018 Jul;33(7):2330-2337

- 1 Zeng C, Li H, Yang T, Deng ZH, Yang Y, Zhang Y, Lei GH. Electrical stimulation for
2 pain relief in knee osteoarthritis: systematic review and network meta-analysis.
3 *Osteoarthritis Cartilage*. 2015 Feb;23(2):189-202
4
- 5 Zhang Y, Hou S, Qi Z, Wu S, Zhu K, Wang W. Non-pharmacological and nonsurgical
6 interventions in male urinary incontinence: A scoping review. *J Clin Nurs*. 2023;32(17-
7 18):6196-6211. doi:10.1111/jocn.16749
8
- 9 Zhu D, Xia Z, Yang Z. Effectiveness of physiotherapy for lower urinary tract symptoms in
10 postpartum women: systematic review and meta-analysis. *Int Urogynecol J*.
11 2022;33(3):507-521
12
- 13 Zhu Q, Gao G, Wang K, Lin J. Effect of Functional Electrical Stimulation on Gait
14 Parameters in Children with Cerebral Palsy: A Meta-Analysis. *Comput Math Methods*
15 *Med*. 2022;2022:3972958. Published 2022 Sep 22. doi:10.1155/2022/3972958
16
- 17 Zuim PR, Garcia AR, Turcio KH, Hamata MM. Evaluation of microcurrent electrical nerve
18 stimulation (MENS) effectiveness on muscle pain in temporomandibular disorders
19 patients. *J Appl Oral Sci*. 2006 Jan;14(1):61-6